<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">102027</article-id><article-id pub-id-type="doi">10.7554/eLife.102027</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.102027.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Coordinated <italic>Tbx3/Tbx5</italic> transcriptional control of the adult ventricular conduction system</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Burnicka-Turek</surname><given-names>Ozanna</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3770-4314</contrib-id><email>burnickatureko@uchicago.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Trampel</surname><given-names>Katy A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5735-1037</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Laforest</surname><given-names>Brigitte</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6919-8922</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Broman</surname><given-names>Michael T</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xinan H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Zoheb</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rytkin</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Binjie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Schaffer</surname><given-names>Ella</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gadek</surname><given-names>Margaret</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Kaitlyn M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Efimov</surname><given-names>Igor R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1483-5039</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Moskowitz</surname><given-names>Ivan P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0014-4963</contrib-id><email>imoskowitz@peds.bsd.uchicago.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024mw5h28</institution-id><institution>Departments of Pediatrics, Pathology, and Human Genetics, University of Chicago</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000e0be47</institution-id><institution>Departments of Biomedical Engineering, Northwestern University</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024mw5h28</institution-id><institution>Department of Medicine, Section of Cardiology, University of Chicago</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Bruneau</surname><given-names>Benoit</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>University of California, San Francisco</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Stainier</surname><given-names>Didier YR</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0165r2y73</institution-id><institution>Max Planck Institute for Heart and Lung Research</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>24</day><month>07</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP102027</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-08-29"><day>29</day><month>08</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-08-30"><day>30</day><month>08</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.08.29.610377"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-11-21"><day>21</day><month>11</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102027.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-04-17"><day>17</day><month>04</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102027.2"/></event></pub-history><permissions><copyright-statement>Â© 2024, Burnicka-Turek et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Burnicka-Turek et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-102027-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-102027-figures-v1.pdf"/><abstract><p>The cardiac conduction system (CCS) orchestrates the electrical impulses that enable coordinated contraction of the cardiac chambers. The T-box transcription factors <italic>TBX3</italic> and <italic>TBX5</italic> are required for CCS development and associated with overlapping and distinct human CCS diseases. We evaluated the coordinated role of <italic>Tbx3</italic> and <italic>Tbx5</italic> in the murine ventricular conduction system (VCS). We engineered a compound <italic>Tbx3:Tbx5</italic> conditional knockout allele for both genes located in cis on mouse chromosome 5. Conditional deletion of both T-box transcriptional factors in the VCS, using the VCS-specific <italic>MinK<sup>CreERT2</sup></italic>, caused loss of VCS function and molecular identity. Combined <italic>Tbx3</italic> and <italic>Tbx5</italic> deficiency in the adult VCS led to conduction defects, including prolonged PR and QRS intervals and elevated susceptibility to ventricular tachycardia. These electrophysiological defects occurred prior to detectable alterations in cardiac contractility or histologic morphology, indicative of a primary conduction system defect. <italic>Tbx3:Tbx5</italic> double-knockout VCS cardiomyocytes revealed a transcriptional shift toward non-CCS-specialized working myocardium, indicating a change to their cellular identity. Furthermore, optical mapping revealed a loss of VCS-specific conduction system propagation. Collectively, these findings indicate that <italic>Tbx3</italic> and <italic>Tbx5</italic> coordinate to control VCS molecular fate and function, with implications for understanding cardiac conduction disorders in humans.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Tbx3</kwd><kwd>Tbx5</kwd><kwd>T-box transcriptional factors</kwd><kwd>cardiac conduction system (CCS)</kwd><kwd>ventricular conduction system (VCS)</kwd><kwd>Tbx3:Tbx5 double-conditional mouse line</kwd><kwd>Tbx3:Tbx5-deficient mice</kwd><kwd>reprogramming of VCS</kwd><kwd>heart rhythm</kwd><kwd>arrhythmia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 HL163523</award-id><principal-award-recipient><name><surname>Moskowitz</surname><given-names>Ivan P</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 HL148719</award-id><principal-award-recipient><name><surname>Moskowitz</surname><given-names>Ivan P</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Leducq Foundation Grant Bioelectronics for Neuroradiology â Diagnosis &amp; Therapeutics</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Efimov</surname><given-names>Igor R</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>13POST17290028</award-id><principal-award-recipient><name><surname>Burnicka-Turek</surname><given-names>Ozanna</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Coordinated removal of <italic>Tbx3</italic> and <italic>Tbx5</italic> function alters the molecular features of the fast ventricular cardiac conduction system toward non-conduction working myocardium, illuminating transcriptional control of cardiac conduction system patterning.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The cardiac conduction system (CCS) constitutes a highly specialized network of cardiomyocytes that initiate and propagate the electrical impulses required for synchronized contractions of the heart. In the mature mammalian heart, the functional components of the CCS can be broadly divided into the slowly propagating atrial nodes (~5 cm/s), containing the sinoatrial node (SAN) and atrioventricular node (AVN), and the rapidly propagating ventricular conduction system (VCS) (~200 cm/s), including the AV (His) bundle and the right and left bundle branches (BBs). The VCS is responsible for rapid propagation of the electrical impulse from the AVN to the ventricular apex to enable synchronous ventricular contraction and effective ejection of blood from the ventricles (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Park and Fishman, 2011</xref>; <xref ref-type="bibr" rid="bib47">Moskowitz et al., 2007</xref>). Defects of CCS can occur in normally formed hearts as well as in patients with structural congenital heart disease and are a major source of morbidity and mortality (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib47">Moskowitz et al., 2007</xref>; <xref ref-type="bibr" rid="bib48">Munshi, 2012</xref>; <xref ref-type="bibr" rid="bib56">Rubart and Zipes, 2005</xref>; <xref ref-type="bibr" rid="bib31">Huikuri et al., 2001</xref>). The VCS specifically has been recognized as a substrate for life-threatening ventricular arrhythmias, including bundle branch reentry tachycardia, idiopathic fascicular tachycardia, short-coupled torsade de pointes, and ventricular fibrillation (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib31">Huikuri et al., 2001</xref>; <xref ref-type="bibr" rid="bib63">van Duijvenboden et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Arnolds and Moskowitz, 2011b</xref>; <xref ref-type="bibr" rid="bib58">Scheinman, 2009</xref>). Despite the severe clinical consequences of CCS disorders, the molecular mechanisms that establish and maintain regional functionality of the mature CCS domains require further study.</p><p>Human genetic studies have identified numerous loci associated with adult human CCS function, including the developmentally important factors <italic>Tbx3</italic> and <italic>Tbx5</italic> (reviewed in <xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib3">Arnolds et al., 2011a</xref>). <italic>Tbx3</italic> and <italic>Tbx5</italic> play crucial roles in adult CCS development and function (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib47">Moskowitz et al., 2007</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Moskowitz et al., 2004</xref>; <xref ref-type="bibr" rid="bib66">van Weerd and Christoffels, 2016</xref>; <xref ref-type="bibr" rid="bib62">van den Boogaard et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Bakker et al., 2012</xref>; <xref ref-type="bibr" rid="bib24">Hatcher and Basson, 2009</xref>; <xref ref-type="bibr" rid="bib6">Bakker et al., 2008</xref>; <xref ref-type="bibr" rid="bib29">Hoogaars et al., 2007b</xref>; <xref ref-type="bibr" rid="bib45">Mori et al., 2006</xref>; <xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>). <italic>Tbx5</italic> encodes a T-box transcriptional activator required for structural and conduction system cardiac development (<xref ref-type="bibr" rid="bib47">Moskowitz et al., 2007</xref>; <xref ref-type="bibr" rid="bib46">Moskowitz et al., 2004</xref>; <xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>; <xref ref-type="bibr" rid="bib28">Hoogaars et al., 2007a</xref>). Dominant mutations in human <italic>TBX5</italic> cause HoltâOram syndrome (HOS, OMIM:142900), an autosomal dominant disorder characterized by upper limb malformations, congenital heart defects, and CCS abnormalities (<xref ref-type="bibr" rid="bib10">Basson et al., 1997</xref>; <xref ref-type="bibr" rid="bib34">Li et al., 1997</xref>; <xref ref-type="bibr" rid="bib9">Basson et al., 1994</xref>). The cardiac phenotype of HOS, including atrioventricular conduction delay, has been recapitulated in the <italic>Tbx5</italic> heterozygous mice (<xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>). Moreover, VCS-specific <italic>Tbx5</italic> knockout caused slowed VCS function and ventricular tachycardia (VT) resulting in sudden death in mice (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>), emphasizing the importance of <italic>Tbx5</italic> in VCS conduction. <italic>Tbx5</italic> is strongly expressed in the atria and VCS (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib47">Moskowitz et al., 2007</xref>; <xref ref-type="bibr" rid="bib46">Moskowitz et al., 2004</xref>; <xref ref-type="bibr" rid="bib6">Bakker et al., 2008</xref>), and directly regulates several targets required for VCS function (<xref ref-type="bibr" rid="bib47">Moskowitz et al., 2007</xref>; <xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>; <xref ref-type="bibr" rid="bib25">Hiroi et al., 2001</xref>), including <italic>Gja5 (Cx40)</italic> (<xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>) and <italic>Scn5a (Nav1.5)</italic> (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>). <italic>Tbx3</italic> encodes a T-box transcriptional repressor which is critical for cardiac development (<xref ref-type="bibr" rid="bib6">Bakker et al., 2008</xref>; <xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>). Dominant mutations in human <italic>TBX3</italic> cause UlnarâMammary syndrome (OMIM:181450), a developmental disorder (<xref ref-type="bibr" rid="bib41">Meneghini et al., 2006</xref>; <xref ref-type="bibr" rid="bib8">Bamshad et al., 1997</xref>), that includes functional conduction system defects (<xref ref-type="bibr" rid="bib36">Linden et al., 2009</xref>). In the heart, <italic>Tbx3</italic> is specifically expressed within CCS (<xref ref-type="bibr" rid="bib6">Bakker et al., 2008</xref>; <xref ref-type="bibr" rid="bib27">Hoogaars et al., 2004</xref>), and its deficiency below critical level leads to lethal arrhythmias (<xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>). Furthermore, <italic>Tbx3</italic> is required for the molecular identity but not the function of the VCS (<xref ref-type="bibr" rid="bib6">Bakker et al., 2008</xref>). In contrast, <italic>Tbx3</italic> in SAN and AVN is required for their proper function (<xref ref-type="bibr" rid="bib27">Hoogaars et al., 2004</xref>), emphasizing its critical role in maintaining proper cardiac rhythm.</p><p>A model for regional CCS specialization suggests that the adult CCS is organized entirely as a slow conduction system ground state by <italic>Tbx3</italic> with a T-box-dependent, physiologically dominant fast conduction system network driven specifically in the VCS by <italic>Tbx5</italic> (<xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>). The adult VCS-specific removal of TBX5 or overexpression of TBX3 shifted the fast VCS into a slow nodal-like system, indicating that the <italic>Tbx3/Tbx5</italic> ratio determines nodal versus VCS function (<xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>). However, a comprehensive assessment of the coordinated requirements for <italic>Tbx3</italic> and <italic>Tbx5</italic> has been hindered by the inability to achieve their compound deletion due to their genomic proximity. <italic>Tbx3</italic> and <italic>Tbx5</italic> are situated in cis within 0.6 Mb on chromosome 5 in mice, rendering their simultaneous deletion unattainable with the available single allele conditional alleles. To investigate the consequences of <italic>Tbx3</italic> and <italic>Tbx5</italic> compound removal from the mature VCS, we generated a novel compound <italic>Tbx3:Tbx5</italic> double-conditional allele. We found that VCS-specific genetic removal of both TBX3 and TBX5 transformed fast-conducting, adult VCS into working myocardium-like cardiomyocytes, shifting them from conduction to non-conduction myocytes. These results demonstrated the coordinated requirements of both <italic>Tbx3</italic> and <italic>Tbx5</italic> for maintained specification of the mature VCS.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>We generated a novel <italic>Tbx3:Tbx5</italic> double-floxed allele to enable the simultaneous conditional deletion of <italic>Tbx3</italic> and <italic>Tbx5</italic> genes specifically from the adult VCS. <italic>Tbx3</italic> and <italic>Tbx5</italic> reside in cis on mouse chromosome 5 (<italic>Tbx3</italic> mm39 chr5:119808734â119822789; <italic>Tbx5</italic> mm39 chr5:119970733â120023284). Therefore, to generate a double-conditional knockout, we targeted <italic>Tbx5</italic> in the background of a previously validated <italic>Tbx3</italic> floxed allele (<xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>) using the CRISPRâCas9 system (<xref ref-type="bibr" rid="bib23">Gurumurthy et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Dow et al., 2015</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). We engineered a <italic>Tbx5</italic> floxed allele mirroring a previously published allele (<xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>). This design enabled us to utilize the previously published individual <italic>Tbx3</italic> floxed allele (<xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>) and individual <italic>Tbx5</italic> floxed allele (<xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>) to serve as controls (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplements 1</xref> and <xref ref-type="fig" rid="fig1s2">2</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Generation of VCS-specific <italic>Tbx3:Tbx5</italic> double-conditional knockout mice.</title><p>(<bold>A</bold>) Strategy to generate VCS-specific Tbx3<italic>:Tbx5</italic> double-conditional knockout mouse line. A new <italic>Tbx3:Tbx5</italic> double-conditional knockout mouse line (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup></italic>) was generated using the CRISPRâCas9 system (<xref ref-type="bibr" rid="bib23">Gurumurthy et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Dow et al., 2015</xref>) which allowed for the targeting of <italic>Tbx5</italic> in the background of the previously validated <italic>Tbx3</italic> floxed allele (<xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>). A newly engineered <italic>Tbx5</italic> floxed allele has been developed to mirror a previously published allele (<xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>). This design has enabled the utilization of the previously published individual <italic>Tbx3</italic> floxed allele (<xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>) and individual <italic>Tbx5</italic> floxed allele (<xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>) as controls. To conditionally delete <italic>Tbx3</italic> and <italic>Tbx5</italic> genes specifically from the adult VCS and generate the experimental animals, the <italic>Tbx3:Tbx5</italic> double-floxed mouse line (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl</sup>/<sup>fl</sup></italic>) was combined with a VCS-specific tamoxifen inducible <italic>Cre</italic> transgenic mouse line (<italic>MinK<sup>CreERT2</sup></italic> [Tg(RP23-276I20<italic>-MinKCreERT2</italic>) <xref ref-type="bibr" rid="bib4">Arnolds and Moskowitz, 2011b</xref>]). All allelic combinations were generated and evaluated as littermates in a mixed genetic background. The experimental mice employed in all studies were administered tamoxifen at 6 weeks of age and subsequently evaluated at 9 weeks of age (3 weeks post-tamoxifen administration). The loss of <italic>Tbx3</italic> and <italic>Tbx5</italic> expression, on both the protein and mRNA levels, assessed by immunohistochemistry (<bold>B</bold>) and qRT-PCR (<bold>C</bold>), respectively, was observed in the VCS of adult <italic>Tbx3:Tbx5</italic> double-conditional mutant mice (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>), but not in their littermate controls (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) (<bold>B, C</bold>). (<bold>C</bold>) qRT-PCR analysis showed a partial loss of <italic>Tbx3</italic> and <italic>Tbx5</italic> expression in the adult VCS of <italic>Tbx3:Tbx5</italic> double-conditional heterozygous mice (<italic>Tbx3<sup>fl/+</sup>;Tbx5<sup>fl/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) compared to their littermate controls (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>). Additionally, qRT-PCR analysis confirmed the specificity of the <italic>Tbx3:Tbx5</italic> double knockout for the VCS by assessing <italic>Tbx3</italic> and <italic>Tbx5</italic> expression levels in the atria and ventricles of tamoxifen-treated experimental mice. Consistent with the VCS selectivity of <italic>Cre</italic> activity in the <italic>MinK<sup>CreERT2</sup></italic> mice (<xref ref-type="bibr" rid="bib4">Arnolds and Moskowitz, 2011b</xref>), <italic>Tbx3</italic> and <italic>Tbx5</italic> expression remained similar in the atrial and ventricular myocardium across all allelic combinations, including <italic>Tbx3:Tbx5</italic> double-conditional knockout mice (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>). (<bold>D</bold>) Conducted longitudinal studies revealed a significantly increased mortality rate in VCS-specific <italic>Tbx3:Tbx5-</italic>deficient mice compared to their littermate controls (***p &lt; 0.0001, log-rank test, GraphPad Prism), suggesting a requirement for both <italic>Tbx3</italic> and <italic>Tbx5</italic> in the mature VCS. All allelic combinations of experimental and control mice (<italic>n</italic> = 40 biological replicates/genotype) were followed longitudinally after tamoxifen administration at 6 weeks of age. <italic>Tbx3:Tbx5</italic> double-conditional knockout mice began to die suddenly at 3â4 weeks post-tamoxifen administration. Within the 3 months post-tamoxifen administration, all tamoxifen-treated <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mice had died suddenly (<italic>n</italic> = 40) without previous signs of illness. In contrast, no mortality was observed among the tamoxifen-treated <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup> and Tbx3<sup>fl/+</sup>;Tbx5<sup>fl/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> littermates (each cohort <italic>n</italic> = 40) during this period. TBX3 and TBX5 protein expression was evaluated by immunohistochemistry (green and red signals, respectively) on serial sections from hearts of all allelic combinations (<italic>n</italic> = 3 biological replicates/genotype). Nuclei were stained with DAPI (blue signal). IHC original magnification: Ã40. qRT-PCR data are presented as mean Â± SD normalized to <italic>Gapdh</italic> and relative to <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mice (set as 1). <italic>N</italic> = 3 biological replicates/genotype (VCS cardiomyocytes pooled from 30 mice per biological replicate); multiple testing correction using Benjamini and Hochberg procedure. Significance was assessed by Welch <italic>t</italic>-test (*FDR &lt;0.05; **FDR &lt;0.005; ***FDR &lt;0.001) and confirmed by one-tailed Wilcoxon test (p value in parentheses) when normally distribution was rejected. Abbreviations: AVB, atrioventricular bundle (also known as bundle of His); FDR, false discovery rate; VCS, ventricular conduction system.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>Generation of a novel <italic>Tbx5</italic> floxed allele in a<italic>Tbx3</italic> floxed background.</title><p>(<bold>A</bold>) Strategy to generate a new <italic>Tbx5</italic> floxed allele using the CRISPR/Cas9 system with long single-strand DNA donor (lssDNA donor) composed of the targeted exon 3 flanked by two lox2272 sites. The schematic shows the Cas9/sgRNA-targeting sites in the second and third introns of murine <italic>Tbx5</italic>, the lssDNA donor, and the targeted allele. (<bold>B</bold>) PCR analysis of <italic>Tbx5</italic> and <italic>Tbx3</italic> loci in G0 founders. Mice #35 to #41 are shown. <bold>Upper left panel:</bold> PCR genotyping of the <italic>Tbx5</italic> locus using primers specific for the 5â² arm of the lssDNA donor with the lox2272 insertion. <bold>Upper right panel:</bold> PCR genotyping of the <italic>Tbx5</italic> locus using primers specific for the 3â² arm of the lssDNA donor with the lox2272 insertion. Green labels indicate founders positive for lox2272 insertion in one arm. Red asterisks indicate founders positive for lox2272 insertion in both arms. Expected fragment sizes: for the 5â² arm with lox2272 insertion, positive band = 269 bp, WT = 229 bp; for the 3â² arm with insertion, positive band = 320 bp, WT = 280 bp. <bold>Lower panel:</bold> PCR genotyping of the <italic>Tbx3</italic> locus using primers indicating <italic>Tbx3</italic> floxed allele. Expected fragment sizes: <italic>Tbx3</italic> floxed allele = 420 bp, Tbx3 WT allele = 330 bp. (<bold>C</bold>) RFLP analysis of the <italic>Tbx5</italic> locus in G0 founders. Mice #35 to #41 are shown. <bold>Upper panel:</bold> PCR products amplified using primers specific for the 5â² arm of the lssDNA donor were digested with <italic>EcoRI</italic> to detect the insertion of the 5â² lox2272. WT amplicon = 229 bp; lox2272 positive amplicon = 269 bp. The WT amplicon lacks the <italic>EcoRI</italic> site. With the 5â² lox2272 insertion, the digestion products are 180 and 89 bp. <bold>Lower panel:</bold> PCR products amplified using primers specific for the 3â² arm of the lssDNA donor were digested with <italic>SphI</italic> to detect the insertion of the 3â² lox2272. WT amplicon = 280 bp; lox2272 positive amplicon = 320 bp. The WT amplicon lacks the <italic>SphI</italic> site. With the 3â² lox2272 insertion, the digestion products are 226 and 94 bp. WT controls are shown in the last lanes. Green labels indicate founders positive for lox2272 insertion in one arm. Red asterisks indicate founders positive for lox2272 insertion in both arms. (<bold>D</bold>) Example of Sanger sequencing results from a representative G0 founder previously identified as positive for 5â² and 3â² lox2272 sites insertion by PCR and RFLP analysis. The sequencing confirmed the precise integration of lox2272 sites in both arms, resulting in exon 3 being flanked by two lox2272 sites.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1âfigure supplement 1âsource data 1.</label><caption><title>File containing original gels corresponding to <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1B</xref>.</title><p>The black rectangle indicates the region included in the final figure panel.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-102027-fig1-figsupp1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1âfigure supplement 1âsource data 2.</label><caption><title>Zipped folder containing original gels corresponding to <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-102027-fig1-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 2.</label><caption><title>Validation of the newly generated <italic>Tbx5</italic> floxed allele.</title><p>(<bold>A</bold>) Strategy to generate a <italic>Tbx5</italic> null allele through recombination of the newly generated <italic>Tbx5</italic> floxed allele in the presence of the <italic>Cre</italic> recombinase. (<bold>B</bold>) Strategy to generate germline <italic>Tbx5</italic> null mice in presence of <italic>Mef2C<sup>Cre</sup></italic> allele. To verify the ability of the newly generated <italic>Tbx5</italic> floxed allele to recombine into the <italic>Tbx5</italic> KO (null) allele, three rounds of breeding were conducted (<bold>left panel</bold>), and a PCR assay (<bold>right panels</bold>) was utilized to distinguish the recombined <italic>Tbx5</italic> null allele (<italic>Tbx5<sup>â</sup></italic>) from the unrecombined floxed allele (<italic>Tbx5<sup>fl</sup></italic>). Initially, homozygous <italic>Tbx5</italic> floxed males (<italic>Tbx5<sup>fl/fl</sup></italic>) were bred with homozygous <italic>Mef2C<sup>Cre/Cre</sup></italic> females, which express <italic>Cre</italic> recombinase at the zygote stage, to produce germline <italic>Tbx5<sup>+/â</sup>:Mef2<sup>Cre/+</sup></italic> double heterozygous mice. PCR analysis confirmed that 100% of the offspring were <italic>Tbx5<sup>+/â</sup>:Mef2C<sup>Cre/+</sup></italic> double heterozygous mice (<bold>right upper and middle panels</bold>), demonstrating complete recombination of the <italic>Tbx5</italic> floxed allele into the <italic>Tbx5</italic> null allele in the presence of the <italic>Mef2C<sup>Cre</sup></italic> allele. Subsequently, <italic>Tbx5<sup>+/â</sup>:Mef2C<sup>Cre/+</sup></italic> double heterozygous mice were backcrossed with wild-type CD1 IGS mice to obtain a germline <italic>Tbx5<sup>+/â</sup></italic> heterozygous mouse line. <italic>Tbx5<sup>+/â</sup></italic> mice were then bred to generate germline <italic>Tbx5</italic> null mice (T<italic>bx5<sup>â/â</sup></italic>). Among 230 offspring (from 50 litters), 113 wild-type pups (<italic>Tbx5<sup>+/+</sup></italic>) and 116 <italic>Tbx5</italic> heterozygous pups (<italic>Tbx5<sup>+/â</sup></italic>) were received, but no null pups (<italic>Tbx5<sup>â/â</sup></italic>) were obtained. (<bold>Right lower panel</bold>) Example of genotyping results showing absence of <italic>Tbx5</italic> null mice in newborn offspring generated by Tbx5<italic><sup>+/â</sup></italic> mice. Expected fragment sizes: <italic>Tbx5 Îflox (null</italic>) allele = 366 bp, <italic>Tbx5 flox</italic> allele = 269 bp, Tbx5 <italic>WT</italic> allele = 229 bp, Cre allele = 350 bp, Internal control allele = 250 bp. (<bold>C</bold>) Breeding strategy to generate <italic>E9.0âE10.0</italic> germline<italic>Tbx5</italic> null embryos. (<bold>Left panel</bold>) To generate germline <italic>Tbx5</italic> null embryos (<italic>Tbx5<sup>â/â</sup></italic>), <italic>Tbx5</italic> heterozygous mice (<italic>Tbx5<sup>+/â</sup></italic>) were bred, and embryos were collected at <italic>E9âE10</italic>. Genotyping analysis of 89 collected embryos from 10 timed pregnancies revealed the presence of 24 wild-type (<italic>Tbx5<sup>+/+</sup></italic>), 42 heterozygous (<italic>Tbx5<sup>+/â</sup></italic>), and 22 null (<italic>Tbx5<sup>â/â</sup></italic>) embryos. These results confirmed that the newly generated <italic>Tbx5</italic> floxed allele could recombine to form the null allele, mimicking the embryonic lethality observed with the previously generated allele (<xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>). (<bold>Right panel</bold>) Example of genotyping results showing the presence of E9.0 <italic>Tbx5</italic> null embryos collected from <italic>Tbx5<sup>+/â</sup></italic> timed breedings. Expected fragment sizes: <italic>Tbx5 Îflox (null</italic>) allele = 366 bp, <italic>Tbx5 WT</italic> allele = 229 bp.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1âfigure supplement 2âsource data 1.</label><caption><title>File containing original gels corresponding to <xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2B</xref>.</title><p>The black rectangle indicates the region included in the final figure panel.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-102027-fig1-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s2sdata2"><label>Figure 1âfigure supplement 2âsource data 2.</label><caption><title>Zipped folder containing original gels corresponding to <xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2B</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-102027-fig1-figsupp2-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 3.</label><caption><title>WT sequence of the targeted region at the mouse <italic>Tbx5</italic> locus.</title><p>The partial intron 2 (black, lowercase letters), entire exon 3 (black, bold, uppercase letters), and partial intron 3 (black, lowercase letters) are shown. The sgRNA-targeting sequence at the 5â² of exon 3 (<italic>Tbx5</italic>-I2-S22) is labeled in bold, light green, while the sgRNA-targeting sequence at the 3â² of exon 3 (<italic>Tbx5</italic>-I2-S31) is labeled in bold, dark green. The cleavage sites at the sgRNA-targeting sequences are underlined. The protospacer-adjacent motif (PAM) sequences are labeled in bold, light blue.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 4.</label><caption><title>Sequence of long ssDNA donor designed to target exon 3 of the mouse <italic>Tbx5</italic> locus.</title><p>It is composed of targeted exon 3 flanked by two lox2272 sites, along with 100/150 bp 5â²/3â² homology arms. The partial intron 2 (black, lowercase letters), entire exon 3 (bold, black, uppercase letters), partial intron 3 (black, lowercase letters), as well as 5â² (purple, lowercase letters) and 3â² (pink, lowercase letters) homology arms are displayed. The lox2272 sites, indicated in bold red, have been inserted at the cleavage sites of the sgRNA-binding sequences. Unique restriction enzyme sites used for RFLP analysis are shown as bold yellow for <italic>EcoRI</italic> and bold navy blue for <italic>SphI</italic>. T7 promoter is labeled in bold orange.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 5.</label><caption><title>Sequence of mouse new <italic>Tbx5</italic> floxed allele generated using CRISPR/Cas9 system with lssDNA composed of targeted exon 3 flanked by two lox2272 sites.</title><p>The partial intron 2 (black, lowercase letters), entire exon 3 (bold, black, uppercase letters), and partial intron 3 (black, lowercase letters) are displayed. The lox2272 sites, indicated in bold red, have been inserted at the cleavage sites of the sgRNA-binding sequences. Unique restriction enzyme sites used for RFLP analysis are shown as bold yellow for <italic>EcoRI</italic> and bold navy blue for <italic>SphI</italic>. PCR primers specific for the 5â² arm of the lssDNA donor with the lox2272 insertion (displayed as green box) as well as primers specific for the 3â² arm of the lssDNA donor with the lox2272 insertion (displayed as pink box) are shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig1-figsupp5-v1.tif"/></fig></fig-group><p>We assessed the impact of removing <italic>Tbx3</italic> and <italic>Tbx5</italic> from the mature VCS by combining the <italic>Tbx3:Tbx5</italic> double-floxed mouse line (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup></italic>) with a VCS-specific, tamoxifen (TM)-inducible <italic>Cre</italic> transgenic mouse line, <italic>Kcne1<sup>CreERT2</sup></italic> [Tg(RP23-276I20-<italic>MinKCreERT2</italic>)] â hereafter referred to as <italic>MinK<sup>CreERT2</sup></italic>, in accordance with existing literature (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib4">Arnolds and Moskowitz, 2011b</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>). Individual <italic>Tbx3</italic> floxed and <italic>Tbx5</italic> floxed mouse lines combined with <italic>MinK<sup>CreERT2</sup></italic> transgenic mouse lines (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>+/+</sup>; R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> and <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>, respectively) were generated as controls, and all allelic combinations were evaluated in a mixed genetic background. We compared VCS-specific <italic>Tbx3:Tbx5</italic> double-conditional mutants (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) with control littermates (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>; R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) and VCS-specific <italic>Tbx3:Tbx5</italic> double-conditional heterozygous littermates (<italic>Tbx3<sup>fl/+</sup>;Tbx5<sup>fl/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>). Additionally, we validated the newly created <italic>Tbx5</italic> floxed allele demonstrating that it is efficiently converted to the <italic>Tbx5</italic> null allele through <italic>Cre</italic> recombinase, causing a phenotype consistent with that observed from conversion of the previously published <italic>Tbx5</italic> floxed allele (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplements 1</xref> and <xref ref-type="fig" rid="fig1s2">2</xref>, Methods section).</p><p>We assessed experimental mice at 8â9 weeks of age following tamoxifen administration at 6 weeks of age (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, Methods section). We observed loss of both <italic>Tbx3</italic> and <italic>Tbx5</italic> expression, on both the mRNA and protein levels, in the VCS of adult <italic>Tbx3:Tbx5</italic> double-conditional mutant mice (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) but not in their littermate controls (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) (<xref ref-type="fig" rid="fig1">Figure 1B, C</xref>). Partial loss of <italic>Tbx3</italic> and <italic>Tbx5</italic> expression in the adult VCS of <italic>Tbx3:Tbx5</italic> double-conditional heterozygous mice (<italic>Tbx3<sup>fl/+</sup>;Tbx5<sup>fl/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) was observed compared to littermate controls (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). We confirmed the specificity of the <italic>Tbx3:Tbx5</italic> double knockout for the VCS by assessing <italic>Tbx3</italic> and <italic>Tbx5</italic> expression levels in the atria and ventricles of tamoxifen-treated experimental mice. Consistent with the VCS selectivity of <italic>Cre</italic> activity in the <italic>MinK<sup>CreERT2</sup></italic> mice (<xref ref-type="bibr" rid="bib4">Arnolds and Moskowitz, 2011b</xref>), <italic>Tbx3</italic> and <italic>Tbx5</italic> expression remained similar in the atrial and ventricular myocardium of all allelic combinations, including <italic>Tbx3:Tbx5</italic> double-conditional knockout mice (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><p><italic>Tbx3:Tbx5</italic> double-conditional knockout mice (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>; MinK<sup>CreERT2/+</sup></italic>) appeared morphologically and functionally normal and indistinguishable from control littermates (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) at 2 weeks post-tamoxifen. However, longitudinal analysis demonstrated sudden death of VCS-specific double-knockout mice beginning 3 weeks post-tamoxifen administration (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Within the 3 months post-tamoxifen administration, all tamoxifen-treated <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>; R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mice had died suddenly (<italic>n</italic> = 40). In contrast, no mortality was observed among the tamoxifen-treated <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> or <italic>Tbx3<sup>fl/+</sup>;Tbx5<sup>fl/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> littermates (each cohort <italic>n</italic> = 40) during this period (<italic>Tbx3:Tbx5</italic> double-conditional knockout mice vs. control mice p &lt; 0.0001; <italic>Tbx3:Tbx5</italic> double-conditional knockout mice vs. <italic>Tbx3:Tbx5</italic> double-conditional heterozygous mice p &lt; 0.0001, log-rank test; <xref ref-type="fig" rid="fig1">Figure 1D</xref>). These results revealed that double deletion of <italic>Tbx3</italic> and <italic>Tbx5</italic> from the adult VCS causes lethality beginning at 3 weeks post-tamoxifen.</p><p>The onset of mortality observed in VCS-specific <italic>Tbx3:Tbx5-</italic>deficient mice starting at 3 weeks post-tamoxifen prompted us to investigate the electrophysiologic consequences of VCS-specific <italic>Tbx3:Tbx5</italic> double-knockout at 2â3 weeks post-tamoxifen, prior to the onset of lethality (<xref ref-type="fig" rid="fig2">Figure 2</xref>). VCS-specific <italic>Tbx3:Tbx5</italic> deficiency caused profound conduction slowing in <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mice by ambulatory telemetry electrocardiography (ECG) analysis compared to <italic>Tbx3:Tbx5</italic> double-conditional heterozygous mice (<italic>Tbx3<sup>fl/+</sup>;Tbx5<sup>fl/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) and littermate controls (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) (<xref ref-type="fig" rid="fig2">Figure 2AâF</xref>). Specifically, the PR interval, representing the period between atrial and ventricular depolarization, and the QRS duration, indicating the length of ventricular depolarization and early repolarization in mice, were both significantly prolonged (<xref ref-type="fig" rid="fig2">Figure 2A, B, D</xref>; PR: <italic>Tbx3:Tbx5</italic> double-conditional knockout mice vs. control mice p &lt; 0.05, <italic>n</italic> = 7, Welch <italic>t</italic>-test; QRS: <italic>Tbx3:Tbx5</italic> double-conditional knockout mice vs. control mice p &lt; 0.05, <italic>n</italic> = 7, Welch <italic>t</italic>-test). Removal of both <italic>Tbx3</italic> and <italic>Tbx5</italic> from the adult VCS resulted in increased episodes of spontaneous VT. Ambulatory studies revealed episodes of spontaneous VT in four out of seven <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mice, in contrast to none observed in seven littermate controls (<xref ref-type="fig" rid="fig2">Figure 2G</xref>, p &lt; 0.05, <italic>n</italic> = 7, Welch <italic>t</italic>-test). Furthermore, <italic>Tbx3:Tbx5</italic> double-conditional knockout mice (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) showed significantly increased susceptibility to VT following burst stimulation in invasive electrophysiology (EP) studies (three of three <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mice vs. zero of seven littermate controls; <xref ref-type="fig" rid="fig2">Figure 2H</xref>, p &lt; 0.05, Welch <italic>t</italic>-test). In contrast, VCS-specific <italic>Tbx3:Tbx5</italic> double-conditional heterozygous mice (<italic>n</italic> = 7) showed neither conduction nor electrophysiological defects (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Consistent with the use of a VCS-specific <italic>Cre</italic> (<italic>MinK<sup>CreERT2</sup></italic>), no changes in the refractory/recovery periods of atrium, ventricle, or nodes (atrial effective refractory period, ventricular effective refractory period (VERP), atrioventricular nodal effective refractory period, or sinus node recovery time) were detected by intracardiac EP conducted on experimental and control mice (<xref ref-type="fig" rid="fig2">Figure 2I</xref>, p &lt; 0.05, Welch <italic>t</italic>-test).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Arrhythmias and conduction abnormalities in mice with VCS-specific <italic>Tbx3:Tbx5</italic> double-conditional knockout.</title><p>(<bold>AâF</bold>) VCS-specific <italic>Tbx3:Tbx5</italic> double-conditional knockout causes significant VCS conduction slowing in adult <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mice. (<bold>A</bold>) PR (left graph) and QRS (right graph) intervals calculated from ambulatory telemetry electrocardiography (ECG) recordings in (<bold>BâF</bold>). <italic>Tbx3:Tbx5</italic> double-conditional adult mice (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) displayed significant PR and QRS intervals prolongation compared to littermate controls (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) (A left and right graphs, respectively). Data are presented as mean Â± SD. <italic>N</italic> = 7 biological replicates/genotype, multiple testing correction using Benjamini and Hochberg procedure; *Welch <italic>t</italic>-test p &lt; 0.05 and FDR &lt;0.05; **Welch <italic>t</italic>-test p &lt; 0.005 and FDR &lt;0.05; ***Welch <italic>t</italic>-test p &lt; 0.001 and FDR &lt;0.05. Representative ambulatory telemetry ECG of <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>; R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>B</bold>), <italic>Tbx3<sup>fl/+</sup>;Tbx5<sup>fl/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>C</bold>), <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>; R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>D</bold>), <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>E</bold>), <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>F</bold>) mice. (<bold>G</bold>) Simultaneous genetic removal of <italic>Tbx3</italic> and <italic>Tbx5</italic> from the adult VCS resulted in significantly increased episodes of spontaneous ventricular tachycardia. Episodes of spontaneous ventricular tachycardia were observed in four of seven <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>; MinK<sup>CreERT2/+</sup></italic> mice versus zero of seven littermate controls (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>; MinK<sup>CreERT2/+</sup></italic>) in ambulatory studies. <italic>N</italic> = 7 biological replicates/genotype; multiple testing correction using Benjamini and Hochberg procedure; *FDR of Welch <italic>t</italic>-test â¤0.05. (<bold>H</bold>) <italic>Tbx3:Tbx5</italic> double-conditional knockout mice (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) showed significantly increased susceptibility to ventricular tachycardia following burst stimulation in invasive electrophysiology studies (three of three <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>; MinK<sup>CreERT2/+</sup></italic> mice vs. zero of seven control <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mice. Fisherâs exact test: *p &lt; 0.05; <italic>n</italic> = 7 biological replicates/genotype). (<bold>I</bold>) Intracardiac electrophysiology detected no significant changes in SNRT, AERP, AVERP, and VERP recorded from experimental and control animals (<italic>n</italic> = 7 biological replicates/genotype; multiple testing correction using Benjamini and Hochberg procedure; *FDR of Welch <italic>t</italic>-test â¤0.05). (<bold>J</bold>) Graphical summary of conduction defects observed in adult, VCS-specific <italic>Tbx3:Tbx5</italic>-deficient mice. Simultaneous genetic deletion of <italic>Tbx3</italic> and <italic>Tbx5</italic> from the mature VCS results in conduction slowing, prolonged PR and QRS intervals, as well as ventricular tachycardia. Abbreviations: AVB, atrioventricular bundle (also known as bundle of His); AVN, atrioventricular node; FDR, false discovery rate; LA, left atrium; LBB, left bundle branches; LV, left ventricle; PFN, Purkinje fiber network; RA, right atrium; RBB, right bundle branches; RV, right ventricle; SAN, sinoatrial node; SVC, superior vena cava; VCS, ventricular conduction system.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig2-v1.tif"/></fig><p>To distinguish a primary conduction system abnormality from a secondary conduction abnormality resulting from cardiac dysfunction or remodeling, we evaluated cardiac form and function at the time of arrhythmia assessment, 2â3 weeks post-tamoxifen treatment (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Transthoracic echocardiography revealed no significant differences in left ventricular ejection fraction (LVEF) and fractional shortening (FS) between VCS-specific <italic>Tbx3:Tbx5</italic>-deficient (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) and control (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) mice (<italic>LVEF</italic>: <italic>Tbx3:Tbx5</italic> double-conditional knockout mice vs. control mice p &lt; 0.05, <italic>n</italic> = 7, Welch <italic>t</italic>-test; and FS: <italic>Tbx3:Tbx5</italic> double-conditional knockout mice vs. control mice p &gt; 0.05, <italic>n</italic> = 7, Welch <italic>t</italic>-test; <xref ref-type="fig" rid="fig3">Figure 3A, B, D</xref>). Histological examination of all four chambers demonstrated no discernible differences between VCS-specific <italic>Tbx3:Tbx5</italic> double-knockout (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>; R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) and control (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>; MinK<sup>CreERT2/+</sup></italic>) mice, nor between the double-knockout (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>; MinK<sup>CreERT2/+</sup></italic>) and single-knockout models for either <italic>Tbx3</italic> (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>) or <italic>Tbx5</italic> (<italic>Tbx3<sup>+/+</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic>). Ventricular muscle appeared normal without hypertrophy or myofibrillar disarray, and no fibrosis was present (<xref ref-type="fig" rid="fig3">Figure 3G, IâK</xref>, respectively). qRT-PCR analysis for fibrosis genes <italic>Col1a1</italic> (<xref ref-type="bibr" rid="bib51">Pan et al., 2022</xref>; <xref ref-type="bibr" rid="bib30">Hua et al., 2020</xref>; <xref ref-type="bibr" rid="bib73">Zhao et al., 2018</xref>) and <italic>Postn</italic> (<xref ref-type="bibr" rid="bib73">Zhao et al., 2018</xref>; <xref ref-type="bibr" rid="bib1">Ackerman et al., 2024</xref>; <xref ref-type="bibr" rid="bib71">Wu et al., 2024</xref>; <xref ref-type="bibr" rid="bib50">Oka et al., 2007</xref>) further confirmed no fibrosis in VCS of <italic>Tbx3:Tbx5</italic>-deficient mice (<xref ref-type="fig" rid="fig3">Figure 3L</xref>). No contractile dysfunction, histological abnormalities, or increased expression of fibrosis genes were observed in VCS-specific <italic>Tbx3:Tbx5</italic> double-conditional heterozygous mice (<italic>Tbx3<sup>fl/+</sup>;Tbx5<sup>fl/+</sup>;R26R<sup>eYFP/+</sup>; MinK<sup>CreERT2/+</sup></italic>) (<xref ref-type="fig" rid="fig3">Figure 3A, C, H, L</xref>). Taken together, these data indicate that the conduction defect and VT observed in mice with VCS-specific <italic>Tbx3:Tbx5</italic> deletion (<xref ref-type="fig" rid="fig2">Figure 2</xref>) occur prior to the onset of left ventricular (LV) dysfunction or evidence of remodeling (<xref ref-type="fig" rid="fig3">Figure 3</xref>), implying a primary origin.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Cardiac function is preserved following double-conditional loss of <italic>Tbx3</italic> and <italic>Tbx5</italic> in the adult ventricular conduction system (VCS).</title><p>(<bold>A</bold>) Left ventricular (LV) fractional shortening (<bold>left graph</bold>) and LV ejection fraction (<bold>right graph</bold>) calculated from the M-mode electrocardiographies (ECGs) in (<bold>BâF</bold>) revealed no contractile dysfunction in VCS-specific <italic>Tbx3:Tbx5</italic> double-conditional mutant mice (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>; MinK<sup>CreERT2/+</sup></italic>). Data are presented as mean Â± SD. Welch <italic>t</italic>-test: ns, not significant (p &gt; 0.05) ; <italic>n</italic> = 7 biological replicates/genotype. (<bold>BâF</bold>) Cardiac function, assessed by M-mode echocardiography from <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>B</bold>), <italic>Tbx3<sup>fl/+</sup>;Tbx5<sup>fl/+</sup>; R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>C</bold>), <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>D</bold>), <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>+/+</sup>; R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>E</bold>), <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>F</bold>) mice shown above surface ECGs. No functional differences between mutant and control mice were detected. The most representative images for each genotype were utilized in the figure. <italic>n</italic> = 7 biological replicates/genotype. (<bold>GâK</bold>) Histological examination of all four chambers from <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>G</bold>), <italic>Tbx3<sup>fl/+</sup>;Tbx5<sup>fl/+</sup>;R26R<sup>eYFP/+</sup>; MinK<sup>CreERT2/+</sup></italic> (<bold>H</bold>), <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>I</bold>), <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>; MinK<sup>CreERT2/+</sup></italic> (<bold>J</bold>), <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> (<bold>K</bold>) mice showed no histological abnormalities. The most representative images for each genotype were utilized in the figure. <italic>n</italic> = 3â4 biological replicates/genotype. Boxed areas in (<bold>GâK</bold>) have been shown at higher magnification at their right sides. (<bold>L</bold>) qRT-PCR analysis for fibrosis genes <italic>Col1a1</italic> and <italic>Postn</italic> confirmed that there was no increase in expression of fibrosis markers in the VCS of <italic>Tbx3:Tbx5</italic>-deficient mice. Data are presented as mean Â± SD normalized to <italic>Gapdh</italic> and relative to <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mice (set as 1). ns: FDR &gt;0.05 in both Welch <italic>t</italic>-test and Wilcoxon test; <italic>n</italic> = 2â3 biological replicates/genotype (VCS cardiomyocytes pooled from 30 mice per biological replicate). Histological examination original magnification: Ã2.5, boxed area showed at the higher magnification: Ã40. Abbreviations: FDR, false discovery rate; LA, left atrium; RA, right atrium; LV, left ventricle; RV, right ventricle.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig3-v1.tif"/></fig><p>To assess the hypothesis that <italic>Tbx3</italic> and <italic>Tbx5</italic> collectively promote VCS versus working myocardium phenotype, we conducted a transcriptional characterization of the adult VCS in <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mutant mice compared to their <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> control littermates using three distinct sets of molecular markers by qRT-PCR (<xref ref-type="fig" rid="fig4">Figure 4AâC</xref>). The first set encompassed genes expressed throughout the entire conduction system (Pan-CCS) and implicated in slow-conducting nodal phenotype, such as <italic>Hcn1</italic>, <italic>Hcn4</italic>, <italic>Cacna1d (Cav1.3)</italic>, <italic>Cacna1g (Cav3.1d)</italic>, <italic>Cacna1h (Cav3.2)</italic>, <italic>Gjd3 (Cx30.2)</italic>, and <italic>Gjc1 (Cx45)</italic> (<xref ref-type="bibr" rid="bib7">Bakker et al., 2012</xref>; <xref ref-type="bibr" rid="bib27">Hoogaars et al., 2004</xref>; <xref ref-type="bibr" rid="bib65">van Eif et al., 2020</xref>; <xref ref-type="bibr" rid="bib67">Verheule and Kaese, 2013</xref>; <xref ref-type="bibr" rid="bib35">Liang et al., 2013</xref>; <xref ref-type="bibr" rid="bib22">Greener et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Mangoni et al., 2006</xref>; <xref ref-type="bibr" rid="bib40">Marionneau et al., 2005</xref>; <xref ref-type="bibr" rid="bib18">Garcia-Frigola et al., 2003</xref>; <xref ref-type="bibr" rid="bib59">Schram et al., 2002</xref>; <xref ref-type="fig" rid="fig4">Figure 4A</xref>). The second set included genes highly expressed in the fast-conducting VCS and important for VCS function, including <italic>Gja5 (Cx40)</italic>, <italic>Scn5a (Nav1.5)</italic>, <italic>Ryr2</italic>, <italic>Kcnk3 (Task-1)</italic>, <italic>Kcnj2 (Kir2.1)</italic>, <italic>Kcnj3 (Kir3.1)</italic>, <italic>Kcnj4</italic> (IRK3), and <italic>Kcnj12 (Kir2.2)</italic> (<xref ref-type="fig" rid="fig4">Figure 4B</xref>; <xref ref-type="bibr" rid="bib65">van Eif et al., 2020</xref>; <xref ref-type="bibr" rid="bib67">Verheule and Kaese, 2013</xref>; <xref ref-type="bibr" rid="bib59">Schram et al., 2002</xref>; <xref ref-type="bibr" rid="bib15">Donner et al., 2011</xref>; <xref ref-type="bibr" rid="bib42">Miquerol et al., 2010</xref>; <xref ref-type="bibr" rid="bib55">Remme et al., 2009</xref>; <xref ref-type="bibr" rid="bib21">Graham et al., 2006</xref>). The third set contained markers specifically present in the working myocardium but absent in the CCS, such as <italic>Gja1</italic> (<italic>Cx43</italic>) and <italic>Smpx</italic> (<xref ref-type="fig" rid="fig4">Figure 4C</xref>; <xref ref-type="bibr" rid="bib27">Hoogaars et al., 2004</xref>; <xref ref-type="bibr" rid="bib65">van Eif et al., 2020</xref>; <xref ref-type="bibr" rid="bib2">AlcolÃ©a et al., 1999</xref>; <xref ref-type="bibr" rid="bib32">Kempen et al., 1996</xref>). VCS-specific <italic>Tbx3:Tbx5</italic>-deficient mice lost VCS expression profile of genes required for the fast ventricular conduction (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) as well as genes normally expressed in whole CCS (Pan-CCS genes) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In contrast, these mice obtained VCS expression of working myocardium-specific molecular markers (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Immunoblotting analysis confirmed transcriptional changes observed by qRT-PCR (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). This molecular characterization indicated that the <italic>Tbx3:Tbx5</italic> double mutant VCS adopted a gene expression profile similar to wild-type working myocardial-like cells (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>In the adult murine heart, <italic>Tbx3</italic> and <italic>Tbx5</italic> collectively promote ventricular conduction system (VCS) versus working myocardium (WM) phenotype.</title><p>(<bold>AâC</bold>) qRT-PCR analysis of molecular changes driven by VCS-specific <italic>Tbx3:Tbx5</italic> double-conditional knockout in adult mice. Transcriptional characterization of the adult VCS in <italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mutant mice, compared to their <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> control littermates, was conducted using three distinct sets of molecular markers. (<bold>A</bold>) Genes expressed throughout the entire conduction system (Pan-CCS), implicated in the slow-conducting nodal phenotype. (<bold>B</bold>) Genes highly expressed in the fast-conducting VCS, critical for VCS function. (<bold>C</bold>) Markers specifically present in the working myocardium but absent in the CCS. VCS-specific <italic>Tbx3:Tbx5</italic>-deficient mice lost the VCS expression profile, including genes necessary for fast ventricular conduction (<bold>B</bold>) and those typically expressed in the entire CCS (Pan-CCS genes), essential for the slow-conducting nodal phenotype (<bold>A</bold>). In contrast, they acquired VCS expression of working myocardium-specific molecular markers important for working myocardial function (<bold>C</bold>). (<bold>D</bold>) Immunoblotting analysis confirmed transcriptional changes indicated by qRT-PCR analysis (<bold>AâC</bold>) in VCS-specific <italic>Tbx3:Tbx5</italic> double-conditional knockout in adult mice. (<bold>E</bold>) Graphical summary of transcriptional changes observed in VCS of VCS-specific <italic>Tbx3:Tbx5</italic>-deficient mice. Simultaneous genetic deletion of <italic>Tbx3</italic> and <italic>Tbx5</italic> from the mature VCS resulted in a transcriptional profile resembling that of ventricular working myocardium. qRT-PCR data are presented as mean Â± SD normalized to <italic>Gapdh</italic> and relative to <italic>Tbx3<sup>+/+</sup>;Tbx5<sup>+/+</sup>;R26R<sup>eYFP/+</sup>;MinK<sup>CreERT2/+</sup></italic> mice (set as 1). <italic>N</italic> = 3 biological replicates/genotype (VCS cardiomyocytes pooled from 30 mice per biological replicate); multiple testing correction using Benjamini and Hochberg procedure. Significance was assessed by Welch <italic>t</italic>-test (*FDR &lt;0.05; **FDR &lt;0.005; ***FDR &lt;0.001) and confirmed by one-tailed Wilcoxon test (p value in parentheses) when normal distribution was rejected. Western blotting, n=2 biological replicates/ genotype (VCS cardiomyocytes pooled from 50 mice per each biological replicate). Abbreviations: AVB, atrioventricular bundle (also known as bundle of His); AVN, atrioventricular node; dCKO, double-conditional knockout; FDR, false discovery rate; LBB, left bundle branches; RBB, right bundle branches; VCS, ventricular conduction system.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4âsource data 1.</label><caption><title>File containing original western blots corresponding to <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title><p>The black rectangle indicates the region included in the final figure panel.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-102027-fig4-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4âsource data 2.</label><caption><title>Zipped folder containing original western blots files corresponding to <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-102027-fig4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig4-v1.tif"/></fig><p>The impact of the <italic>Tbx3:Tbx5</italic> double-conditional knockout on electrical impulse propagation in the VCS of the heart was assessed with optical mapping of the anterior epicardial surface of the ventricles and right septal preparations where VCS function should be observed (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Optical mapping records changes in transmembrane potential from multiple cells in tissue preparations, where ventricular septal optical action potentials (OAPs) have two distinct action potential upstrokes. The first peak is a result of depolarization of the specialized fast VCS, followed by depolarization of ventricular working myocardium.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Loss of VCS optical action potential (OAP) morphology in <italic>Tbx3:Tbx5</italic> double-conditional knockout mice.</title><p>(<bold>A</bold>) Schematic of the posterior view of a mouse heart with right ventricle (RV) free wall removed, highlighting the RV, septum, His bundle, and right atria (RA). (<bold>B</bold>) Representative 100 Ã 100 OAP map of OAP recorded during sinus rhythm from <italic>Tbx3:Tbx</italic>5 double-conditional knockout mice and control littermates with the free wall removed. The region of the His bundle is highlighted in red. (<bold>C</bold>) Representative 10 Ã 10 OAP map from the region of the His bundle. (<bold>D</bold>) Representative 10 Ã 10 map of the first derivative of the OAP from the region of the His bundle. (<bold>E</bold>) Representative ventricular OAP from whole heart intact preparation from <italic>Tbx3:Tbx</italic>5 double-conditional knockout mice (red) and control littermates (black). (<bold>F</bold>) Quantification of APD50 and APD80 at a basic cycle length of 125 ms. For (C-F), n=10 or 8 animals/ genotype.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 1.</label><caption><title><italic>Tbx3:Tbx5</italic> double-conditional knockout mice exhibit QRS prolongation.</title><p>(<bold>A</bold>) Representative electrocardiography (ECG) traces recorded from <italic>Tbx3:Tbx5</italic> double-conditional knockout mice (red) and control littermates (black). (<bold>B</bold>) Quantification of P, PR, QRS, QT, and RR intervals. For (A and B), n=10 or 8 animals/ genotype.*p &lt; 0.05 denotes significance.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig5-figsupp1-v1.tif"/></fig></fig-group><p>To visualize electrical impulse propagation in <italic>Tbx3:Tbx5</italic> double-conditional knockout mice, a 100 Ã 100 pixel data frame was plotted for the entire field of view of the right septal preparation (<xref ref-type="fig" rid="fig5">Figure 5A, B</xref>). For enhanced analysis of the VCS, the region encompassing the His bundle was distinguished in a red 10 Ã 10 area (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). To specifically assess electrical impulse propagation within the His bundle, the same 10 Ã 10 pixel area representing this region was isolated from adult hearts of both control and <italic>Tbx3:Tbx5</italic> double-conditional knockout mice (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). We observed only one OAP upstroke in <italic>Tbx3:Tbx5</italic> double-conditional knockout mice in contrast to control mice which showed two OAP upstrokes. The first derivative of the OAP (dOAP/dt) from the region of the His bundle was calculated and plotted in a dOAP/dt map further highlighting the number of temporally distinct upstrokes within the OAP (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). In control mice, we observed two distinct depolarization upstrokes, one pertaining to the VCS and the second for working ventricular myocardium. However, in <italic>Tbx3:Tbx5</italic> double-conditional knockout mice, only one maximum dOAP/dt was observed (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). The OAP morphology observed in <italic>Tbx3:Tbx5</italic> double-conditional knockout mice suggested a loss or reduction of the specialized fast VCS conduction (<xref ref-type="fig" rid="fig5">Figure 5C, D</xref>).</p><p>OAPs from the anterior epicardial surface of the ventricles were compared between control littermates and <italic>Tbx3:Tbx5</italic> double-conditional knockout mice to assess changes in electrical impulse propagation in the ventricular working myocardium. Paced at a basic cycle length of 125 ms, control littermates and <italic>Tbx3:Tbx5</italic> double-conditional knockout mice did not exhibit significant differences in action potential duration at 50% (APD50) or 80% (APD80) repolarization (<xref ref-type="fig" rid="fig5">Figure 5E, F</xref>). These observations suggested that the electrical activity of the ventricular working myocardium was not appreciably altered in double-knockout mice compared to controls. This finding is consistent with the lack of changes in the VERP observed in invasive EP studies of both control and <italic>Tbx3:Tbx5</italic> double-conditional knockout mice (<xref ref-type="fig" rid="fig3">Figure 3I</xref>).</p><p>We further predicted that the double knockout would not affect action potentials or conduction properties distal to the VCS (<xref ref-type="fig" rid="fig6">Figure 6</xref>). OAP and dOAP/dt maps were created to observe the effects on electrical impulse propagation distal to the His bundle on the right septal preparation (<xref ref-type="fig" rid="fig6">Figure 6</xref>), similar to the methods applied to create OAP and dOAP/dt maps in the region of the His bundle (<xref ref-type="fig" rid="fig5">Figure 5</xref>), with the key difference being that the signals were recorded from the red 10 Ã 10 pixel regions plotted in the working ventricular myocardium distal to the His bundle instead of in the area of the His bundle (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref> vs. <xref ref-type="fig" rid="fig5">Figure 5A, B</xref>, respectively). In both control littermates and <italic>Tbx3:Tbx5</italic> double-conditional knockout mice, only one action potential upstroke and one dOAP/dt maximum are observed, which indicates that most of this region consists of the ventricular working myocardium (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>, respectively). In summary, the significant remodeling of electrical impulse propagation due to <italic>Tbx3:Tbx5</italic> double-conditional knockout was observed by the loss of a distinct fast VCS impulse in the region of the His bundle, but not on the anterior epicardial surface of the ventricles or distal to the His bundle on the right ventricular (RV) septum (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Ventricular optical action potentials (OAPs) distal from His bundle have only one OAP upstroke.</title><p>(<bold>A</bold>) Schematic of the posterior view of mouse heart with right ventricle (RV) free wall removed. (<bold>B</bold>) Representative 100 Ã 100 pixel OAP map recorded during sinus rhythm from <italic>Tbx3:Tbx</italic>5 double-conditional knockout mice and control littermates with RV free wall removed. The region of the working ventricular myocardium distal from the His bundle is highlighted in red. (<bold>C</bold>) Representative 10 Ã 10 pixel OAP map from the region distal to the His bundle. (<bold>D</bold>) Representative 10 Ã 10 dOAP/dt map from the region distal to the His bundle. For (C and D), n=10 or 8 animals/ genotype.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig6-v1.tif"/></fig></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our study investigated the impact of compound <italic>Tbx3:Tbx5</italic> deficiency on mature VCS function and molecular identity. Using a double-conditional knockout strategy, both genes were targeted specifically in the adult VCS. Loss of <italic>Tbx3</italic> and <italic>Tbx5</italic> expression in the mature VCS led to profound conduction defects, characterized by prolonged PR interval and QRS duration, increased susceptibility to VT, and sudden death. These alterations were observed in the absence of discernible changes in cardiac contractility or histological morphology, indicating a primary conduction system defect. Molecular characterization of the adult VCS unveiled an altered gene expression profile in <italic>Tbx3:Tbx5</italic> double-conditional knockout mice, suggesting a transition from the distinctive fast VCS transcriptional profile to that resembling ventricular working myocardium. Optical mapping demonstrated loss of the specialized fast VCS function in <italic>Tbx3:Tbx5</italic> double-conditional knockout mice, further suggesting that this region acquired an electrophysiological phenotype similar to the ventricular working myocardium.</p><p>Our previous research (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib47">Moskowitz et al., 2007</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Moskowitz et al., 2004</xref>) and published literature <xref ref-type="bibr" rid="bib63">van Duijvenboden et al., 2014</xref>; <xref ref-type="bibr" rid="bib7">Bakker et al., 2012</xref>; <xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>; <xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>; <xref ref-type="bibr" rid="bib44">Mohan et al., 2020</xref>; <xref ref-type="bibr" rid="bib64">van Eif et al., 2018</xref> have suggested that the balance between <italic>Tbx3</italic> and T<italic>bx5</italic> expression determines the regional specialization of the mature central CCS (<xref ref-type="fig" rid="fig7">Figure 7</xref>). <italic>Tbx3</italic> expression dominates in nodal myocardium, imparting nodal physiological characteristics. <italic>Tbx5</italic> expression dominates in fast VCS myocardium, where a T-box-dependent fast conduction system network drives physiologically dominant fast conduction physiology, overriding nodal physiology (<xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>; <xref ref-type="fig" rid="fig7">Figure 7</xref>). This model accurately predicts the outcome of targeted manipulations, such as adult VCS-specific removal of TBX5 or overexpression of TBX3, which convert the fast VCS into a slow nodal-like system (<xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>; <xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title><italic>Tbx3</italic> and <italic>Tbx5</italic> play distinct roles in the adult VCS while collectively promoting CCS regional identity â a model elucidating our hypothesis for <italic>Tbx3/Tbx5</italic> dose-dependent CCS regional specialization.</title><p>(<bold>A</bold>) The <italic>Tbx3/Tbx5</italic> balance not only governs nodal versus ventricular conduction system (VCS) function but also collaboratively promotes the VCS versus working myocardium (WM) phenotype. Specifically, a high level of <italic>Tbx3</italic> is linked to the specialization to the nodal conduction system, while an elevated <italic>Tbx5</italic> level in nodal cells activates local expression of the <italic>Tbx5</italic>-dependent fast conduction network, resulting in the generation of VCS. (<bold>B</bold>) CCS regional specialization is driven by local expression of <italic>Tbx5</italic>-dependent fast conduction network in the VCS, which overlaps underlying Pan-CCS expression of nodal, slow conduction network. (<bold>C</bold>) VCS-specific simultaneous genetic removal of both the <italic>Tbx3</italic> and <italic>Tbx5</italic> transcription factors transforms the fast-conducting, adult VCS into cells resembling working myocardium, thereby shifting them from conduction to non-conduction myocytes. Therefore, within the adult CCS, the <italic>Tbx3</italic> and <italic>Tbx5</italic> expression levels are crucial not only for normal fast versus slow conduction system identity but also for maintaining the conduction versus contraction specialization of the VCS. AVB, atrioventricular bundle; AVN, atrioventricular node; CCS, cardiac conduction system; CKO, conditional knockout; LBB, left bundle branch; RBB, right bundle branch; VCS, ventricular conduction system.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102027-fig7-v1.tif"/></fig><p>The adult CCS organization model posits that <italic>Tbx3</italic> and <italic>Tbx5</italic> coordinately establish CCS characteristics and suggests their compound necessity to maintain specialized VCS identity (<xref ref-type="fig" rid="fig7">Figure 7</xref>), a hypothesis that remained untested. This model predicted that VCS-specific genetic ablation of both the TBX3 and TBX5 transcription factors would transform fast-conducting adult VCS into cells resembling working myocardium, eliminating specialized CCS identity (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Testing this model necessitated the generation of a <italic>Tbx3:Tbx5</italic> double-conditional knockout allele due to their proximal chromosomal location in cis on mouse Chr5. VCS-specific double-knockout mice showed a notable deceleration in VCS conduction, manifested by prolonged PR and QRS intervals, along with increased susceptibility to VT. A similar functional phenotype was observed in single deletion of <italic>Tbx5</italic> from the adult VCS, leading to the transformation of the fast VCS into a nodal-like phenotype (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>). However, we predicted that the nodal-like characteristics of the <italic>Tbx5</italic>-ablated VCS were due to retained expression of <italic>Tbx3</italic>. In fact, the autonomous beating and impulse initiation observed in the <italic>Tbx5</italic>-mutant VCS (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>) were absent from the double <italic>Tbx3:Tbx5</italic> mutant VCS, further suggesting the transformation from a nodal-like to an inert myocardial functionally and a shift from conduction toward simple working myocardium.</p><p>Molecular studies support a transformation from conduction to working myocardium in the <italic>Tbx3:Tbx5</italic> double VCS knockout. Previous studies investigating the roles of <italic>Tbx3</italic> and <italic>Tbx5</italic> in maintaining adult VCS identity demonstrated that <italic>Tbx3</italic> deletion resulted in the silencing of Pan-CCS gene expression in the atrioventricular conduction system (<xref ref-type="bibr" rid="bib63">van Duijvenboden et al., 2014</xref>; <xref ref-type="bibr" rid="bib7">Bakker et al., 2012</xref>; <xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>; <xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>; <xref ref-type="bibr" rid="bib44">Mohan et al., 2020</xref>). Alternately, specific deletion of <italic>Tbx5</italic> from the adult VCS led to the decreased expression of VCS-specific markers while Pan-CCS markers remained unchanged, indicating a transformation toward a nodal-like transcriptional phenotype in the absence of <italic>Tbx5</italic> (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>). Consistently, a similar transformation was induced by <italic>Tbx3</italic> overexpression in the adult VCS. These findings underscored the significance of the <italic>Tbx3:Tbx5</italic> ratio in preserving the molecular and functional characteristics of the fast versus slow conduction system. In <italic>Tbx3:Tbx5</italic> double VCS knockout, we observed a reduction in the expression of both fast VCS markers and Pan-CCS markers transcribed throughout the entire CCS. As expected, not all VCS markers were ablated in VCS-specific <italic>Tbx3:Tbx5</italic> mutants. A significant portion of VCS fast conduction markers are also transcribed in ventricular working myocardium, albeit at lower levels than in the VCS, and are crucial for normal working myocardial function, for example, <italic>Ryr2</italic>, <italic>Scn5a</italic>, and <italic>Kcnj2</italic> (<xref ref-type="bibr" rid="bib65">van Eif et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Schram et al., 2002</xref>; <xref ref-type="bibr" rid="bib55">Remme et al., 2009</xref>). Consistent with a shift from fast VCS to working myocardium, their expression levels are present, but at significantly lower levels in the double-knockout mutants than in normal VCS. Furthermore, the expression of markers specific for working myocardium, which are normally excluded in the VCS, emerged in the VCS of <italic>Tbx3:Tbx5</italic> double mutant. These observations are consistent with a transcriptional shift from VCS conduction cardiomyocytes to working myocardium-like characteristics in the absence of both <italic>Tbx3</italic> and <italic>Tbx5</italic>.</p><p>Our study highlights the critical role of <italic>Tbx3</italic> and <italic>Tbx5</italic> in maintaining the specialized electrical properties of the VCS. Comparative analysis of the phenotypes observed in single <italic>Tbx3</italic> or <italic>Tbx5</italic> knockouts and the <italic>Tbx3:Tbx5</italic> double-conditional knockout supports a coordinated function for these transcription factors in preserving VCS functionality. In a normal mammalian heart, electrical or optical recordings from the proximal part of the VCS typically display two distinct electrical excitations, reflected as two spikes in electrograms or two upstrokes in OAPs. These signals correspond to the sequential activation of the VCS, followed by ventricular excitation, a phenomenon well documented in both basic and clinical studies across species, including mice and humans. Previous whole-heart EP and optical mapping studies demonstrated that the single conditional knockout of <italic>Tbx5</italic> in the adult VCS caused significant ventricular conduction slowing (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>), accompanied by a phenotypic shift of VCS cells toward a pacemaker-like cell, evidenced by ectopic beats originating in the ventricles, retrograde activation, and inappropriate automaticity (<xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>). Whole-cell patch clamp recordings of <italic>Tbx5</italic>-deficient VCS cells further supported these findings, revealing action potential characteristics resembling pacemaker cells, including a slower upstroke (phase 0), prolonged plateau (phase 2), delayed repolarization (phase 3), and enhanced phase 4 depolarization (<xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>). In contrast, reduced expression of <italic>Tbx3</italic> in the <italic>Tbx3</italic> haploinsufficiency model resulted in AV bundle hypoplasia, PR interval shortening, and prolonged QRS duration (<xref ref-type="bibr" rid="bib44">Mohan et al., 2020</xref>). Optical mapping in these mice showed delayed apical activation with multiple small breakthroughs separated by regions of delayed activation. This fragmented activation pattern suggests that the reduced <italic>Tbx3</italic> expression impaired the homogeneity and efficiency of ventricular electrical impulse propagation due to AV bundle and bundle branch hypoplasia (<xref ref-type="bibr" rid="bib44">Mohan et al., 2020</xref>). In the <italic>Tbx3:Tbx5</italic> double-conditional knockout mice, we observed a complete loss of fast VCS conduction, similar to the phenotype of the <italic>Tbx5</italic> single conditional knockouts. However, unlike in the <italic>Tbx5</italic> single CKO, the VCS in <italic>Tbx3:Tbx5</italic> double mutants did not acquire pacemaker-like activity. Instead, optical mapping revealed a single upstroke in the His bundle region of <italic>Tbx3:Tbx5</italic> double-conditional knockout mice, indicating the absence of rapid AV bundle electrical impulse propagation. Functionally, this transformation resulted in significantly slowed ventricular activation, without the retrograde activation observed in the <italic>Tbx5</italic> single conditional knockouts or the rapid electrical impulse propagation typically associated with an intact VCS. The homogenous morphological and molecular transformation of His bundle and VCS cells in the <italic>Tbx3:Tbx5</italic> double-conditional knockout mice rendered the electrical properties of the VCS-located cells functionally indistinguishable from those of ventricular working myocardium. Our data, including gene expression analysis of the double mutant VCS, are most consistent with the transition of double mutant VCS cells toward a working myocardium phenotype.</p><p>These findings emphasize the interdependent roles of <italic>Tbx3</italic> and <italic>Tbx5</italic> in maintaining the specialized electrical properties and identity of the VCS, distinguishing it from non-specialized ventricular working myocardium (<xref ref-type="fig" rid="fig7">Figure 7</xref>). While <italic>Tbx5</italic> alone is critical for suppressing pacemaker-like characteristics and preserving fast conduction properties, <italic>Tbx3</italic> plays a pivotal role in ensuring the structural and functional integrity of the AV and BB conduction pathways. The simultaneous deletion of both <italic>Tbx3</italic> and <italic>Tbx5</italic> disrupts these regulatory mechanisms, leading to a loss of VCS identity and a functional shift toward a working myocardium phenotype. Our study combined with prior literature (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib63">van Duijvenboden et al., 2014</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>; <xref ref-type="bibr" rid="bib7">Bakker et al., 2012</xref>; <xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>; <xref ref-type="bibr" rid="bib44">Mohan et al., 2020</xref>; <xref ref-type="bibr" rid="bib64">van Eif et al., 2018</xref>) indicates that the concurrent presence of both <italic>Tbx3</italic> and <italic>Tbx5</italic> is necessary for maintaining VCS identity in the adult heart, ensuring efficient electrical conduction and preventing the transition of VCS cells into a working myocardium-like state (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Experimental animals</title><p>All animal experiments were performed under the University of Chicago Institutional Animal Care and Use Committee (IACUC) approved protocol (ACUP no. 71737) and in compliance with the USA Public Health Service Policy on Humane Care and Use of Laboratory Animals. <italic>MinK<sup>CreERT2</sup></italic> [Tg(RP23-276I20<italic>-MinKCreERT2</italic>)] and <italic>Tbx3<sup>fl/fl</sup></italic> mice have been reported previously (<xref ref-type="bibr" rid="bib4">Arnolds and Moskowitz, 2011b</xref>; <xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>).</p><p><italic>Tbx3:Tbx5</italic> double-floxed mouse line was generated by University of Utah Core Research Facility using CRISPR/Cas9. Guide RNA (sgRNA) constructs were designed with software tools (ZiFiT Targeter <xref ref-type="bibr" rid="bib57">Sander et al., 2010</xref> and crispr.genome-engineering.org) predicting unique target sites throughout the mouse genome (<xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplement 3â5</xref>). The sgRNA constructs were transcribed in vitro using MEGAshortscript T7 (Invitrogen AM1354) and mMessage Machine T7 transcription kit (Invitrogen AM1344) according to the manufacturerâs instructions. The strategy to generate mouse founders involved a single-step microinjection into one-cell <italic>Tbx3</italic> floxed zygotes (on a mixed background) with 10 ng/Âµl of each sgRNA (<italic>Tbx5</italic>-I2-S22 and <italic>Tbx5</italic>-I3-S31, <xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplements 3</xref>â<xref ref-type="fig" rid="fig1s5">5</xref>), 30 ng/Âµl of Cas9 protein, and 10 ng/Âµl of a long ssDNA donor. The donor contained two lox2272 sites in cis, spanning partial intron 2, entire exon 3, and partial intron 3 of the mouse <italic>Tbx5</italic> gene, along with 100/150 bp 5â²/3â² homology arms (<xref ref-type="fig" rid="fig1s4">Figure 1âfigure supplement 4</xref>). Founders were validated by PCR, restriction enzyme digestion, and Sanger sequencing (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1BâD</xref>). Founders were backcrossed with wild-type CD1 IGS mice (Charles River Lab, USA) to confirm germline transmission of the CRISPR/Cas9-generated compound <italic>Tbx3:Tbx5</italic> double-floxed allele and obtain the F1 generation. F1 mice were then interbred to establish a stable <italic>Tbx3:Tbx5</italic> double-floxed mouse line. Downstream experiments were performed on F4âF6 mice.</p><p>To simultaneously conditionally delete the <italic>Tbx3</italic> and <italic>Tbx5</italic> genes specifically from the adult VCS, we crossed our <italic>Tbx3:Tbx5</italic> double-floxed mouse line (<italic>Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup></italic>) with a VCS-specific tamoxifen (TM)-inducible <italic>Cre</italic> transgenic mouse line (<italic>MinK<sup>CreERT2</sup></italic> [Tg(RP23-276I20<italic>-MinKCreERT2</italic>); <xref ref-type="bibr" rid="bib4">Arnolds and Moskowitz, 2011b</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>]). All mice were maintained on a mixed genetic background. Tamoxifen (MP Biomedical) was administered at a dose of 0.167 mg/g body weight for 5 consecutive days by oral gavage at 6 weeks of age and then mice were evaluated at 9 weeks of age, as previously described (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib4">Arnolds and Moskowitz, 2011b</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>). Age-, gender-, and genetic strain-matched controls were used in all experiments to account for any variations in datasets across experiments. Mice were bred and housed in specific pathogen-free conditions in a 12-hr light/12-hr dark cycle and allowed ad libitum access to standard mouse chow and water. Mice requiring medical attention were provided with appropriate veterinary care by a licensed veterinarian and were excluded from the experiments described. No other exclusion criteria were applied.</p><p>All experiments and subsequent analysis were conducted in a blinded fashion, with animals randomly assigned to experimental groups. Following genotyping, mice were randomly allocated to the studies based on their genotypes. Subsequently, their identities were anonymized using a numerical code to ensure that all experiments and analyses were performed in a blinded manner. Both male and female animals have been used in our studies in the ratio of 41%/59%, based on availability of relatively rare compound genotypes, respectively.</p></sec><sec id="s4-2"><title>Validation of the newly generated Tbx5 floxed allele</title><p>The <italic>Tbx3:Tbx5</italic> double-floxed mouse line (<italic>Tbx3<sup>fl/fl</sup>:Tbx5<sup>fl/fl</sup></italic>) was engineered by generating a novel <italic>Tbx5</italic> floxed allele in the background of a previously published <italic>Tbx3</italic> floxed allele (<xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>). We utilized single <italic>Tbx3</italic> (<xref ref-type="bibr" rid="bib17">Frank et al., 2011</xref>) and the novel <italic>Tbx5</italic> floxed mouse lines (<italic>Tbx3<sup>fl/fl</sup></italic> and <italic>Tbx5<sup>fl/fl</sup></italic>, respectively) to serve as controls in our studies (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplements 1</xref> and <xref ref-type="fig" rid="fig1s2">2</xref>). Although the newly engineered <italic>Tbx5</italic> floxed allele was designed to mirror a previously published allele (<xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>), the location of the flox sites was altered slightly, requiring validation.</p><p>To verify the ability of the newly generated <italic>Tbx5</italic> floxed allele to recombine into the <italic>Tbx5</italic> KO (null) allele, we conducted three rounds of breeding and utilized a PCR assay to distinguish the recombined <italic>Tbx5</italic> KO (null) allele (<italic>Tbx5<sup>â</sup></italic>) from the unrecombined floxed allele (<italic>Tbx5<sup>fl</sup></italic>) (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2A, B</xref>). First, we bred newly generated homozygous <italic>Tbx5</italic> floxed males (<italic>Tbx5<sup>fl/fl</sup></italic>) with homozygous <italic>Mef2C<sup>Cre/Cre</sup></italic> females, which express <italic>Cre</italic> recombinase at the zygote stage (<xref ref-type="bibr" rid="bib26">Hoffmann et al., 2014</xref>; <xref ref-type="bibr" rid="bib72">Xie et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Verzi et al., 2005</xref>), to produce germline <italic>Tbx5<sup>+/â</sup>;Mef2<sup>Cre/+</sup></italic> double heterozygous mice. PCR analysis showed that 100% of the generated offspring were <italic>Tbx5<sup>+/â</sup>;Mef2C<sup>Cre/+</sup></italic> double heterozygous mice (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2B</xref>). This result confirmed complete recombination of the new <italic>Tbx5</italic> floxed allele into the <italic>Tbx5</italic> null allele in the presence of the <italic>Mef2C<sup>Cre</sup></italic> allele. Next, we backcrossed <italic>Tbx5<sup>+/â</sup>;Mef2C<sup>Cre/â</sup></italic> double heterozygote mice with wild-type CD1 IGS mice (Charles River Lab, USA) to obtain a germline <italic>Tbx5<sup>+/â</sup></italic> heterozygous mouse line (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2B</xref>). Subsequently, we bred <italic>Tbx5<sup>+/â</sup></italic> mice to generate germline <italic>Tbx5</italic> null mice (<italic>Tbx5<sup>â/â</sup></italic>). Among 230 offspring (generated in 50 litters), we observed 113 wild-type pups (<italic>Tbx5<sup>+/+</sup></italic>) and 116 <italic>Tbx5</italic> heterozygous pups (Tbx5<sup>+/â</sup>), but no null newborn pups (<italic>Tbx5<sup>â/â</sup></italic>) were obtained (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2B</xref>). These results align with previous breeding outcomes indicating complete embryonic lethality of <italic>Tbx5</italic> null mice (<xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>).</p><p>To further confirm the ability of the newly generated <italic>Tbx5</italic> floxed allele to produce germline <italic>Tbx5</italic> null embryos (<italic>Tbx5<sup>â/â</sup></italic>), we bred <italic>Tbx5</italic> heterozygous mice and collected embryos at E9âE10. Genotyping analysis of 89 collected embryos from 10 timed pregnancies revealed the presence of 24 wild-type (<italic>Tbx5<sup>+/+</sup></italic>), 42 heterozygous (<italic>Tbx5<sup>+/â</sup></italic>), and 22 null (<italic>Tbx5<sup>â/â</sup></italic>) embryos (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2C</xref>). Supported by Chi-square analysis, these results collectively verified that the newly generated <italic>Tbx5</italic> floxed allele could recombine to form the null allele, mimicking the embryonic lethality observed with the previously generated allele (<xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>).</p><p>To confirm that the newly engineered <italic>Tbx5</italic> conditional allele can generate VCS-specific <italic>Tbx5</italic>-deficient mice with the same phenotype as VCS-specific <italic>Tbx5</italic> knockout mice obtained from the previously generated allele (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Bruneau et al., 2001</xref>), we crossed the newly generated <italic>Tbx5</italic> floxed mouse line (<italic>Tbx5<sup>fl/fl</sup></italic>) with a VCS-specific tamoxifen-inducible Cre transgenic mouse line (<italic>MinK<sup>CreERT2</sup></italic> [Tg(RP23-276I20-<italic>MinKCreERT2</italic>)]) (<xref ref-type="bibr" rid="bib4">Arnolds and Moskowitz, 2011b</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). The same tamoxifen regimen was administered as in the previous study (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>). We confirmed VCS-specific genetic deletion of <italic>Tbx5</italic> via immunofluorescence (IF) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) and qPCR (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The resulting VCS-specific <italic>Tbx5</italic>-deficient mice exhibited slowed conduction, indicated by increased PR and QRS intervals (<xref ref-type="fig" rid="fig2">Figure 2A, and E vs. B</xref>), as well as episodes of VT resulting in sudden death (<xref ref-type="fig" rid="fig2">Figure 2G, H</xref>), consistent with the previously reported phenotype (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>). Additionally, we confirmed the absence of histological and structural abnormalities in these mice, aligning with previous findings (<xref ref-type="fig" rid="fig3">Figure 3A, F vs. B, and K vs. G</xref>, respectively) (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Burnicka-Turek et al., 2020</xref>).</p></sec><sec id="s4-3"><title>Echocardiography studies</title><p>Transthoracic echocardiography in mice was conducted under inhaled isoflurane anesthesia administered through a nose cone. Prior to imaging, chest hairs were removed using a topical depilatory agent. Limb leads were affixed for electrocardiogram gating, and animals were imaged in the left lateral decubitus position with a VisualSonics Vevo 770 machine using a 30-MHz high-frequency transducer. To ensure stability, body temperature was carefully maintained using a heated imaging platform and warming lamps. Two-dimensional images were meticulously recorded in parasternal long- and short-axis projections, accompanied by guided M-mode recordings at the midventricular level in both views. LV cavity size and percent FS were measured in at least three beats from each projection and averaged. M-mode measurements were employed to ascertain LV chamber dimensions and percent LV FS, calculated as ([LVIDd â LVIDs]/LVIDd), where LVIDd and LVIDs represent LV internal diameter in diastole and systole, respectively.</p></sec><sec id="s4-4"><title>Surface ECG</title><p>Nine weeks old, tamoxifen-treated control and mutant mice were anesthetized with a mixture of 2â3% isoflurane in 100% oxygen. Anesthetized mice were secured in a supine position on a regulated heat pad while lead I and lead II ECGs were recorded using platinum subdermal needle electrodes in a three-limb configuration. Core temperature was continuously monitored using a rectal probe and maintained at 36â37Â°C throughout the procedure. ECG data were collected and analyzed using Ponemah Physiology Platform (DSI) software and an ACQ-7700 acquisition interface unit (Gould Instruments, Valley View, OH, USA). Key parameters derived from the ECG measurements included: heart rate (HR), PR interval (from the beginning of the P wave to the beginning of the QRS complex), and QRS complex duration.</p></sec><sec id="s4-5"><title>Telemetry ECG analysis</title><p>Nine weeks old, tamoxifen-treated control and mutant mice were anesthetized with 2â3% isoflurane in 100% oxygen, and wireless telemetry transmitters (ETA-F10; DSI) were surgically implanted in the back with leads tunneled to the right upper and left lower thorax, as previously described (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib70">Wheeler et al., 2004</xref>). Following a 24-hr recovery period after surgical instrumentation, heart rate and PR and QRS intervals were calculated using Ponemah Physiology Platform (DSI) from 48-hr recordings.</p></sec><sec id="s4-6"><title>Catheter-based intracardiac EP</title><p>Detailed protocols for invasive EP studies have been previously described (<xref ref-type="bibr" rid="bib49">Nadadur et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Liu et al., 2008</xref>). Briefly, 9 weeks old, tamoxifen-treated control and mutant mice were anesthetized using 2â3% isoflurane in 100% oxygen. Then, a 1.1-Fr octapolar electrode catheter (EPR-800; Millar Instruments) was advanced via a right jugular venous cut-down to record right atrial, His bundle, and RV potentials, as well as to perform programmed electrical stimulation. Signals were identified through alignment with simultaneous surface ECG using subcutaneous needle electrodes in a lead II configuration. âNear-Fieldâ and âFar-Fieldâ signals were identified based on ECG alignment, signal deflection upstroke speed, and total signal duration. Standard tachycardia induction protocols included an eight-beat drive train with beats 80â120 ms apart (S1), followed by five beats (S2) at 50 ms apart (penta-extrastimulus, PES). Two attempts at this PES protocol were carried out. Mice also underwent single extrastimulus testing (SES) with eight beats 80â120 ms apart (S1) followed by a single S2 at 50 ms. This SES protocol was carried out five separate times per mouse. If these two protocols in the right atrium and RV (separately) failed to initiate their respective tachycardias, the study was deemed negative. S1 drive train intervals varied slightly due to the presence of the AV Wenckebach block at faster pacing rates in some mice; the S1 interval was lengthened to prevent this during the drive train.</p><p>Additional atrial and ventricular pacing protocols were carried out to obtain atrial, atrio-ventricular, and ventricular effective refractory periods (AERP, AVERP, and VERP) as well as sinus node recovery time, as described previously (<xref ref-type="bibr" rid="bib49">Nadadur et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Liu et al., 2008</xref>; <xref ref-type="bibr" rid="bib53">Patel et al., 2003</xref>; <xref ref-type="bibr" rid="bib19">Gehrmann and Berul, 2000</xref>). Effective refractory periods were measured using eight-beat S1 drive trains of 100 ms followed by SES.</p></sec><sec id="s4-7"><title>ECG and optical mapping</title><sec id="s4-7-1"><title>ECG acquisition and analysis</title><p>ECGs were recorded in conscious <italic>Tbx3:Tbx5</italic> double-conditional knockout mice and control littermates using the ecgTUNNEL device (emka Technologies) 2 weeks after tamoxifen treatment. Mice were positioned in the tunnel and ECGs were recorded for 5 min at a sampling rate of 1 kHz using lead I. ECGs were analyzed using a custom MATLAB program to measure P and QRS durations, as well as PR, QT, and RR intervals (<xref ref-type="bibr" rid="bib20">George et al., 2020</xref>; <xref ref-type="bibr" rid="bib69">Warhol et al., 2021</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1</xref>).</p></sec></sec><sec id="s4-8"><title>Langendorff perfusion</title><p><italic>Tbx3:Tbx5</italic> double-conditional knockout mice (<italic>n</italic> = 8) and control littermates (<italic>n</italic> = 10) were deeply anesthetized with isoflurane. The heart was quickly excised following cervical dislocation and thoracotomy. The aorta was cannulated, and the heart was retrogradely perfused with warmed (37Â°C) and oxygenated (95% O<sub>2</sub> and 5% CO<sub>2</sub>) modified Tyrodeâs solution (in mM, NaCl 130, NaHCO<sub>3</sub> 24, NaH<sub>2</sub>PO<sub>4</sub> 1.2, MgCl<sub>2</sub> 1, glucose 5.6, KCl 4, and CaCl<sub>2</sub> 1.8) at a pH of 7.4. The heart was placed in a constant-flow (1.0â2.0 ml/min) Langendorff perfusion system, laying horizontally in a tissue bath.</p></sec><sec id="s4-9"><title>Ventricular optical mapping</title><p>The Langendorff perfused heart was electromechanically uncoupled by 15 Î¼M of blebbistatin (Cayman Chemicals 13186) perfusion. A voltage-sensitive fluorescent dye, 80 ÂµM di-4-ANEPPs (Thermo Fisher Scientific D1199), was administered through the dye injection port. The heart was illuminated using a 520 Â± 5 nm (Prizmatix, UHP-Mic-LED-520) wavelength light source to excite di-4-ANEPPs. Emitted photons were captured using complementary metalâoxide semiconductor cameras (MiCAM, SciMedia).</p><p>The stimulation threshold, where the heart would capture the stimuli and action potential 1:1, was determined using a point source platinum electrode placed on the anterior surface of the heart on the anterior epicardial surface of the ventricles. Pacing was applied at 1.5Ã the threshold amplitude to maintain 1:1 capture over the duration of the experiment. Optical recordings were analyzed using Rhythm 1.2 to analyze transmembrane potential (<xref ref-type="bibr" rid="bib14">Cathey et al., 2019</xref>). Action potential duration at 50% and 80% repolarization was calculated for the ventricles of the intact whole heart preparation.</p></sec><sec id="s4-10"><title>Right septal preparation optical mapping experiments</title><p>Following intact whole heart ex vivo optical mapping, the heart was removed from the tissue bath for the dissection of the RV free wall to expose the RV septal surface (<xref ref-type="bibr" rid="bib61">Tamaddon et al., 2000</xref>). The heart was quickly returned to the tissue bath and the RV septal surface was focused into the field of view. Sinus rhythm optical recordings were acquired.</p><p>A custom MATLAB program was written to plot individual pixels in a 100 Ã 100 pixel image stack. A Butterworth filter of order 5 was applied to provide temporal filtering (<xref ref-type="bibr" rid="bib33">Laughner et al., 2012</xref>). The location of the His bundle was identified as the region at the base of the interventricular septum (a red 10 Ã 10 pixel area in <xref ref-type="fig" rid="fig5">Figure 5B</xref>). Signals from the working ventricular myocardium were recorded from the 10x10 pixel region plotted in the working ventricular myocardium distal to the His bundle (<xref ref-type="fig" rid="fig6">Figure 6B</xref>).</p></sec><sec id="s4-11"><title>Isolation of adult VCS cardiomyocytes and cell sorting</title><p>Adult mouse EYFP-positive VCS cardiomyocytes were isolated using the method described by <xref ref-type="bibr" rid="bib43">Mitra and Morad, 1985</xref>. Briefly, 9 weeks old tamoxifen-treated control and <italic>Tbx3:Tbx5</italic> double-conditional mutant mice were heparinized (100 units IP) and anesthetized with pentobarbital (50 mg/kg of body weight). Hearts were excised and mounted on a Langendorff apparatus, then perfused with Ca<sup>2+</sup>-free Tyrodeâs solution with collagenase B and D (Roche Chemical Co) plus protease (Fraction IV, Sigma Chemical Co). When the hearts appeared pale and flaccid, they were removed from the Langendorff apparatus and a tip of ventricular septum below the AV annulus was microdissected out (<xref ref-type="bibr" rid="bib5">Arnolds et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Park and Fishman, 2011</xref>; <xref ref-type="bibr" rid="bib60">Silverman et al., 2006</xref>) and kept in Ca<sup>2+</sup>-free Tyrodeâs solution with 1 mg/ml of bovine serum albumin (Fraction XIV, Sigma Chemical Co). The intraventricular sections were then minced into small pieces ~1 Ã 1 Ã 1 mm and then gently triturated with a Pasteur pipette to dissociate individual VCS myocytes. Propidium iodide (Thermo Fisher Scientific) was added immediately before FACS to facilitate live/dead discrimination. Cells were sorted on a FacsAria flow cytometer (BD Biosciences) located at the University of Chicago Flow Cytometry Core using Influx software. Samples from wild-type age-matched hearts were used for gating. Samples were gated to exclude debris and cell clumps. Fluorescent cells were collected into ice-cold RNase-free PBS and processed for RNA extraction and protein isolation.</p></sec><sec id="s4-12"><title>RNA isolation and qRT-PCR</title><p>Total RNA was isolated from EYFP-positive VCS cardiomyocytes sorted from 9-week-old control and VCS-specific <italic>Tbx3:Tbx5</italic>-deficient mice, which had received tamoxifen at 6 weeks of age. RNA was also extracted from atrial and ventricular tissues dissected from the same mice. All RNA extractions were performed using RNeasy Mini Kit (QIAGEN), followed by DNase treatment according to the manufacturerâs instructions.</p><p>Reverse transcription reaction was carried out using the SuperScript III First-Strand Synthesis SuperMix for quantitative RT-PCR (Invitrogen) as per the manufacturerâs recommendations. qRT-PCR was performed using the POWER SYBR Green PCR master mix from Applied Biosystems and run on an Applied Biosystems AB7500 machine in 96-well plates. The relative gene expression level was calculated by the ÎÎCt method (<xref ref-type="bibr" rid="bib38">Livak and Schmittgen, 2001</xref>) using glyceraldehyde-3-phosphate dehydrogenase (<italic>Gapdh</italic>) gene expression level as internal control. The data presented are the average of three independent experiments.</p></sec><sec id="s4-13"><title>Protein isolation and western blotting</title><p>Total protein was isolated from EYFP-positive VCS cardiomyocytes sorted from 9-week-old control and VCS-specific <italic>Tbx3:Tbx5</italic>-deficient mice that had been administered tamoxifen at 6 weeks of age. Protein was also obtained from atrial and ventricular tissues dissected from the same animals. The tissues were snap-frozen in liquid nitrogen, pulverized, and homogenized in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% Triton-X, 0.5% sodium deoxycholate, 0.1% SDS, 5 mM EDTA) with 1 Roche EDTA-Free complete protease inhibitor tablet per 50 ml of buffer. Samples were tumbled for 1 hr at 4Â°C and then centrifuged for 10 min at 13,200 Ã <italic>g</italic>. Protein concentration was determined using the BCA assay (Pierce) with BSA as a standard.</p><p>For Western blot analysis, 25 Âµg of protein was diluted in Laemmli buffer, heated at 70Â°C for 10 min, and subjected to SDSâPAGE on 4â20% TGX gels (Bio-Rad). Proteins were then transferred to nitrocellulose membranes, blocked with 5% milk in TBS-T, and incubated overnight at 4Â°C with primary antibodies diluted in 2.5% milk in TBS-T. The primary antibodies used were: goat polyclonal anti-TBX3 (Santa Cruz Biotechnology, sc-31656, 1:250), rabbit polyclonal anti-HCN4 (Millipore, AB5808, 1:500), rabbit polyclonal anti-CAV1.3/CACNA1D (Alomone, ACC-005, 1:200), rabbit polyclonal anti-Cx45/GJC1 (Thermo Fisher Scientific, PA5-77357, 1:250), sheep polyclonal anti-TBX5 (R&amp;D, AF5918, 1:200), rabbit polyclonal anti-CX40/GJA5 (Zymed/Invitrogen, 36-4900, 1:500), rabbit polyclonal anti-NAV1.5/SCN5A (Alomone, ASC-005, 1:200), mouse monoclonal anti-KCNK3/TASK1 (Abcam, ab186352, 1:1000), rabbit polyclonal anti-CX43/GJA1 (Cell Signaling Technology, 3512, 1:1000), and mouse monoclonal anti-GAPDH (Abcam, ab8245, 1:1000). After rinsing in TBS-T, membranes were incubated for 1 hr at room temperature (RT) with secondary antibodies diluted in 2.5% milk in TBS-T, rinsed again, and visualized using enhanced chemiluminescence reagents (Pierce ECL/ECL Plus, Thermo Fisher Scientific) and Kodak X-OMAT film. Results were normalized to GAPDH loading control and then quantified using ImageJ software (<xref ref-type="bibr" rid="bib54">Rasband, 1997</xref>; <xref ref-type="bibr" rid="bib70">Wheeler et al., 2004</xref>). Secondary antibodies used were donkey anti-goat IgG AlexaFluor-594 (Invitrogen, A-11058, 1:250 dilution) and donkey anti-goat IgG AlexaFluor-488 (Invitrogen, A-11055, 1:250 dilution) for experiments involving co-staining for goat primary antibodies. Secondary antibodies were as follows: rabbit anti-goat-HRP (Jackson ImmunoResearch, 305-035-003, 1:10,000), goat anti-rabbit-HRP (Jackson ImmunoResearch, 111-035-144, 1:3000), donkey anti-sheep-HRP (Abcam, ab6900, 1:5000), and sheep anti-mouse-HRP (Amersham GE, NA931, 1:2500).</p></sec><sec id="s4-14"><title>Histology</title><p>Hearts from 9-week-old control and mutant mice were carefully dissected, flushed with ice-cold PBS, and then fixed for 48 hr at 4Â°C in a 4% paraformaldehyde solution (Sigma-Aldrich). Following fixation, the hearts were processed for paraffin-embedded sections and subjected to analysis through H&amp;E staining, following the manufacturerâs protocol provided by Sigma-Aldrich.</p></sec><sec id="s4-15"><title>Immunofluorescence</title><p>Hearts from 9-week-old control and mutant mice were dissected out and placed in ice-cold PBS, followed by freezing in OCT (Fisher) within the gas phase of liquid nitrogen. Cryosections of 7 Î¼m thickness were mounted onto Superfrost Plus glass slides (Fisher Scientific), air-dried, and fixed for 10 min in ice-cold 4% paraformaldehyde (Sigma-Aldrich). Subsequently, sections were permeabilized in 1% Triton-X100 (Sigma-Aldrich) in PBS for 10 min, then blocked in 10% normal goat serum (Invitrogen) in PBS-T (PBS + 0.1% Tween-20) for 30 min at RT. Sections were then incubated overnight at 4Â°C in primary antibody diluted in blocking buffer, rinsed in PBS, then subsequently incubated for 60 min at RT in secondary antibody diluted in blocking buffer. Slides were mounted in VectaShield + DAPI (Vector Laboratories) or counterstained with DAPI and mounted in ProLog Gold (Invitrogen) prior to visualizing fluorescence. Primary antibodies were as follows: goat polyclonal anti-TBX3 (Santa Cruz, sc-31656, 1:250 dilution) and goat polyclonal anti-TBX5 (Santa Cruz, sc-17866, 1:250 dilution). Secondary antibodies used were donkey anti-goat IgG AlexaFluor-594 (Invitrogen, A-11058, 1:250 dilution) and donkey anti-goat IgG AlexaFluor-488 (Invitrogen, A-11055, 1:250 dilution) for experiments involving co-staining for goat primary antibodies. A secondary antibody-only control was employed in each case to ensure the specificity of immunostaining.</p></sec><sec id="s4-16"><title>Statistics</title><p>The numbers of independent experiments are specified in the relevant figure legends. Quantitative data are presented as mean Â± SD. Statistical analysis was performed using R version 3.6.2 or the GraphPad Prism statistical package version 10.2.1 (GraphPad Software, Boston, MA, USA). For all datasets, except qRT-PCR data, normality was assessed using the ShapiroâWilk normality test. If the data followed a normal distribution, the two-sample Welch <italic>t</italic>-test was performed for comparison. If normal distribution was not present, the non-parametric MannâWhitney <italic>U</italic> test or KruskalâWallis <italic>H</italic> test was used, as indicated in the text. Statistical significance was assumed if p reached a value â¤0.05.</p><p>For qRT-PCR data, statistical analysis was performed using R version 4.2.0. Normality within each experimental group was assessed using the ShapiroâWilk test. Between-group comparisons were conducted using Welch <italic>t</italic>-test, and multiple comparisons were corrected using the Benjamini and Hochberg method to control the false discovery rate (FDR) (<xref ref-type="bibr" rid="bib11">Benjamini and Hochberg, 1995</xref>). If a significant difference was detected between two groups (<italic>t</italic>-test FDR &lt;0.05) but normality was rejected in any of the compared groups (ShapiroâWilk p &lt; 0.05), a non-parametric Wilcoxon rank-sum test was used for verification. A significant group-mean difference was confirmed at one-tailed Wilcoxon p â¤ 0.05 (<xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing â original draft, Project administration, Writing â review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing â original draft, Writing â review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con4"><p>Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Visualization, Writing â review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Validation, Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Data curation, Investigation, Visualization</p></fn><fn fn-type="con" id="con10"><p>Data curation, Validation, Investigation</p></fn><fn fn-type="con" id="con11"><p>Data curation, Validation, Investigation</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Methodology, Writing â original draft, Project administration, Writing â review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing â original draft, Project administration, Writing â review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments were performed under the University of Chicago Institutional Animal Care and Use Committee (IACUC) approved protocol (ACUP no. 71737) and in compliance with the USA Public Health Service Policy on Humane Care and Use of Laboratory Animals.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Expanded statistical analysis of the qRT-PCR data presented in <xref ref-type="fig" rid="fig1">Figures 1C</xref>, <xref ref-type="fig" rid="fig3">3L</xref> and <xref ref-type="fig" rid="fig4">4AâC</xref>.</title><p>Statistical analyses were performed in R (v4.2.0). Normality for each experimental group was assessed using the Shapiro-Wilk test. Group comparisons were conducted using Welchâs t-test, with multiple testing correction by the Benjamini &amp; Hochberg method to control the false discovery rate (FDR) (74). If FDR &lt; 0.05 but normality was rejected (Shapiro-Wilk P &lt; 0.05), significance was confirmed using a one-tailed Wilcoxon rank-sum test (P â¤ 0.05).</p></caption><media xlink:href="elife-102027-data1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-102027-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated and analyzed during this study are included in the main manuscript and its supplementary materials. The source data for statistical analyses are provided in Source Data 1. Uncropped gels and blots have been supplied for Figure 1-figure supplements 1 and 2, as well as for Figure 4. No additional data are required to interpret the findings.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by National Institutes of Health (R01 HL163523 and R01 HL148719 to IP Moskowitz), Leducq Foundation Grant Bioelectronics for Neuroradiology â Diagnosis &amp; Therapeutics (to IR Efimov), and American Heart Association (13POST17290028 to O Burnicka-Turek).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackerman</surname><given-names>JE</given-names></name><name><surname>Muscat</surname><given-names>SN</given-names></name><name><surname>Adjei-Sowah</surname><given-names>E</given-names></name><name><surname>Korcari</surname><given-names>A</given-names></name><name><surname>Nichols</surname><given-names>AEC</given-names></name><name><surname>Buckley</surname><given-names>MR</given-names></name><name><surname>Loiselle</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Identification of Periostin as a critical niche for myofibroblast dynamics and fibrosis during tendon healing</article-title><source>Matrix Biology</source><volume>125</volume><fpage>59</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2023.12.004</pub-id><pub-id pub-id-type="pmid">38101460</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AlcolÃ©a</surname><given-names>S</given-names></name><name><surname>ThÃ©veniau-Ruissy</surname><given-names>M</given-names></name><name><surname>Jarry-Guichard</surname><given-names>T</given-names></name><name><surname>Marics</surname><given-names>I</given-names></name><name><surname>Tzouanacou</surname><given-names>E</given-names></name><name><surname>Chauvin</surname><given-names>JP</given-names></name><name><surname>Briand</surname><given-names>JP</given-names></name><name><surname>Moorman</surname><given-names>AF</given-names></name><name><surname>Lamers</surname><given-names>WH</given-names></name><name><surname>Gros</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Downregulation of connexin 45 gene products during mouse heart development</article-title><source>Circulation Research</source><volume>84</volume><fpage>1365</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1161/01.res.84.12.1365</pub-id><pub-id pub-id-type="pmid">10381888</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnolds</surname><given-names>DE</given-names></name><name><surname>Chu</surname><given-names>A</given-names></name><name><surname>McNally</surname><given-names>EM</given-names></name><name><surname>Nobrega</surname><given-names>MA</given-names></name><name><surname>Moskowitz</surname><given-names>IP</given-names></name></person-group><year iso-8601-date="2011">2011a</year><article-title>The emerging genetic landscape underlying cardiac conduction system function</article-title><source>Birth Defects Research. Part A, Clinical and Molecular Teratology</source><volume>91</volume><fpage>578</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1002/bdra.20800</pub-id><pub-id pub-id-type="pmid">21538814</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnolds</surname><given-names>DE</given-names></name><name><surname>Moskowitz</surname><given-names>IP</given-names></name></person-group><year iso-8601-date="2011">2011b</year><article-title>Inducible recombination in the cardiac conduction system of minK: CreERT</article-title><source>Genesis</source><volume>49</volume><fpage>878</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1002/dvg.20759</pub-id><pub-id pub-id-type="pmid">21504046</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnolds</surname><given-names>DE</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Fahrenbach</surname><given-names>JP</given-names></name><name><surname>Kim</surname><given-names>GH</given-names></name><name><surname>Schillinger</surname><given-names>KJ</given-names></name><name><surname>Smemo</surname><given-names>S</given-names></name><name><surname>McNally</surname><given-names>EM</given-names></name><name><surname>Nobrega</surname><given-names>MA</given-names></name><name><surname>Patel</surname><given-names>VV</given-names></name><name><surname>Moskowitz</surname><given-names>IP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TBX5 drives Scn5a expression to regulate cardiac conduction system function</article-title><source>The Journal of Clinical Investigation</source><volume>122</volume><fpage>2509</fpage><lpage>2518</lpage><pub-id pub-id-type="doi">10.1172/JCI62617</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakker</surname><given-names>ML</given-names></name><name><surname>Boukens</surname><given-names>BJ</given-names></name><name><surname>Mommersteeg</surname><given-names>MTM</given-names></name><name><surname>Brons</surname><given-names>JF</given-names></name><name><surname>Wakker</surname><given-names>V</given-names></name><name><surname>Moorman</surname><given-names>AFM</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transcription factor Tbx3 is required for the specification of the atrioventricular conduction system</article-title><source>Circulation Research</source><volume>102</volume><fpage>1340</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.169565</pub-id><pub-id pub-id-type="pmid">18467625</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakker</surname><given-names>ML</given-names></name><name><surname>Boink</surname><given-names>GJJ</given-names></name><name><surname>Boukens</surname><given-names>BJ</given-names></name><name><surname>Verkerk</surname><given-names>AO</given-names></name><name><surname>van den Boogaard</surname><given-names>M</given-names></name><name><surname>den Haan</surname><given-names>AD</given-names></name><name><surname>Hoogaars</surname><given-names>WMH</given-names></name><name><surname>Buermans</surname><given-names>HP</given-names></name><name><surname>de Bakker</surname><given-names>JMT</given-names></name><name><surname>Seppen</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>HL</given-names></name><name><surname>Moorman</surname><given-names>AFM</given-names></name><name><surname>ât Hoen</surname><given-names>PAC</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>T-box transcription factor TBX3 reprogrammes mature cardiac myocytes into pacemaker-like cells</article-title><source>Cardiovascular Research</source><volume>94</volume><fpage>439</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvs120</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamshad</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>RC</given-names></name><name><surname>Law</surname><given-names>DJ</given-names></name><name><surname>Watkins</surname><given-names>WC</given-names></name><name><surname>Krakowiak</surname><given-names>PA</given-names></name><name><surname>Moore</surname><given-names>ME</given-names></name><name><surname>Franceschini</surname><given-names>P</given-names></name><name><surname>Lala</surname><given-names>R</given-names></name><name><surname>Holmes</surname><given-names>LB</given-names></name><name><surname>Gebuhr</surname><given-names>TC</given-names></name><name><surname>Bruneau</surname><given-names>BG</given-names></name><name><surname>Schinzel</surname><given-names>A</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Jorde</surname><given-names>LB</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome</article-title><source>Nature Genetics</source><volume>16</volume><fpage>311</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1038/ng0797-311</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basson</surname><given-names>CT</given-names></name><name><surname>Cowley</surname><given-names>GS</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Weissman</surname><given-names>B</given-names></name><name><surname>Poznanski</surname><given-names>AK</given-names></name><name><surname>Traill</surname><given-names>TA</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome)</article-title><source>The New England Journal of Medicine</source><volume>330</volume><fpage>885</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1056/NEJM199403313301302</pub-id><pub-id pub-id-type="pmid">8114858</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basson</surname><given-names>CT</given-names></name><name><surname>Bachinsky</surname><given-names>DR</given-names></name><name><surname>Lin</surname><given-names>RC</given-names></name><name><surname>Levi</surname><given-names>T</given-names></name><name><surname>Elkins</surname><given-names>JA</given-names></name><name><surname>Soults</surname><given-names>J</given-names></name><name><surname>Grayzel</surname><given-names>D</given-names></name><name><surname>Kroumpouzou</surname><given-names>E</given-names></name><name><surname>Traill</surname><given-names>TA</given-names></name><name><surname>Leblanc-Straceski</surname><given-names>J</given-names></name><name><surname>Renault</surname><given-names>B</given-names></name><name><surname>Kucherlapati</surname><given-names>R</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome</article-title><source>Nature Genetics</source><volume>15</volume><fpage>30</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/ng0197-30</pub-id><pub-id pub-id-type="pmid">8988165</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title><source>Journal of the Royal Statistical Society Series B</source><volume>57</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruneau</surname><given-names>BG</given-names></name><name><surname>Nemer</surname><given-names>G</given-names></name><name><surname>Schmitt</surname><given-names>JP</given-names></name><name><surname>Charron</surname><given-names>F</given-names></name><name><surname>Robitaille</surname><given-names>L</given-names></name><name><surname>Caron</surname><given-names>S</given-names></name><name><surname>Conner</surname><given-names>DA</given-names></name><name><surname>Gessler</surname><given-names>M</given-names></name><name><surname>Nemer</surname><given-names>M</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease</article-title><source>Cell</source><volume>106</volume><fpage>709</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(01)00493-7</pub-id><pub-id pub-id-type="pmid">11572777</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnicka-Turek</surname><given-names>O</given-names></name><name><surname>Broman</surname><given-names>MT</given-names></name><name><surname>Steimle</surname><given-names>JD</given-names></name><name><surname>Boukens</surname><given-names>BJ</given-names></name><name><surname>Petrenko</surname><given-names>NB</given-names></name><name><surname>Ikegami</surname><given-names>K</given-names></name><name><surname>Nadadur</surname><given-names>RD</given-names></name><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Arnolds</surname><given-names>DE</given-names></name><name><surname>Yang</surname><given-names>XH</given-names></name><name><surname>Patel</surname><given-names>VV</given-names></name><name><surname>Nobrega</surname><given-names>MA</given-names></name><name><surname>Efimov</surname><given-names>IR</given-names></name><name><surname>Moskowitz</surname><given-names>IP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptional patterning of the ventricular cardiac conduction system</article-title><source>Circulation Research</source><volume>127</volume><fpage>e94</fpage><lpage>e106</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.314460</pub-id><pub-id pub-id-type="pmid">32290757</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cathey</surname><given-names>B</given-names></name><name><surname>Obaid</surname><given-names>S</given-names></name><name><surname>Zolotarev</surname><given-names>AM</given-names></name><name><surname>Pryamonosov</surname><given-names>RA</given-names></name><name><surname>Syunyaev</surname><given-names>RA</given-names></name><name><surname>George</surname><given-names>SA</given-names></name><name><surname>Efimov</surname><given-names>IR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Open-Source Multiparametric Optocardiography</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>721</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-36809-y</pub-id><pub-id pub-id-type="pmid">30679527</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donner</surname><given-names>BC</given-names></name><name><surname>Schullenberg</surname><given-names>M</given-names></name><name><surname>Geduldig</surname><given-names>N</given-names></name><name><surname>HÃ¼ning</surname><given-names>A</given-names></name><name><surname>Mersmann</surname><given-names>J</given-names></name><name><surname>Zacharowski</surname><given-names>K</given-names></name><name><surname>Kovacevic</surname><given-names>A</given-names></name><name><surname>Decking</surname><given-names>U</given-names></name><name><surname>Aller</surname><given-names>MI</given-names></name><name><surname>Schmidt</surname><given-names>KG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Functional role of TASK-1 in the heart: studies in TASK-1-deficient mice show prolonged cardiac repolarization and reduced heart rate variability</article-title><source>Basic Research in Cardiology</source><volume>106</volume><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1007/s00395-010-0128-x</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dow</surname><given-names>LE</given-names></name><name><surname>Fisher</surname><given-names>J</given-names></name><name><surname>OâRourke</surname><given-names>KP</given-names></name><name><surname>Muley</surname><given-names>A</given-names></name><name><surname>Kastenhuber</surname><given-names>ER</given-names></name><name><surname>Livshits</surname><given-names>G</given-names></name><name><surname>Tschaharganeh</surname><given-names>DF</given-names></name><name><surname>Socci</surname><given-names>ND</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inducible in vivo genome editing with CRISPR-Cas9</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>390</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1038/nbt.3155</pub-id><pub-id pub-id-type="pmid">25690852</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>DU</given-names></name><name><surname>Carter</surname><given-names>KL</given-names></name><name><surname>Thomas</surname><given-names>KR</given-names></name><name><surname>Burr</surname><given-names>RM</given-names></name><name><surname>Bakker</surname><given-names>ML</given-names></name><name><surname>Coetzee</surname><given-names>WA</given-names></name><name><surname>Tristani-Firouzi</surname><given-names>M</given-names></name><name><surname>Bamshad</surname><given-names>MJ</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name><name><surname>Moon</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Lethal arrhythmias in Tbx3-deficient mice reveal extreme dosage sensitivity of cardiac conduction system function and homeostasis</article-title><source>PNAS</source><volume>109</volume><fpage>154</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1073/pnas.1115165109</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Frigola</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Evans</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Expression of the hyperpolarization-activated cyclic nucleotide-gated cation channel HCN4 during mouse heart development</article-title><source>Gene Expression Patterns</source><volume>3</volume><fpage>777</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1016/s1567-133x(03)00125-x</pub-id><pub-id pub-id-type="pmid">14643687</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gehrmann</surname><given-names>J</given-names></name><name><surname>Berul</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cardiac electrophysiology in genetically engineered mice</article-title><source>Journal of Cardiovascular Electrophysiology</source><volume>11</volume><fpage>354</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8167.2000.tb01806.x</pub-id><pub-id pub-id-type="pmid">10749360</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>SA</given-names></name><name><surname>Kiss</surname><given-names>A</given-names></name><name><surname>Obaid</surname><given-names>SN</given-names></name><name><surname>Venegas</surname><given-names>A</given-names></name><name><surname>Talapatra</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>C</given-names></name><name><surname>Efimova</surname><given-names>T</given-names></name><name><surname>Efimov</surname><given-names>IR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>p38Î´ genetic ablation protects female mice from anthracycline cardiotoxicity</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>319</volume><fpage>H775</fpage><lpage>H786</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00415.2020</pub-id><pub-id pub-id-type="pmid">32822209</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Willis</surname><given-names>S</given-names></name><name><surname>Creazzo</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Expression of a two-pore domain K+ channel (TASK-1) in developing avian and mouse ventricular conduction systems</article-title><source>Developmental Dynamics</source><volume>235</volume><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1002/dvdy.20558</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greener</surname><given-names>ID</given-names></name><name><surname>Monfredi</surname><given-names>O</given-names></name><name><surname>Inada</surname><given-names>S</given-names></name><name><surname>Chandler</surname><given-names>NJ</given-names></name><name><surname>Tellez</surname><given-names>JO</given-names></name><name><surname>Atkinson</surname><given-names>A</given-names></name><name><surname>Taube</surname><given-names>M-A</given-names></name><name><surname>Billeter</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>RH</given-names></name><name><surname>Efimov</surname><given-names>IR</given-names></name><name><surname>Molenaar</surname><given-names>P</given-names></name><name><surname>Sigg</surname><given-names>DC</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Boyett</surname><given-names>MR</given-names></name><name><surname>Dobrzynski</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular architecture of the human specialised atrioventricular conduction axis</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>50</volume><fpage>642</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2010.12.017</pub-id><pub-id pub-id-type="pmid">21256850</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurumurthy</surname><given-names>CB</given-names></name><name><surname>OâBrien</surname><given-names>AR</given-names></name><name><surname>Quadros</surname><given-names>RM</given-names></name><name><surname>Adams</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Alcaide</surname><given-names>P</given-names></name><name><surname>Ayabe</surname><given-names>S</given-names></name><name><surname>Ballard</surname><given-names>J</given-names></name><name><surname>Batra</surname><given-names>SK</given-names></name><name><surname>Beauchamp</surname><given-names>M-C</given-names></name><name><surname>Becker</surname><given-names>KA</given-names></name><name><surname>Bernas</surname><given-names>G</given-names></name><name><surname>Brough</surname><given-names>D</given-names></name><name><surname>Carrillo-Salinas</surname><given-names>F</given-names></name><name><surname>Chan</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Dawson</surname><given-names>R</given-names></name><name><surname>DeMambro</surname><given-names>V</given-names></name><name><surname>DâHont</surname><given-names>J</given-names></name><name><surname>Dibb</surname><given-names>K</given-names></name><name><surname>Eudy</surname><given-names>JD</given-names></name><name><surname>Gan</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Gonzales</surname><given-names>A</given-names></name><name><surname>Guntur</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Harms</surname><given-names>DW</given-names></name><name><surname>Harrington</surname><given-names>A</given-names></name><name><surname>Hentges</surname><given-names>KE</given-names></name><name><surname>Humphreys</surname><given-names>N</given-names></name><name><surname>Imai</surname><given-names>S</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Iwama</surname><given-names>M</given-names></name><name><surname>Jonasch</surname><given-names>E</given-names></name><name><surname>Karolak</surname><given-names>M</given-names></name><name><surname>Keavney</surname><given-names>B</given-names></name><name><surname>Khin</surname><given-names>N-C</given-names></name><name><surname>Konno</surname><given-names>M</given-names></name><name><surname>Kotani</surname><given-names>Y</given-names></name><name><surname>Kunihiro</surname><given-names>Y</given-names></name><name><surname>Lakshmanan</surname><given-names>I</given-names></name><name><surname>Larochelle</surname><given-names>C</given-names></name><name><surname>Lawrence</surname><given-names>CB</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lindner</surname><given-names>V</given-names></name><name><surname>Liu</surname><given-names>X-D</given-names></name><name><surname>Lopez-Castejon</surname><given-names>G</given-names></name><name><surname>Loudon</surname><given-names>A</given-names></name><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Jerome-Majeweska</surname><given-names>L</given-names></name><name><surname>Matsusaka</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>H</given-names></name><name><surname>Miyasaka</surname><given-names>Y</given-names></name><name><surname>Morpurgo</surname><given-names>B</given-names></name><name><surname>Motyl</surname><given-names>K</given-names></name><name><surname>Nabeshima</surname><given-names>Y-I</given-names></name><name><surname>Nakade</surname><given-names>K</given-names></name><name><surname>Nakashiba</surname><given-names>T</given-names></name><name><surname>Nakashima</surname><given-names>K</given-names></name><name><surname>Obata</surname><given-names>Y</given-names></name><name><surname>Ogiwara</surname><given-names>S</given-names></name><name><surname>Ouellet</surname><given-names>M</given-names></name><name><surname>Oxburgh</surname><given-names>L</given-names></name><name><surname>Piltz</surname><given-names>S</given-names></name><name><surname>Pinz</surname><given-names>I</given-names></name><name><surname>Ponnusamy</surname><given-names>MP</given-names></name><name><surname>Ray</surname><given-names>D</given-names></name><name><surname>Redder</surname><given-names>RJ</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><name><surname>Ross</surname><given-names>N</given-names></name><name><surname>Ruhe</surname><given-names>MT</given-names></name><name><surname>Ryzhova</surname><given-names>L</given-names></name><name><surname>Salvador</surname><given-names>AM</given-names></name><name><surname>Alam</surname><given-names>SS</given-names></name><name><surname>Sedlacek</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Staes</surname><given-names>K</given-names></name><name><surname>Starrs</surname><given-names>L</given-names></name><name><surname>Sugiyama</surname><given-names>F</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Trafford</surname><given-names>A</given-names></name><name><surname>Uno</surname><given-names>Y</given-names></name><name><surname>Vanhoutte</surname><given-names>L</given-names></name><name><surname>Vanrockeghem</surname><given-names>F</given-names></name><name><surname>Willis</surname><given-names>BJ</given-names></name><name><surname>Wright</surname><given-names>CS</given-names></name><name><surname>Yamauchi</surname><given-names>Y</given-names></name><name><surname>Yi</surname><given-names>X</given-names></name><name><surname>Yoshimi</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ohtsuka</surname><given-names>M</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Garry</surname><given-names>DJ</given-names></name><name><surname>Hochepied</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Parker-Thornburg</surname><given-names>J</given-names></name><name><surname>Adamson</surname><given-names>AD</given-names></name><name><surname>Yoshiki</surname><given-names>A</given-names></name><name><surname>Schmouth</surname><given-names>J-F</given-names></name><name><surname>Golovko</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>WR</given-names></name><name><surname>Lloyd</surname><given-names>KCK</given-names></name><name><surname>Wood</surname><given-names>JA</given-names></name><name><surname>Cowan</surname><given-names>M</given-names></name><name><surname>Mashimo</surname><given-names>T</given-names></name><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Kasparek</surname><given-names>P</given-names></name><name><surname>Liaw</surname><given-names>L</given-names></name><name><surname>Miano</surname><given-names>JM</given-names></name><name><surname>Burgio</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Response to correspondence on âReproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluationâ</article-title><source>Genome Biology</source><volume>22</volume><elocation-id>99</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-021-02320-3</pub-id><pub-id pub-id-type="pmid">33827648</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatcher</surname><given-names>CJ</given-names></name><name><surname>Basson</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Specification of the cardiac conduction system by transcription factors</article-title><source>Circulation Research</source><volume>105</volume><fpage>620</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.204123</pub-id><pub-id pub-id-type="pmid">19797194</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiroi</surname><given-names>Y</given-names></name><name><surname>Kudoh</surname><given-names>S</given-names></name><name><surname>Monzen</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Yazaki</surname><given-names>Y</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name><name><surname>Komuro</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation</article-title><source>Nature Genetics</source><volume>28</volume><fpage>276</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1038/90123</pub-id><pub-id pub-id-type="pmid">11431700</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>AD</given-names></name><name><surname>Yang</surname><given-names>XH</given-names></name><name><surname>Burnicka-Turek</surname><given-names>O</given-names></name><name><surname>Bosman</surname><given-names>JD</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Steimle</surname><given-names>JD</given-names></name><name><surname>Vokes</surname><given-names>SA</given-names></name><name><surname>McMahon</surname><given-names>AP</given-names></name><name><surname>Kalinichenko</surname><given-names>VV</given-names></name><name><surname>Moskowitz</surname><given-names>IP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Foxf genes integrate tbx5 and hedgehog pathways in the second heart field for cardiac septation</article-title><source>PLOS Genetics</source><volume>10</volume><elocation-id>e1004604</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004604</pub-id><pub-id pub-id-type="pmid">25356765</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogaars</surname><given-names>WM</given-names></name><name><surname>Tessari</surname><given-names>A</given-names></name><name><surname>Moorman</surname><given-names>AF</given-names></name><name><surname>Boer</surname><given-names>PA</given-names></name><name><surname>Hagoort</surname><given-names>J</given-names></name><name><surname>Soufan</surname><given-names>AT</given-names></name><name><surname>Campione</surname><given-names>M</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The transcriptional repressor Tbx3 delineates the developing central conduction system of the heart</article-title><source>Cardiovascular Research</source><volume>62</volume><fpage>489</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2004.01.030</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogaars</surname><given-names>WMH</given-names></name><name><surname>Barnett</surname><given-names>P</given-names></name><name><surname>Moorman</surname><given-names>AFM</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2007">2007a</year><article-title>T-box factors determine cardiac design</article-title><source>Cellular and Molecular Life Sciences</source><volume>64</volume><fpage>646</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1007/s00018-007-6518-z</pub-id><pub-id pub-id-type="pmid">17380306</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogaars</surname><given-names>WMH</given-names></name><name><surname>Engel</surname><given-names>A</given-names></name><name><surname>Brons</surname><given-names>JF</given-names></name><name><surname>Verkerk</surname><given-names>AO</given-names></name><name><surname>de Lange</surname><given-names>FJ</given-names></name><name><surname>Wong</surname><given-names>LYE</given-names></name><name><surname>Bakker</surname><given-names>ML</given-names></name><name><surname>Clout</surname><given-names>DE</given-names></name><name><surname>Wakker</surname><given-names>V</given-names></name><name><surname>Barnett</surname><given-names>P</given-names></name><name><surname>Ravesloot</surname><given-names>JH</given-names></name><name><surname>Moorman</surname><given-names>AFM</given-names></name><name><surname>Verheijck</surname><given-names>EE</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2007">2007b</year><article-title>Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria</article-title><source>Genes &amp; Development</source><volume>21</volume><fpage>1098</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1101/gad.416007</pub-id><pub-id pub-id-type="pmid">17473172</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y-Y</given-names></name><name><surname>Jia</surname><given-names>P</given-names></name><name><surname>Xiong</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multi-level transcriptome sequencing identifies COL1A1 as a candidate marker in human heart failure progression</article-title><source>BMC Medicine</source><volume>18</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-019-1469-4</pub-id><pub-id pub-id-type="pmid">31902369</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huikuri</surname><given-names>HV</given-names></name><name><surname>Castellanos</surname><given-names>A</given-names></name><name><surname>Myerburg</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Sudden death due to cardiac arrhythmias</article-title><source>The New England Journal of Medicine</source><volume>345</volume><fpage>1473</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1056/NEJMra000650</pub-id><pub-id pub-id-type="pmid">11794197</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempen</surname><given-names>MJA</given-names></name><name><surname>Vermeulen</surname><given-names>JLM</given-names></name><name><surname>Moorman</surname><given-names>AFM</given-names></name><name><surname>Gros</surname><given-names>DB</given-names></name><name><surname>Paul</surname><given-names>DL</given-names></name><name><surname>Lamers</surname><given-names>WH</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Developmental changes of connexin40 and connexin43 mRNA distribution patterns in the rat heart</article-title><source>Cardiovascular Research</source><volume>32</volume><fpage>886</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1016/0008-6363(96)00131-9</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laughner</surname><given-names>JI</given-names></name><name><surname>Ng</surname><given-names>FS</given-names></name><name><surname>Sulkin</surname><given-names>MS</given-names></name><name><surname>Arthur</surname><given-names>RM</given-names></name><name><surname>Efimov</surname><given-names>IR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Processing and analysis of cardiac optical mapping data obtained with potentiometric dyes</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>303</volume><fpage>H753</fpage><lpage>H765</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00404.2012</pub-id><pub-id pub-id-type="pmid">22821993</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>QY</given-names></name><name><surname>Newbury-Ecob</surname><given-names>RA</given-names></name><name><surname>Terrett</surname><given-names>JA</given-names></name><name><surname>Wilson</surname><given-names>DI</given-names></name><name><surname>Curtis</surname><given-names>AR</given-names></name><name><surname>Yi</surname><given-names>CH</given-names></name><name><surname>Gebuhr</surname><given-names>T</given-names></name><name><surname>Bullen</surname><given-names>PJ</given-names></name><name><surname>Robson</surname><given-names>SC</given-names></name><name><surname>Strachan</surname><given-names>T</given-names></name><name><surname>Bonnet</surname><given-names>D</given-names></name><name><surname>Lyonnet</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>ID</given-names></name><name><surname>Raeburn</surname><given-names>JA</given-names></name><name><surname>Buckler</surname><given-names>AJ</given-names></name><name><surname>Law</surname><given-names>DJ</given-names></name><name><surname>Brook</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family</article-title><source>Nature Genetics</source><volume>15</volume><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1038/ng0197-21</pub-id><pub-id pub-id-type="pmid">8988164</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Bu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Evans</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>HCN4 dynamically marks the first heart field and conduction system precursors</article-title><source>Circulation Research</source><volume>113</volume><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.113.301588</pub-id><pub-id pub-id-type="pmid">23743334</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linden</surname><given-names>H</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>King</surname><given-names>J</given-names></name><name><surname>Blair</surname><given-names>E</given-names></name><name><surname>Kini</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ulnar Mammary syndrome and TBX3: expanding the phenotype</article-title><source>American Journal of Medical Genetics</source><volume>149A</volume><fpage>2809</fpage><lpage>2812</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.33096</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Levin</surname><given-names>MD</given-names></name><name><surname>Petrenko</surname><given-names>NB</given-names></name><name><surname>Lu</surname><given-names>MM</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>LJ</given-names></name><name><surname>Stout</surname><given-names>AL</given-names></name><name><surname>Epstein</surname><given-names>JA</given-names></name><name><surname>Patel</surname><given-names>VV</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>45</volume><fpage>715</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2008.08.015</pub-id><pub-id pub-id-type="pmid">18926829</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangoni</surname><given-names>ME</given-names></name><name><surname>Traboulsie</surname><given-names>A</given-names></name><name><surname>Leoni</surname><given-names>A-L</given-names></name><name><surname>Couette</surname><given-names>B</given-names></name><name><surname>Marger</surname><given-names>L</given-names></name><name><surname>Le Quang</surname><given-names>K</given-names></name><name><surname>Kupfer</surname><given-names>E</given-names></name><name><surname>Cohen-Solal</surname><given-names>A</given-names></name><name><surname>Vilar</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>H-S</given-names></name><name><surname>Escande</surname><given-names>D</given-names></name><name><surname>Charpentier</surname><given-names>F</given-names></name><name><surname>Nargeot</surname><given-names>J</given-names></name><name><surname>Lory</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Bradycardia and slowing of the atrioventricular conduction in mice lacking CaV3.1/alpha1G T-type calcium channels</article-title><source>Circulation Research</source><volume>98</volume><fpage>1422</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000225862.14314.49</pub-id><pub-id pub-id-type="pmid">16690884</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marionneau</surname><given-names>C</given-names></name><name><surname>Couette</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Mangoni</surname><given-names>ME</given-names></name><name><surname>Nargeot</surname><given-names>J</given-names></name><name><surname>Lei</surname><given-names>M</given-names></name><name><surname>Escande</surname><given-names>D</given-names></name><name><surname>Demolombe</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart</article-title><source>The Journal of Physiology</source><volume>562</volume><fpage>223</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2004.074047</pub-id><pub-id pub-id-type="pmid">15498808</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meneghini</surname><given-names>V</given-names></name><name><surname>Odent</surname><given-names>S</given-names></name><name><surname>Platonova</surname><given-names>N</given-names></name><name><surname>Egeo</surname><given-names>A</given-names></name><name><surname>Merlo</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Novel TBX3 mutation data in families with ulnar-mammary syndrome indicate a genotype-phenotype relationship: Mutations that do not disrupt the T-domain are associated with less severe limb defects</article-title><source>European Journal of Medical Genetics</source><volume>49</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.ejmg.2005.04.021</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miquerol</surname><given-names>L</given-names></name><name><surname>Moreno-Rascon</surname><given-names>N</given-names></name><name><surname>Beyer</surname><given-names>S</given-names></name><name><surname>Dupays</surname><given-names>L</given-names></name><name><surname>Meilhac</surname><given-names>SM</given-names></name><name><surname>Buckingham</surname><given-names>ME</given-names></name><name><surname>Franco</surname><given-names>D</given-names></name><name><surname>Kelly</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Biphasic development of the mammalian ventricular conduction system</article-title><source>Circulation Research</source><volume>107</volume><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.218156</pub-id><pub-id pub-id-type="pmid">20466980</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>R</given-names></name><name><surname>Morad</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>A uniform enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates</article-title><source>The American Journal of Physiology</source><volume>249</volume><fpage>H1056</fpage><lpage>H1060</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.1985.249.5.H1056</pub-id><pub-id pub-id-type="pmid">2998207</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>RA</given-names></name><name><surname>Bosada</surname><given-names>FM</given-names></name><name><surname>van Weerd</surname><given-names>JH</given-names></name><name><surname>van Duijvenboden</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Mommersteeg</surname><given-names>MTM</given-names></name><name><surname>Hooijkaas</surname><given-names>IB</given-names></name><name><surname>Wakker</surname><given-names>V</given-names></name><name><surname>de Gier-de Vries</surname><given-names>C</given-names></name><name><surname>Coronel</surname><given-names>R</given-names></name><name><surname>Boink</surname><given-names>GJJ</given-names></name><name><surname>Bakkers</surname><given-names>J</given-names></name><name><surname>Barnett</surname><given-names>P</given-names></name><name><surname>Boukens</surname><given-names>BJ</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>T-box transcription factor 3 governs a transcriptional program for the function of the mouse atrioventricular conduction system</article-title><source>PNAS</source><volume>117</volume><fpage>18617</fpage><lpage>18626</lpage><pub-id pub-id-type="doi">10.1073/pnas.1919379117</pub-id><pub-id pub-id-type="pmid">32675240</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>AD</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Vahora</surname><given-names>I</given-names></name><name><surname>Nieman</surname><given-names>B</given-names></name><name><surname>Koshiba-Takeuchi</surname><given-names>K</given-names></name><name><surname>Davidson</surname><given-names>L</given-names></name><name><surname>Pizard</surname><given-names>A</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Chen</surname><given-names>XJ</given-names></name><name><surname>Henkelman</surname><given-names>RM</given-names></name><name><surname>Bruneau</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Tbx5-dependent rheostatic control of cardiac gene expression and morphogenesis</article-title><source>Developmental Biology</source><volume>297</volume><fpage>566</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2006.05.023</pub-id><pub-id pub-id-type="pmid">16870172</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moskowitz</surname><given-names>IPG</given-names></name><name><surname>Pizard</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>VV</given-names></name><name><surname>Bruneau</surname><given-names>BG</given-names></name><name><surname>Kim</surname><given-names>JB</given-names></name><name><surname>Kupershmidt</surname><given-names>S</given-names></name><name><surname>Roden</surname><given-names>D</given-names></name><name><surname>Berul</surname><given-names>CI</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The T-Box transcription factor Tbx5 is required for the patterning and maturation of the murine cardiac conduction system</article-title><source>Developmenf</source><volume>131</volume><fpage>4107</fpage><lpage>4116</lpage><pub-id pub-id-type="doi">10.1242/dev.01265</pub-id><pub-id pub-id-type="pmid">15289437</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moskowitz</surname><given-names>IPG</given-names></name><name><surname>Kim</surname><given-names>JB</given-names></name><name><surname>Moore</surname><given-names>ML</given-names></name><name><surname>Wolf</surname><given-names>CM</given-names></name><name><surname>Peterson</surname><given-names>MA</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Nobrega</surname><given-names>MA</given-names></name><name><surname>Yokota</surname><given-names>Y</given-names></name><name><surname>Berul</surname><given-names>C</given-names></name><name><surname>Izumo</surname><given-names>S</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A molecular pathway including Id2, Tbx5, and Nkx2-5 required for cardiac conduction system development</article-title><source>Cell</source><volume>129</volume><fpage>1365</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.04.036</pub-id><pub-id pub-id-type="pmid">17604724</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munshi</surname><given-names>NV</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Gene regulatory networks in cardiac conduction system development</article-title><source>Circulation Research</source><volume>110</volume><fpage>1525</fpage><lpage>1537</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.260026</pub-id><pub-id pub-id-type="pmid">22628576</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadadur</surname><given-names>RD</given-names></name><name><surname>Broman</surname><given-names>MT</given-names></name><name><surname>Boukens</surname><given-names>B</given-names></name><name><surname>Mazurek</surname><given-names>SR</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>van den Boogaard</surname><given-names>M</given-names></name><name><surname>Bekeny</surname><given-names>J</given-names></name><name><surname>Gadek</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Martin</surname><given-names>JF</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Seidman</surname><given-names>J</given-names></name><name><surname>Christoffels</surname><given-names>V</given-names></name><name><surname>Efimov</surname><given-names>IR</given-names></name><name><surname>McNally</surname><given-names>EM</given-names></name><name><surname>Weber</surname><given-names>CR</given-names></name><name><surname>Moskowitz</surname><given-names>IP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pitx2 modulates a Tbx5-dependent gene regulatory network to maintain atrial rhythm</article-title><source>Science Translational Medicine</source><volume>8</volume><elocation-id>354ra115</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf4891</pub-id><pub-id pub-id-type="pmid">27582060</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oka</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Kaiser</surname><given-names>RA</given-names></name><name><surname>Melendez</surname><given-names>J</given-names></name><name><surname>Hambleton</surname><given-names>M</given-names></name><name><surname>Sargent</surname><given-names>MA</given-names></name><name><surname>Lorts</surname><given-names>A</given-names></name><name><surname>Brunskill</surname><given-names>EW</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name><name><surname>Conway</surname><given-names>SJ</given-names></name><name><surname>Aronow</surname><given-names>BJ</given-names></name><name><surname>Robbins</surname><given-names>J</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling</article-title><source>Circulation Research</source><volume>101</volume><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.149047</pub-id><pub-id pub-id-type="pmid">17569887</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>Q</given-names></name><name><surname>Yue</surname><given-names>L</given-names></name><name><surname>Niu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Zhen</surname><given-names>R</given-names></name><name><surname>Ban</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Single-cell transcriptomics identifies Col1a1 and Col1a2 as hub genes in obesity-induced cardiac fibrosis</article-title><source>Biochemical and Biophysical Research Communications</source><volume>618</volume><fpage>30</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2022.06.018</pub-id><pub-id pub-id-type="pmid">35714568</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>DS</given-names></name><name><surname>Fishman</surname><given-names>GI</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The cardiac conduction system</article-title><source>Circulation</source><volume>123</volume><fpage>904</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.942284</pub-id><pub-id pub-id-type="pmid">21357845</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>VV</given-names></name><name><surname>Arad</surname><given-names>M</given-names></name><name><surname>Moskowitz</surname><given-names>IPG</given-names></name><name><surname>Maguire</surname><given-names>CT</given-names></name><name><surname>Branco</surname><given-names>D</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Berul</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Electrophysiologic characterization and postnatal development of ventricular pre-excitation in a mouse model of cardiac hypertrophy and Wolff-Parkinson-White syndrome</article-title><source>Journal of the American College of Cardiology</source><volume>42</volume><fpage>942</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1016/s0735-1097(03)00850-7</pub-id><pub-id pub-id-type="pmid">12957447</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Rasband</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="1997">1997</year><data-title>ImageJ, u. s. national institutes of health, bethesda, MD, USA, 1997-2016</data-title><version designator="0.1">0.1</version><source>Imagej</source><ext-link ext-link-type="uri" xlink:href="http://imagej.nih.gov/ij">http://imagej.nih.gov/ij</ext-link></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remme</surname><given-names>CA</given-names></name><name><surname>Verkerk</surname><given-names>AO</given-names></name><name><surname>Hoogaars</surname><given-names>WMH</given-names></name><name><surname>Aanhaanen</surname><given-names>WTJ</given-names></name><name><surname>Scicluna</surname><given-names>BP</given-names></name><name><surname>Annink</surname><given-names>C</given-names></name><name><surname>van den Hoff</surname><given-names>MJB</given-names></name><name><surname>Wilde</surname><given-names>AAM</given-names></name><name><surname>van Veen</surname><given-names>TAB</given-names></name><name><surname>Veldkamp</surname><given-names>MW</given-names></name><name><surname>de Bakker</surname><given-names>JMT</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name><name><surname>Bezzina</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The cardiac sodium channel displays differential distribution in the conduction system and transmural heterogeneity in the murine ventricular myocardium</article-title><source>Basic Research in Cardiology</source><volume>104</volume><fpage>511</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1007/s00395-009-0012-8</pub-id><pub-id pub-id-type="pmid">19255801</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubart</surname><given-names>M</given-names></name><name><surname>Zipes</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mechanisms of sudden cardiac death</article-title><source>The Journal of Clinical Investigation</source><volume>115</volume><fpage>2305</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1172/JCI26381</pub-id><pub-id pub-id-type="pmid">16138184</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sander</surname><given-names>JD</given-names></name><name><surname>Maeder</surname><given-names>ML</given-names></name><name><surname>Reyon</surname><given-names>D</given-names></name><name><surname>Voytas</surname><given-names>DF</given-names></name><name><surname>Joung</surname><given-names>JK</given-names></name><name><surname>Dobbs</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>ZiFiT (Zinc Finger Targeter): an updated zinc finger engineering tool</article-title><source>Nucleic Acids Research</source><volume>38</volume><fpage>W462</fpage><lpage>W468</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq319</pub-id><pub-id pub-id-type="pmid">20435679</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheinman</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Role of the His-Purkinje system in the genesis of cardiac arrhythmia</article-title><source>Heart Rhythm</source><volume>6</volume><fpage>1050</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2009.03.011</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schram</surname><given-names>G</given-names></name><name><surname>Pourrier</surname><given-names>M</given-names></name><name><surname>Melnyk</surname><given-names>P</given-names></name><name><surname>Nattel</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function</article-title><source>Circulation Research</source><volume>90</volume><fpage>939</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1161/01.res.0000018627.89528.6f</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>ME</given-names></name><name><surname>Grove</surname><given-names>D</given-names></name><name><surname>Upshaw</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Why does the heart beat? The discovery of the electrical system of the heart</article-title><source>Circulation</source><volume>113</volume><fpage>2775</fpage><lpage>2781</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.616771</pub-id><pub-id pub-id-type="pmid">16769927</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamaddon</surname><given-names>HS</given-names></name><name><surname>Vaidya</surname><given-names>D</given-names></name><name><surname>Simon</surname><given-names>AM</given-names></name><name><surname>Paul</surname><given-names>DL</given-names></name><name><surname>Jalife</surname><given-names>J</given-names></name><name><surname>Morley</surname><given-names>GE</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>High-resolution optical mapping of the right bundle branch in connexin40 knockout mice reveals slow conduction in the specialized conduction system</article-title><source>Circulation Research</source><volume>87</volume><fpage>929</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1161/01.res.87.10.929</pub-id><pub-id pub-id-type="pmid">11073890</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Boogaard</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>LYE</given-names></name><name><surname>Tessadori</surname><given-names>F</given-names></name><name><surname>Bakker</surname><given-names>ML</given-names></name><name><surname>Dreizehnter</surname><given-names>LK</given-names></name><name><surname>Wakker</surname><given-names>V</given-names></name><name><surname>Bezzina</surname><given-names>CR</given-names></name><name><surname>ât Hoen</surname><given-names>PAC</given-names></name><name><surname>Bakkers</surname><given-names>J</given-names></name><name><surname>Barnett</surname><given-names>P</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genetic variation in T-box binding element functionally affects SCN5A/SCN10A enhancer</article-title><source>Journal of Clinical Investigation</source><volume>122</volume><fpage>2519</fpage><lpage>2530</lpage><pub-id pub-id-type="doi">10.1172/JCI62613</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Duijvenboden</surname><given-names>K</given-names></name><name><surname>Ruijter</surname><given-names>JM</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Gene regulatory elements of the cardiac conduction system</article-title><source>Briefings in Functional Genomics</source><volume>13</volume><fpage>28</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1093/bfgp/elt031</pub-id><pub-id pub-id-type="pmid">23969024</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Eif</surname><given-names>VWW</given-names></name><name><surname>Devalla</surname><given-names>HD</given-names></name><name><surname>Boink</surname><given-names>GJJ</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Transcriptional regulation of the cardiac conduction system</article-title><source>Nature Reviews. Cardiology</source><volume>15</volume><fpage>617</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1038/s41569-018-0031-y</pub-id><pub-id pub-id-type="pmid">29875439</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Eif</surname><given-names>VWW</given-names></name><name><surname>Stefanovic</surname><given-names>S</given-names></name><name><surname>Mohan</surname><given-names>RA</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Gradual differentiation and confinement of the cardiac conduction system as indicated by marker gene expression</article-title><source>Biochimica et Biophysica Acta. Molecular Cell Research</source><volume>1867</volume><elocation-id>118509</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbamcr.2019.07.004</pub-id><pub-id pub-id-type="pmid">31306714</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Weerd</surname><given-names>JH</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The formation and function of the cardiac conduction system</article-title><source>Development</source><volume>143</volume><fpage>197</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1242/dev.124883</pub-id><pub-id pub-id-type="pmid">26786210</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verheule</surname><given-names>S</given-names></name><name><surname>Kaese</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Connexin diversity in the heart: insights from transgenic mouse models</article-title><source>Frontiers in Pharmacology</source><volume>4</volume><elocation-id>81</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2013.00081</pub-id><pub-id pub-id-type="pmid">23818881</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verzi</surname><given-names>MP</given-names></name><name><surname>McCulley</surname><given-names>DJ</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name><name><surname>Dodou</surname><given-names>E</given-names></name><name><surname>Black</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field</article-title><source>Developmental Biology</source><volume>287</volume><fpage>134</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2005.08.041</pub-id><pub-id pub-id-type="pmid">16188249</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warhol</surname><given-names>A</given-names></name><name><surname>George</surname><given-names>SA</given-names></name><name><surname>Obaid</surname><given-names>SN</given-names></name><name><surname>Efimova</surname><given-names>T</given-names></name><name><surname>Efimov</surname><given-names>IR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Differential cardiotoxic electrocardiographic response to doxorubicin treatment in conscious versus anesthetized mice</article-title><source>Physiological Reports</source><volume>9</volume><elocation-id>e14987</elocation-id><pub-id pub-id-type="doi">10.14814/phy2.14987</pub-id><pub-id pub-id-type="pmid">34337891</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>MT</given-names></name><name><surname>Allikian</surname><given-names>MJ</given-names></name><name><surname>Heydemann</surname><given-names>A</given-names></name><name><surname>Hadhazy</surname><given-names>M</given-names></name><name><surname>Zarnegar</surname><given-names>S</given-names></name><name><surname>McNally</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy</article-title><source>The Journal of Clinical Investigation</source><volume>113</volume><fpage>668</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1172/JCI20410</pub-id><pub-id pub-id-type="pmid">14991064</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The gene expression of CALD1, CDH2, and POSTN in fibroblast are related to idiopathic pulmonary fibrosis</article-title><source>Frontiers in Immunology</source><volume>15</volume><elocation-id>1275064</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1275064</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Hoffmann</surname><given-names>AD</given-names></name><name><surname>Burnicka-Turek</surname><given-names>O</given-names></name><name><surname>Friedland-Little</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Moskowitz</surname><given-names>IP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Tbx5-hedgehog molecular networks are essential in the second heart field for atrial septation</article-title><source>Developmental Cell</source><volume>23</volume><fpage>280</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2012.06.006</pub-id><pub-id pub-id-type="pmid">22898775</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>T</given-names></name><name><surname>Quan</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Ran</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of target genes in cardiomyopathy with fibrosis and cardiac remodeling</article-title><source>Journal of Biomedical Science</source><volume>25</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.1186/s12929-018-0459-8</pub-id><pub-id pub-id-type="pmid">30115125</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1âkey resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat polyclonal anti-TBX3</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">sc-31656</td><td align="left" valign="bottom">IF (1:250) WB (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat polyclonal anti-TBX5</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">sc-17866</td><td align="left" valign="bottom">IF (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-goat IgG AlexaFluor-594</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">A-11058</td><td align="left" valign="bottom">IF (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-goat IgG AlexaFluor-488</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">A-11055</td><td align="left" valign="bottom">IF (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal anti-HCN4</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">AB5808</td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal anti-CAV1.3/CACNA1D</td><td align="left" valign="bottom">Alomone</td><td align="left" valign="bottom">ACC-005</td><td align="left" valign="bottom">WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal anti-Cx45/GJC1</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">PA5-77357</td><td align="left" valign="bottom">WB (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Sheep polyclonal anti-TBX5</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">AF5918</td><td align="left" valign="bottom">WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal anti-CX40/GJA5</td><td align="left" valign="bottom">Zymed/ Invitrogen</td><td align="char" char="ndash" valign="bottom">36â4900</td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal anti-NAV1.5/SCN5A</td><td align="left" valign="bottom">Alomone</td><td align="left" valign="bottom">ASC-005</td><td align="left" valign="bottom">WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-KCNK3/TASK1</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab186352</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal anti-CX43/GJA1</td><td align="left" valign="bottom">Cell Signalling Technology</td><td align="char" char="." valign="bottom">3512</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-GAPDH</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab8245</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit anti-goat-HRP</td><td align="left" valign="bottom">Jackson Immuno Research</td><td align="char" char="hyphen" valign="bottom">305-035-003</td><td align="left" valign="bottom">WB (1:10 000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-rabbit-HRP</td><td align="left" valign="bottom">Jackson Immuno Research</td><td align="char" char="hyphen" valign="bottom">111-035-144</td><td align="left" valign="bottom">WB (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-sheep-HRP</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab6900</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Sheep anti-mouse-HRP</td><td align="left" valign="bottom">Amersham GE</td><td align="left" valign="bottom">NA931</td><td align="left" valign="bottom">WB (1:2500)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BSA</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">A9576</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail</td><td align="left" valign="bottom">Roche</td><td align="char" char="." valign="bottom">11836170001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DAPI</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">62248</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Isoflurane</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="char" char="hyphen" valign="bottom">26675-46-7</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">POWER SYBR Green PCR Master Mix</td><td align="left" valign="bottom">Applied Biosystems</td><td align="char" char="hyphen" valign="bottom">43-676-59</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ProLong Gold Antifade Mountant</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">P10144</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Propidium Iodide</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">P3566</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tamoxifen</td><td align="left" valign="bottom">MP Biomedical</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dosage details look at Materials &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">MEGAshortscript T7 transcription kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">AM1354</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">mMessage Machine T7 transcription kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">AM1344</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce BCA Protein Assay Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="char" char="." valign="bottom">23225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce ECL</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="char" char="." valign="bottom">32106</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce ECL Plus</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="char" char="." valign="bottom">32132</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Mini Kit</td><td align="left" valign="bottom">Qiagen</td><td align="char" char="." valign="bottom">74104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SuperScript III First-Strand Synthesis SuperMix</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">18080400</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup> Mixed 129/SvJ:C57BL/6 J:CD-1 background</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Generated using CRISPRâCas9 technology (look at Experimental animals section)</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Tbx3<sup>fl/fl</sup>;Tbx5<sup>fl/fl</sup>; R26R<sup>eYFP/+</sup>; MinK<sup>CreERT2/+</sup> Mixed 129/SvJ:C57BL/6 J:CD-1 background</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Generated using CRISPRâCas9 technology (look at Experimental animals section)</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Kcne1<sup>CreERT2</sup> [Tg(RP23-276I20-MinKCreERT2)] â referred to as MinK<sup>CreERT2</sup> in the manuscript for consistency with field-standard nomenclature and to avoid confusion. Mixed 129/SvJ:C57BL/6 J:CD-1 background</td><td align="left" valign="bottom">PMID: 21504046</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dr. Ivan P. Moskowitz (University of Chicago)</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Tbx3<sup>fl/fl</sup> Mixed 129/SvJ:C57BL/6 J:CD-1 background</td><td align="left" valign="bottom">PMID: 22203979</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dr. Anne M Moon (University of Utah)</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">CD-1</td><td align="left" valign="bottom">Charles Rivers Laboratories</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.criver.com/products-services/find-model/cd-1r-igs-mouse?region=3611">https://www.criver.com/products-services/find-model/cd-1r-igs-mouse?region=3611</ext-link></td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C57Bl/6 J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.jax.org/strain/000664">https://www.jax.org/strain/000664</ext-link></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Long ssDNA donor</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Sequence details look at <xref ref-type="fig" rid="fig1s4">Figure 1âfigure supplement 4</xref></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">SDS-PAGE on 4â20% TGX Gels</td><td align="left" valign="bottom">Bio-Rad</td><td align="char" char="." valign="bottom">4561096</td><td align="left" valign="bottom">4â20% Mini-PROTEAN TGX Precast Protein Gels</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Tbx5-I2-S22</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">sgRNA</td><td align="left" valign="bottom">Sequence details look at <xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplement 3</xref></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Tbx5-I2-S31</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">sgRNA</td><td align="left" valign="bottom">Sequence details look at <xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplement 3</xref></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">VectaShield +DAPI</td><td align="left" valign="bottom">Vector Laboratories</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://vectorlabs.com/vectashield-mounting-medium-with-dapi.html">https://vectorlabs.com/vectashield-mounting-medium-with-dapi.html</ext-link></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tbx5 locus: 5âarm-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">Sequence details look at <xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tbx5 locus: 5âarm-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">Sequence details look at <xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tbx5 locus: 3âarm-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">Sequence details look at <xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tbx5 locus: 3âarm-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">Sequence details look at <xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tbx3 locus: WT-F</td><td align="left" valign="bottom">PMID: 22203979</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">Dr. Anne M Moon (University of Utah)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tbx3 locus: WT-R</td><td align="left" valign="bottom">PMID: 22203979</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">Dr. Anne M Moon (University of Utah)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tbx3 locus: Flox-F</td><td align="left" valign="bottom">PMID: 22203979</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">Dr. Anne M Moon (University of Utah)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Tbx3 locus: Flox-R</td><td align="left" valign="bottom">PMID: 22203979</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">Dr. Anne M Moon (University of Utah)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Tbx3-F</td><td align="left" valign="bottom">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">AGATCCGGTT</named-content> <named-content content-type="sequence">ATCCCTGGGAC</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Tbx3-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CAGCAGCCCC</named-content> CACTAACTG-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Tbx5-F</td><td align="left" valign="bottom">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">GGCATGGAAG</named-content> <named-content content-type="sequence">GAATCAAGGT</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Tbx5-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CTAGGAAACATT</named-content> <named-content content-type="sequence">CTCCTCCCTGC</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Gja1-F</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID:166091435 c3)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">ACAGCGGTTG</named-content> <named-content content-type="sequence">AGTCAGCTTG</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Gja1-R</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID:166091435 c3)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">GAGAGATGGG</named-content> <named-content content-type="sequence">GAAGGACTTGT</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Gja5-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">AGCTCCAGTC</named-content> <named-content content-type="sequence">ACCCATCTTG</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Gja5-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CAGTTGAACA</named-content> <named-content content-type="sequence">GCAGCCAGAG</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Gjc1-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">AGATCCACAA</named-content> <named-content content-type="sequence">CCATTCGACATTT</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Gjc1-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">TCCCAGGTAC</named-content> <named-content content-type="sequence">ATCACAGAGGG</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Gjd3-F</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 30519904 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">TCATGCTGAT</named-content> <named-content content-type="sequence">CTTCCGCATCC</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Gjd3-R</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 30519904 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">GAAGCGGTAG</named-content> TGGGACACC-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Scn5a-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CGCTCCTCCA</named-content> <named-content content-type="sequence">GGTAGATGTC</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Scn5a-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CTACCGCATA</named-content> <named-content content-type="sequence">GTGGAGCACA</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Ryr2-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CAAATCCTTC</named-content> <named-content content-type="sequence">TGCTGCCAAG</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Ryr2-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CGAGGATGAG</named-content> <named-content content-type="sequence">ATCCAGTTCC</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Kcnk3-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CTCCTTCTAC</named-content> <named-content content-type="sequence">TTCGCCATCA</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Kcnk3-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">GAAGGTGTTG</named-content> ATGCGTTCA-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Kcnj2-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CGACTGCCAT</named-content> <named-content content-type="sequence">GACAACTCAA</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Kcnj2-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CATATCTCCG</named-content> <named-content content-type="sequence">ATTCTCGCCT</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Kcnj3-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">GCTGGCAACT</named-content> <named-content content-type="sequence">ACACTCCCTG</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Kcnj3-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">AACATGCAGC</named-content> <named-content content-type="sequence">CGATGAGGAA</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Kcnj4-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CACGTAAACG</named-content> <named-content content-type="sequence">GCTTTTTGGGG</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Kcnj4-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CCGTCTCGAA</named-content> <named-content content-type="sequence">CGGAGATGAC</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Kcnj12-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">ACCCCTACAG</named-content> <named-content content-type="sequence">CATCGTATCAT</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Kcnj12-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">GTTGCACTGA</named-content> <named-content content-type="sequence">CCGTTCTTCTT</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Hcn1-F</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 6754168 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CAAATTCTCC</named-content> <named-content content-type="sequence">CTCCGCATGTT</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Hcn1-R</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 6754168 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">TGAAGAACGT</named-content> <named-content content-type="sequence">GATTCCAACTGG</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Hcn4-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">GGCGGACACC</named-content> GCTATCAAA-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Hcn4-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">TGCCGAACAT</named-content> <named-content content-type="sequence">CCTTAGGGAGA</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Cacna1d-F</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 27413155 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">GACTGATGCC</named-content> <named-content content-type="sequence">CGATATAAAGGC</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Cacna1d-R</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 27413155 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CCTTCACCAGA</named-content> <named-content content-type="sequence">AATAGGGAGTCT</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Cacna1g-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">TGTCTCCGCA</named-content> <named-content content-type="sequence">CGGTCTGTAA</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Cacna1g-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">AGATACCCAA</named-content> <named-content content-type="sequence">AGCGACCATCTT</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Cacna1h-F</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">GAACGTGGTT</named-content> <named-content content-type="sequence">CTTTACAACGGC</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Cacna1h-R</td><td align="left" valign="top">PMID: 32290757</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">GCACATAGTT</named-content> <named-content content-type="sequence">CCCAAAGGTCA</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Smpx-F</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 14149752 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">ATGTCGAAGC</named-content> <named-content content-type="sequence">AGCCAATTTCC</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Smpx-R</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 14149752 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">TCAGACAAGT</named-content> <named-content content-type="sequence">TGACAACAGGTC</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Col1a1-F</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 34328108 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">GCTCCTCTTA</named-content> GGGGCCACT-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Col1a1-R</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 34328108 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CCACGTCTCA</named-content> CCATTGGGG-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Postn-F</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 7657429 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">CCTGCCCTTA</named-content> <named-content content-type="sequence">TATGCTCTGCT</named-content>-3â</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR_Postn-R</td><td align="left" valign="top">PMID: 22086960 (Primer Bank ID: 7657429 a1)</td><td align="left" valign="bottom">qRT-PCR primers</td><td align="left" valign="bottom">5â-<named-content content-type="sequence">AAACATGGTCA</named-content> <named-content content-type="sequence">ATAGGCATCACT</named-content>-3â</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102027.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bruneau</surname><given-names>Benoit</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of California, San Francisco</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>The work presented is <bold>important</bold> for our understanding of the development of the cardiac conduction system and its regulation by T-box transcription factors. The conclusions are supported by <bold>convincing</bold> data. Overall this is an excellent study that advances our understanding of cardiac biology and has implications beyond the immediate field of study.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102027.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The goal of this work is to define the functions of T-box transcription factors Tbx3 and Tbx5 in the adult mouse ventricular cardiac conduction system (VCS) using a novel conditional mouse allele in which both genes are targeted in cis. A series of studies over the past 2 decades by this group and others have shown that Tbx3 is a transcriptional repressor that patterns the conduction system by repressing genes associated with working myocardium, while Tbx5 is a potent transcriptional activator of &quot;fast&quot; conduction system genes in the VCS. In a previous work, the authors of the present study further demonstrated that Tbx3 and Tbx5 exhibit an epistatic relationship whereby the relief of Tbx3-mediated repression through VCS conditional haploinsufficiency allows better toleration of Tbx5 VCS haploinsufficiency. Conversely, excess Tbx3-mediated repression through overexpression results in disruption of the fast-conduction gene network despite normal levels of Tbx5. Based on these data the authors proposed a model in which repressive functions of Tbx3 drive adoption of conduction system fate, followed by segregation into a fast-conducting VCS and slow-conduction AVN through modulation of the Tbx5/Tbx3 ratio in these respective tissue compartments.</p><p>The question motivating the present work is: If Tbx5/Tbx3 ratio is important for slow versus fast VCS identity, what happens when both genes are completely deleted from the VCS? Is conduction system identity completely lost without both factors and if so, does the VCS network transform into a working myocardium-like state? To address this question, the authors have generated a novel mouse line in which both Tbx5 and Tbx3 are floxed on the same allele, allowing complete conditional deletion of both factors using the VCS-specific MinK-CreERT2 line, convincingly validated in previous work. The goal is to use these double conditional knockout mice to further explore the model of Tbx3/Tbx5 co-dependent gene networks and VCS patterning. First the authors demonstrate that the double conditional knockout allele results in the expected loss of Tbx3 and Tbx5 specifically in the VCS when crossed with Mink-CreERT2 and induced with tamoxifen. The double conditional knockout also results in premature mortality. Detailed electrophysiological phenotyping demonstrated prolonged PR and QRS intervals, inducible ventricular tachycardia, and evidence of abnormal impulse propagation along the septal aspect of the right ventricle. In addition, the mutants exhibit downregulation of VCS genes responsible for both fast conduction AND slow conduction phenotypes with upregulation of 2 working myocardial genes including connexin-43. The authors conclude that loss of both Tbx3 and Tbx5 results in &quot;reversion&quot; or &quot;transformation&quot; of the VCS network to a working myocardial phenotype, which they further claim is a prediction of their model and establishes that Tbx3 and Tbx5 &quot;coordinate&quot; transcriptional control of VCS identity.</p><p>Overall Appraisal:</p><p>As noted above, the present study does not further explore the Tbx5/Tbx3 ratio concept since both genes are completely knocked out in the VCS. Instead, the main claims are that absence of both factors results in a transcriptional shift of conduction tissue towards a working myocardial phenotype, and that this shift indicates that Tbx5 and Tbx3 &quot;coordinate&quot; to control VCS identity and function. However, only limited data are presented to support the claim of transcriptional reprogramming since the knockout cells are not directly compared to working myocardial cells at the transcriptional level and only a small number of key genes are assessed (versus genome-wide assessment). In addition, the optical mapping dataset has alternative interpretations that are not excluded or thoroughly discussed.</p><p>In sum, while this study adds an elegantly constructed genetic model to the field, the data presented mostly fit within the existing paradigm of established functions of Tbx3 and Tbx5. The authors present some evidence to support the claim that VCS cells adopt a working myocardial phenotype in the absence of Tbx3 and Tbx5, but some key experiments that could more definitively test this model were not performed, reducing the degree to which the data support the conclusions.</p><p>Strengths:</p><p>(1) Successful generation of a novel Tbx3-Tbx5 double conditional mouse model</p><p>(2) Successful VCS-specific deletion of Tbx3 and Tbx5 using a VCS-specific inducible Cre driver line</p><p>(3) Well-powered and convincing assessments of mortality and physiological phenotypes</p><p>(4) Isolation of genetically modified VCS cells using flow.</p><p>Weaknesses:</p><p>(1) In general, the data is consistent with a long-standing and well-supported model in which Tbx3 represses working myocardial genes and Tbx5 activates expression of VCS genes, which seem like distinct roles in VCS patterning.</p><p>(2) More direct quantitative comparison of Tbx5 Adult VCS KO with Tbx5/Tbx3 Adult VCS double KO would be helpful to ascertain whether deletion of Tbx3 on top of Tbx5 deletion changes the underlying phenotype in some discernable way beyond mRNA expression of a few genes. Superficially, the phenotypes look quite similar at the EKG and arrhythmia inducibility level and no optical mapping data from single Tbx5 KO is presented for comparison to the double KO. I understand that single Tbx5 VCS KO mutants have been evaluated in previous publications but I think in order to evaluate the claims presented here, it would be important to do a direct comparison using the same assays and conditions.</p><p>(3) The authors claim that double knockout VCS cells transform to working myocardial fate, but there is no comparison of gene expression levels between actual working myocardial cells and the Tbx3/Tbx5 DKO VCS cells so it's hard to know if the data reflect an actual cell state change or a more non-specific phenomenon with global dysregulation of gene expression or perhaps dedifferentiation. I understand that the upregulation of Gja1 and Smpx is intended to address this, but it's only two genes and it seems relevant to understand their degree of expression relative to actual working myocardium. In addition, the gene panel is somewhat limited and does not include other key transcriptional regulators in the VCS such as Irx3 and Nkx2-5. RNA-seq in these populations would provide a clearer comparison among the groups.</p><p>(4) From the optical mapping data, it is difficult to distinguish between the presence of (1) a focal proximal right bundle branch block due to dysregulation of gene expression in the VCS but overall preservation of the right bundle and its distal ramifications; from (2) actual loss of the VCS with reversion of VCS cells to a working myocardial fate. Related to this, the authors claim that this experiment allows for direct visualization of His bundle activation, but can the authors confirm or provide evidence that the tissue penetration of their imaging modality allows for imaging of a deep structure like the AV bundle as opposed to the right bundle branch which is more superficial? Does the timing of the separation of the sharp deflection from the subsequent local activation suggest visualization of more distal components of the VCS rather than the AV bundle itself? Additional clarification would be helpful.</p><p>impact:</p><p>The present study contributes a novel and elegantly constructed mouse model to the field. The data presented generally corroborate existing models of transcriptional regulation in the VCS. Acknowledging that the present work is strong start, some additional studies not included in the present manuscript will be needed for this new mouse model to decisively advance the field of VCS transcriptional biology.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102027.3.sa2</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In the study presented by Burnicka-Turek et al., the authors generated for the first time a mouse model to cause the combined conditional deletion of Tbx3 and Tbx5 genes. This has been impossible to achieve to date due to the proximity of these genes in chromosome 5, preventing the generation of loss of function strategies to delete simultaneously both genes. It is known that both Tbx3 and Tbx5 are required for the development of the cardiac conduction system by transcription factor-specific but also overlapping roles as seen in the common and diverse cardiac defects found in patients with mutations for these genes. After validating the deletion efficiency and specificity of the line, the authors characterised the cardiac phenotype associated to cardiac conduction system (CCS)-specific combined deletion of Tbx5 and Tbx3 in the adult by inducing the activation of the CCS-specific tamoxifen inducible Cre recombination (MinK-creERT) at 6 weeks after birth. Their analysis of 8-9 weeks old animals did not identify any major morphological cardiac defects. However, the authors found conduction defects including prolonged PR and QTR intervals and ventricular tachycardia causing the death of the double mutants, which do not survive more than 3 months after tamoxifen induction. Molecular and optical mapping analysis of the ventricular conduction system (VCS) of these mutants concluded that, in the absence of Tbx5 and Tbx3 function, the cells forming the ventricular conduction system (VCS) become working myocardium and lose the specific contractile features characterising VCS cells. Altogether, the study identified the critical combined role of Tbx3 and Tbx5 in the maintenance of the VCS in adulthood.</p><p>Strengths:</p><p>The study generated a new animal model to study the combined deletion of Tbx5 and Tbx3 in the cardiac conduction system. This unique model has provided the authors with the perfect tool to answer their biological questions. The study includes top-class methodologies to assess the functional defects present in the different mutants analysed, and gathered very robust functional data on the conduction defects present in these mutants. They also applied optical action potential (OAP) methods to demonstrate the loss of conduction action potential and the acquisition of working myocardium action potentials in the affected cells because of Tbx5/Tbx3 loss of function. The study used simpler molecular and morphological analysis to demonstrate that there are no major morphological defects in these mutant and that indeed, the conduction defects found are due to the acquisition of working myocardium features by the VCS cells. Altogether, this study identified the critical role of these transcription factors in the maintenance of the VCS in the adult heart.</p><p>Weaknesses:</p><p>In the opinion of this reviewer, the weakness in the study lays in the morphological and molecular characterization. The morphological analysis simply described the absence of general cardiac defects in the adult heart, however, whether the CCS tissues are present or not was not investigated. Linage tracing analysis using the reporter lines included in the crosses described in the study, will determine if there are changes in CCS tissue composition in the different mutants studied. Similarly, combining this reporter analysis with the molecular markers found to be dysregulated by qPCR and western blot will demonstrate that indeed the cells that were specified as VCS in the adult heart become working myocardium in the absence of Tbx3 and Tbx5 function.</p><p>Comments on revisions:</p><p>I would like to thank the authors for their revised manuscript and for their corrections based on the suggestions from the 3 reviewers. Although I would have preferred to see some of the additional experiments suggested by any of the reviewers to improve the robustness and depth of the study integrated in the revised version of the manuscript, I acknowledge that the authors may prefer to develop them as follow-up studies. So, looking forward to seeing the follow-up study unravelling the detailed molecular regulation controlled by Tbx3/Tbx5 during the formation and maintenance of the ventricular cardiac conduction system.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102027.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Burnicka-Turek</surname><given-names>Ozanna</given-names></name><role specific-use="author">Author</role><aff><institution>University of Chicago Medical Center</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Trampel</surname><given-names>Katy A</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Laforest</surname><given-names>Brigitte</given-names></name><role specific-use="author">Author</role><aff><institution>University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Broman</surname><given-names>Michael T</given-names></name><role specific-use="author">Author</role><aff><institution>University of Chicago Medical Center</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xinan H</given-names></name><role specific-use="author">Author</role><aff><institution>University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Zoheb</given-names></name><role specific-use="author">Author</role><aff><institution>University of Chicago Medical Center</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Rytkin</surname><given-names>Eric</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Binjie</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Schaffer</surname><given-names>Ella</given-names></name><role specific-use="author">Author</role><aff><institution>University of Chicago Medical Center</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Gadek</surname><given-names>Margaret</given-names></name><role specific-use="author">Author</role><aff><institution>University of Chicago Medical Center</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Kaitlyn M</given-names></name><role specific-use="author">Author</role><aff><institution>University of Chicago Medical Center</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Efimov</surname><given-names>Igor R</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago IL</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Moskowitz</surname><given-names>Ivan P</given-names></name><role specific-use="author">Author</role><aff><institution>University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authorsâ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>In a heroic effort, Ozanna Burnicka-Turek et al. have made and investigated conduction system-specific <italic>Tbx3-Tbx5</italic> deficient mice and investigated their cardiac phenotype. Perhaps according to expectations, given the body of literature on the function of the two T-box transcription factors in the heart/conduction system, the cardiomyocytes of the ventricular conduction system seemed to convert to &quot;ordinary&quot; ventricular working myocytes. As a consequence, loss of VCS-specific conduction system propagation was observed in the compound KO mice, associated with PR and QRS prolongation and elevated susceptibility to ventricular tachycardia.</p><p>Strengths:</p><p>Great genetic model. Phenotypic consequences at the organ and organismal levels are well investigated. The requirement of both <italic>Tbx3</italic> and <italic>Tbx5</italic> for maintaining VCS cell state has been demonstrated.</p></disp-quote><p>We thank Reviewer #1 for acknowledging the effort involved in generating and characterizing the <italic>Tbx3/Tbx5</italic> double conditional knockout mouse model and for highlighting the significance of this work in elucidating the role of these transcription factors in maintaining the functional and transcriptional identity of the ventricular conduction system.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>The actual cell state of the <italic>Tbx3/Tbx5</italic> deficient conducting cells was not investigated in detail, and therefore, these cells could well only partially convert to working cardiomyocytes, and may, in reality, acquire a unique state.</p></disp-quote><p>We agree with Reviewer #1 that the <italic>Tbx3/Tbx5</italic> double mutant ventricular conduction myocardial cells may only partially convert to working cardiomyocytes or may acquire a unique state. The transcriptional state of the double mutant VCS cells was investigated by bulk profiling of key genes associated with specific conduction and non-conduction cardiac regions, including fast conduction, slow conduction, or working myocardium. Neither the bulk transcriptional approaches nor the optical mapping approaches we employed capture single-cell data; in both cases, the data represents aggregated signals from multiple cells (1, 2). Single cell approaches for transcriptional profiling and cellular electrophysiology would clarify this concern and are appropriate for future studies.</p><p>(1) OâShea C, Nashitha Kabri S, Holmes AP, Lei M, Fabritz L, Rajpoot K, Pavlovic D (2020) Cardiac optical mapping â State-of-the-art and future challenges. The International Journal of Biochemistry &amp; Cell Biology 126:105804. doi: 10.1016/j.biocel.2020.105804. (2) Efimov IR, Nikolski VP, and Salama G (2004) Optical Imaging of the Heart. Circulation Research 95:21-33. doi: 10.1161/01.RES.0000130529.18016.35.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>The goal of this work is to define the functions of T-box transcription factors <italic>Tbx3</italic> and <italic>Tbx5</italic> in the adult mouse ventricular cardiac conduction system (VCS) using a novel conditional mouse allele in which both genes are targeted in cis. A series of studies over the past 2 decades by this group and others have shown that <italic>Tbx3</italic> is a transcriptional repressor that patterns the conduction system by repressing genes associated with working myocardium, while <italic>Tbx5</italic> is a potent transcriptional activator of &quot;fast&quot; conduction system genes in the VCS. In a previous work, the authors of the present study further demonstrated that <italic>Tbx3</italic> and <italic>Tbx5</italic> exhibit an epistatic relationship whereby the relief of <italic>Tbx3</italic>-mediated repression through VCS conditional haploinsufficiency allows better toleration of <italic>Tbx5</italic> VCS haploinsufficiency. Conversely, excess <italic>Tbx3</italic>-mediated repression through overexpression results in disruption of the fast-conduction gene network despite normal levels of <italic>Tbx5</italic>. Based on these data the authors proposed a model in which repressive functions of <italic>Tbx3</italic> drive the adoption of conduction system fate, followed by segregation into a fast-conducting VCS and slow-conduction AVN through modulation of the <italic>Tbx5/Tbx3</italic> ratio in these respective tissue compartments.</p><p>The question motivating the present work is: If <italic>Tbx5/Tbx3</italic> ratio is important for slow versus fast VCS identity, what happens when both genes are completely deleted from the VCS? Is conduction system identity completely lost without both factors and if so, does the VCS network transform into a working myocardium-like state? To address this question, the authors have generated a novel mouse line in which both <italic>Tbx5</italic> and <italic>Tbx3</italic> are floxed on the same allele, allowing complete conditional deletion of both factors using the VCS-specific <italic>MinK-CreERT2</italic> line, convincingly validated in previous work. The goal is to use these double conditional knockout mice to further explore the model of <italic>Tbx3/Tbx5</italic> co-dependent gene networks and VCS patterning. First, the authors demonstrate that the double conditional knockout allele results in the expected loss of <italic>Tbx3</italic> and <italic>Tbx5</italic> specifically in the VCS when crossed with <italic>Mink-CreERT2</italic> and induced with tamoxifen. The double conditional knockout also results in premature mortality. Detailed electrophysiological phenotyping demonstrated prolonged PR and QRS intervals, inducible ventricular tachycardia, and evidence of abnormal impulse propagation along the septal aspect of the right ventricle. In addition, the mutants exhibit downregulation of VCS genes responsible for both fast conduction AND slow conduction phenotypes with upregulation of 2 working myocardial genes including connexin-43. The authors conclude that loss of both <italic>Tbx3</italic> and <italic>Tbx5</italic> results in &quot;reversion&quot; or &quot;transformation&quot; of the VCS network to a working myocardial phenotype, which they further claim is a prediction of their model and establishes that <italic>Tbx3</italic> and <italic>Tbx5</italic> &quot;coordinate&quot; transcriptional control of VCS identity.</p></disp-quote><p>We appreciate Reviewer #2âs detailed summary of the studyâs aims, methodologies, and findings, as well as their thoughtful suggestions for further analysis. We are grateful for their recognition of our genetic modelâs novelty and robustness.</p><disp-quote content-type="editor-comment"><p>Overall Appraisal:</p><p>As noted above, the present study does not further explore the <italic>Tbx5/Tbx3</italic> ratio concept since both genes are completely knocked out in the VCS. Instead, the main claims are that the absence of both factors results in a transcriptional shift of conduction tissue towards a working myocardial phenotype, and that this shift indicates that <italic>Tbx5</italic> and <italic>Tbx3</italic> &quot;coordinate&quot; to control VCS identity and function.</p></disp-quote><p>We agree with this reviewerâs assessment of the assertions in our manuscript. The novel combined <italic>Tbx5/Tbx3</italic> double mutant model does not further explore the TBX5/TBX3 ratio concept, which we previously examined in detail (1). Instead, as the Reviewer notes, this manuscript focuses on testing a model that the coordinated activity of <italic>Tbx3</italic> and <italic>Tbx5</italic> defines specialized ventricular conduction identity.</p><p>(1) Burnicka-Turek O, Broman MT, Steimle JD, Boukens BJ, Petrenko NB, Ikegami K, Nadadur RD, Qiao Y, Arnolds DE, Yang XH, Patel VV, Nobrega MA, Efimov IR, Moskowitz IP (2020) Transcriptional Patterning of the Ventricular Cardiac Conduction System. Circulation Research 127:e94-e106. doi:10.1161/CIRCRESAHA.118.314460.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>(1) Successful generation of a novel <italic>Tbx3-Tbx5</italic> double conditional mouse model.</p><p>(2) Successful VCS-specific deletion of <italic>Tbx3</italic> and <italic>Tbx5</italic> using a VCS-specific inducible Cre driver line.</p><p>(3) Well-powered and convincing assessments of mortality and physiological phenotypes. (4) Isolation of genetically modified VCS cells using flow.</p></disp-quote><p>We thank <italic>Reviewer #2</italic> for acknowledging the listed strengths of our study.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>(1) In general, the data is consistent with a long-standing and well-supported model in which <italic>Tbx3</italic> represses working myocardial genes and <italic>Tbx5</italic> activates the expression of VCS genes, which seem like distinct roles in VCS patterning. However, the authors move between different descriptions of the functional relationship and epistatic relationship between these factors, including terms like &quot;cooperative&quot;, &quot;coordinated&quot;, and &quot;distinct&quot; at various points. In a similar vein, sometimes terms like &quot;reversion&quot; are used to describe how VCS cells change after <italic>Tbx3/Tbx5</italic> conditional knockout, and other times &quot;transcriptional shift&quot; and at other times &quot;reprogramming&quot;. But these are all different concepts. The lack of a clear and consistent terminology for describing the phenomena observed makes the overarching claims of the manuscript more difficult to evaluate.</p></disp-quote><p>We discriminate prior work on the âlong-standing and well-supported modelâ supported by investigation of the role of <italic>Tbx5</italic> and <italic>Tbx3</italic> independently from this work examining the coordinated role of <italic>Tbx5</italic> and <italic>Tbx3</italic>. Prior work demonstrated that <italic>Tbx3</italic> represses working myocardial genes and <italic>Tbx5</italic> activates expression of VCS genes, consistent with the reviewerâs suggestion of their distinct roles in VCS patterning. However, the current study uniquely evaluates the combined role of <italic>Tbx3</italic> and <italic>Tbx5</italic> in distinguishing specialized conduction identify from working myocardium, for the first time.</p><p>We appreciate Reviewer #2âs feedback regarding the need for consistent terminology when describing the impact of the double <italic>Tbx3</italic> and <italic>Tbx5</italic> mutant. We will edit the manuscript to replace terms like âreversionâ with âtranscriptional shiftâ or âtransformationâ when describing the observed phenotype, and we will use âcoordinationâ to describe the combined role of <italic>Tbx5</italic> and <italic>Tbx3</italic> in maintaining VCS-specific identity.</p><disp-quote content-type="editor-comment"><p>(2) A more direct quantitative comparison of <italic>Tbx5</italic> Adult VCS KO with <italic>Tbx5/Tbx3</italic> Adult VCS double KO would be helpful to ascertain whether deletion of <italic>Tbx3</italic> on top of <italic>Tbx5</italic> deletion changes the underlying phenotype in some discernable way beyond mRNA expression of a few genes. Superficially, the phenotypes look quite similar at the EKG and arrhythmia inducibility level and no optical mapping data from a single <italic>Tbx5</italic> KO is presented for comparison to the double KO.</p></disp-quote><p>We thank Reviewer #2 for the suggestions that a direct comparison between <italic>Tbx5</italic> single conditional knockout and <italic>Tbx3/Tbx5</italic> double conditional knockout models may help isolate the specific contribution of <italic>Tbx3</italic> deletion in addition to <italic>Tbx5</italic> deletion.</p><p>Previous studies have assessed the effect of single <italic>Tbx5</italic> CKO in the VCS of murine hearts (1, 3, 5). Arnolds <italic>et al.</italic> demonstrated that the removal of <italic>Tbx5</italic> from the adult ventricular conduction system results in VCS slowing, including prolonged PR and QRS intervals, prolongation of the His duration and His-ventricular (HV) interval (3).</p><p>Furthermore, Burnicka-Turek <italic>et al.</italic> demonstrated that the single conditional knockout of <italic>Tbx5</italic> in the adult VCS caused a shift toward a pacemaker cell state, with ectopic beats and inappropriate automaticity (1). Whole-cell patch clamping of VCS-specific <italic>Tbx5</italic> deficient cells revealed action potentials characterized by a slower upstroke (phase 0), prolonged plateau (phase 2), delayed repolarization (phase 3), and enhanced phase 4 depolarization - features characteristic of nodal action potentials rather than typical VCS action potentials (3). These observations were interpreted as uncovering nodal potential of the VCS in the absence of <italic>Tbx5</italic>. Based on the role of Tbx3 in CCS specification (2), we hypothesized that the nodal state of the VCS uncovered in the absence of <italic>Tbx5</italic> was enabled by maintained <italic>Tbx3</italic> expression. This motivated us to generate the double <italic>Tbx5</italic></p><p><italic>/ Tbx3</italic> knockout model to examine the state of the VCS in the absence of both T-box TFs. In the current study, we demonstrate that the VCS-specific deletion of <italic>Tbx3</italic> and <italic>Tbx5</italic> results in the loss of fast electrical impulse propagation in the VCS, similar to that observed in the single <italic>Tbx5</italic> mutant. However, unlike the <italic>Tbx5</italic> single mutant, the <italic>Tbx3/Tbx5</italic> double deletion does not cause a gain of pacemaker cell state in the VCS. Instead, the physiological data suggests a transition toward non-conduction working myocardial physiology. This conclusion is supported by the presence of only a single upstroke in the optical action potential (OAP) recorded from the His bundle region and VCS cells in <italic>Tbx3/Tbx5</italic> double conditional knockout mice. The electrical properties of VCS cells in the double knockout are functionally indistinguishable from those of ventricular working myocardial cells. As a result, ventricular impulse propagation is significantly slowed, resembling activation through exogenous pacing rather than the rapid conduction typically associated with the VCS. We will edit the text of the manuscript to more carefully distinguish the observations between these models, as suggested.</p><p>(1) Burnicka-Turek O, Broman MT, Steimle JD, Boukens BJ, Petrenko NB, Ikegami K, Nadadur RD, Qiao Y, Arnolds DE, Yang XH, Patel VV, Nobrega MA, Efimov IR, Moskowitz IP (2020) Transcriptional Patterning of the Ventricular Cardiac Conduction System. Circulation Research 127:e94-e106. doi:10.1161/CIRCRESAHA.118.314460.</p><p>(2) Mohan RA, Bosada FM, van Weerd JH, van Duijvenboden K, Wang J, Mommersteeg MTM, Hooijkaas IB, Wakker V, de Gier-de Vries C, Coronel R, Boink GJJ, Bakkers J, Barnett P, Boukens BJ, Christoffels VM (2020) T-box transcription factor 3 governs a transcriptional program for the function of the mouse atrioventricular conduction system. Proc Natl Acad Sci U S A. 117:18617-18626. doi: 10.1073/pnas.1919379117.</p><p>(3) Arnolds DE, Liu F, Fahrenbach JP, Kim GH, Schillinger KJ, Smemo S, McNally EM, Nobrega MA, Patel VV, Moskowitz IP (2012) TBX5 drives Scn5a expression to regulate cardiac conduction system function. The Journal of Clinical Investigation 122:2509â2518. doi: 10.1172/JCI62617.</p><p>(4) Frank DU, Carter KL, Thomas KR, Burr RM, Bakker ML, Coetzee WA, Tristani-Firouzi M, Bamshad MJ, Christoffels VM, Moon AM (2012) Lethal arrhythmias in Tbx3-deficient mice reveal extreme dosage sensitivity of cardiac conduction system function and homeostasis. Proc Natl Acad Sci U S A. 109:E154-63. doi: 10.1073/pnas.1115165109.</p><p>(5) Moskowitz IP, Pizard A, Patel VV, Bruneau BG, Kim JB, Kupershmidt S, Roden D, Berul CI, Seidman CE, Seidman JG (2004) The T-Box transcription factor Tbx5 is required for the patterning and maturation of the murine cardiac conduction system. Development 131:4107-4116. doi: 10.1242/dev.01265. PMID: 15289437.</p><disp-quote content-type="editor-comment"><p>(3) The authors claim that double knockout VCS cells transform to working myocardial fate, but there is no comparison of gene expression levels between actual working myocardial cells and the <italic>Tbx3/Tbx5</italic> DKO VCS cells so it's hard to know if the data reflect an actual cell state change or a more non-specific phenomenon with global dysregulation of gene expression or perhaps dedifferentiation. I understand that the upregulation of <italic>Gja1</italic> and <italic>Smpx</italic> is intended to address this, but it's only two genes and it seems relevant to understand their degree of expression relative to actual working myocardium. In addition, the gene panel is somewhat limited and does not include other key transcriptional regulators in the VCS such as <italic>Irx3</italic> and <italic>Nkx2-5</italic>. RNA-seq in these populations would provide a clearer comparison among the groups.</p><p>And</p><p>the main claims are that the absence of both factors results in a transcriptional shift of conduction tissue towards a working myocardial phenotype, and that this shift indicates that <italic>Tbx5</italic> and <italic>Tbx3</italic> &quot;coordinate&quot; to control VCS identity and function. However, only limited data are presented to support the claim of transcriptional reprogramming since the knockout cells are not directly compared to working myocardial cells at the transcriptional level and only a small number of key genes are assessed (versus genome-wide assessment).</p></disp-quote><p>We appreciate Reviewer #2âs suggestion to expand the gene expression analysis in <italic>Tbx3/Tbx5</italic>-deficient VCS cells by including other specific genes and comparisons with ânativeâ/actual working ventricular myocardial cells and broadening the gene panel. In this study, we evaluated core cardiac conduction system markers, revealing a loss of conduction system-specific gene expression in the double mutant VCS. Furthermore, we evaluated key working myocardial markers normally excluded from the conduction system, <italic>Gja1</italic> and <italic>Smpx</italic>, revealing a shift towards a working myocardial state in the double mutant VCS (Figure 4). We agree that a more comprehensive analysis, such as transcriptome-wide approaches, would offer greater clarity on the extent and specificity of the observed shift from conduction to non-conduction identity. These approaches are appropriate directions for future studies.</p><disp-quote content-type="editor-comment"><p>(4) From the optical mapping data, it is difficult to distinguish between the presence of (a) a focal proximal right bundle branch block due to dysregulation of gene expression in the VCS but overall preservation of the right bundle and its distal ramifications; from (b) actual loss of the VCS with reversion of VCS cells to a working myocardial fate. Related to this, the authors claim that this experiment allows for direct visualization of His bundle activation, but can the authors confirm or provide evidence that the tissue penetration of their imaging modality allows for imaging of a deep structure like the AV bundle as opposed to the right bundle branch which is more superficial? Does the timing of the separation of the sharp deflection from the subsequent local activation suggest visualization of more distal components of the VCS rather than the AV bundle itself? Additional clarification would be helpful.</p><p>And</p><p>In addition, the optical mapping dataset is incomplete and has alternative interpretations that are not excluded or thoroughly discussed.</p></disp-quote><p>We agree with Reviewer #2 that the resolution of the optical mapping experiment may be insufficient to precisely localize the conduction block due to the limited signal strength from the VCS. It is possible that the region defined as the His Bundle also includes portions of the right bundle branch. Our control mice show VCS OAP upstrokes consistent with those reported by Tamaddon <italic>et al.</italic> (2000) using Di-4-ANEPPS (1). We appreciate the Reviewerâs attention to alternative interpretations, and we will incorporate these caveats into the manuscript text.</p><p>(1) Tamaddon HS, Vaidya D, Simon AM, Paul DL, Jalife J, Morley GE (2000) Highresolution optical mapping of the right bundle branch in connexin40 knockout mice reveals slow conduction in the specialized conduction system. Circulation Research 87:929-36. doi: 10.1161/01.res.87.10.929.</p><disp-quote content-type="editor-comment"><p>Impact:</p><p>The present study contributes a novel and elegantly constructed mouse model to the field. The data presented generally corroborate existing models of transcriptional regulation in the VCS but do not, as presented, constitute a decisive advance.</p><p>And</p><p>In sum, while this study adds an elegantly constructed genetic model to the field, the data presented fit well within the existing paradigm of established functions of <italic>Tbx3</italic> and <italic>Tbx5</italic> in the VCS and in that sense do not decisively advance the field. Moreover, the authors' claims about the implications of the data are not always strongly supported by the data presented and do not fully explore alternative possibilities.</p></disp-quote><p>We appreciate Reviewer # 2âs acknowledgment of the elegance and novelty of the mouse model we generated. However, we respectfully disagree with their assessment that this work merely corroborates existing models without providing a decisive advance. Previous studies have investigated single <italic>Tbx5</italic> or <italic>Tbx3</italic> gene knockouts in-depth and established the T-box ratio model for distinguishing fast VCS from slow nodal conduction identity (1) that the reviewer alludes to in earlier comments. In contrast, this study aimed to explore a different model, that the combined effects of <italic>Tbx5</italic> and <italic>Tbx3</italic> distinguish adult VCS identity from non-conduction working myocardium. The coordinated <italic>Tbx3</italic> and <italic>Tbx5</italic> role in conduction system identify remained untested due to the lack of a mouse model that allowed their simultaneous removal. The very model the reviewer recognizes as ânovel and elegantly constructedâ has allowed the examination of the coordinated role of <italic>Tbx5</italic> and <italic>Tbx3</italic> for the first time. While we acknowledge the opportunity for additional depth of investigation of this model in future studies, the data we present provides consistent experimental support for the coordinated requirement of both <italic>Tbx5</italic> and <italic>Tbx3</italic> for ventricular cardiac conduction system identity.</p><p>(1) Burnicka-Turek O, Broman MT, Steimle JD, Boukens BJ, Petrenko NB, Ikegami K, Nadadur RD, Qiao Y, Arnolds DE, Yang XH, Patel VV, Nobrega MA, Efimov IR, Moskowitz IP (2020) Transcriptional Patterning of the Ventricular Cardiac Conduction System. <italic>Circulation Research</italic> 127:e94-e106. doi:10.1161/CIRCRESAHA.118.314460.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>Summary:</p><p>In the study presented by Burnicka-Turek <italic>et al.,</italic> the authors generated for the first time a mouse model to cause the combined conditional deletion of <italic>Tbx3</italic> and <italic>Tbx5</italic> genes. This has been impossible to achieve to date due to the proximity of these genes in chromosome 5, preventing the generation of loss of function strategies to delete simultaneously both genes. It is known that both <italic>Tbx3</italic> and <italic>Tbx5</italic> are required for the development of the cardiac conduction system by transcription factor-specific but also overlapping roles as seen in the common and diverse cardiac defects found in patients with mutations for these genes. After validating the deletion efficiency and specificity of the line, the authors characterized the cardiac phenotype associated with the cardiac conduction system (CCS)-specific combined deletion of T_bx5_ and <italic>Tbx3</italic> in the adult by inducing the activation of the CCS-specific tamoxifen-inducible Cre recombination (<italic>MinKcreERT</italic>) at 6 weeks after birth. Their analysis of 8-9-week-old animals did not identify any major morphological cardiac defects. However, the authors found conduction defects including prolonged PR and QTR intervals and ventricular tachycardia causing the death of the double mutants, which do not survive more than 3 months after tamoxifen induction. Molecular and optical mapping analysis of the ventricular conduction system (VCS) of these mutants concluded that, in the absence of <italic>Tbx5</italic> and <italic>Tbx3</italic> function, the cells forming the ventricular conduction system (VCS) become working myocardium and lose the specific contractile features characterizing VCS cells. Altogether, the study identified the critical combined role of <italic>Tbx3</italic> and <italic>Tbx5</italic> in the maintenance of the VCS in adulthood.</p><p>Strengths:</p><p>The study generated a new animal model to study the combined deletion of <italic>Tbx5</italic> and <italic>Tbx3</italic> in the cardiac conduction system. This unique model has provided the authors with the perfect tool to answer their biological questions. The study includes top-class methodologies to assess the functional defects present in the different mutants analyzed, and gathered very robust functional data on the conduction defects present in these mutants. They also applied optical action potential (OAP) methods to demonstrate the loss of conduction action potential and the acquisition of working myocardium action potentials in the affected cells because of <italic>Tbx5/Tbx3</italic> loss of function. The study used simpler molecular and morphological analysis to demonstrate that there are no major morphological defects in these mutants and that indeed, the conduction defects found are due to the acquisition of working myocardium features by the VCS cells. Altogether, this study identified the critical role of these transcription factors in the maintenance of the VCS in the adult heart.</p></disp-quote><p>We appreciate the Reviewerâs comments regarding the originality and utility of our model and the strengths of our methodological approach. The Reviewerâs appreciation of the molecular and morphological analyses as well as their constructive feedback is highly valuable.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>In the opinion of this reviewer, the weakness in the study lies in the morphological and molecular characterization. The morphological analysis simply described the absence of general cardiac defects in the adult heart, however, whether the CCS tissues are present or not was not investigated. Lineage tracing analysis using the reporter lines included in the crosses described in the study will determine if there are changes in CCS tissue composition in the different mutants studied. Similarly, combining this reporter analysis with the molecular markers found to be dysregulated by qPCR and western blot, will demonstrate that indeed the cells that were specified as VCS in the adult heart, become working myocardium in the absence of <italic>Tbx3</italic> and <italic>Tbx5</italic> function.</p></disp-quote><p>We appreciate the reviewerâs concern regarding the morphology of the cardiac conduction system in the <italic>Tbx3/Tbx5</italic> double conditional knockout model. We did not observe any structural abnormalities, as the Reviewer notes. We agree with their suggestion for using Genetic Inducible Fate Mapping to mark cardiac conduction cells expressing <italic>MinKCre</italic>. In fact, we utilized this approach to isolate VCS cells for transcriptional profiling. Specifically, we combined the tamoxifen-inducible <italic>MinKCreERT</italic> allele with the Cre-dependent <italic>R26Eyfp</italic> reporter allele to label <italic>MinKCre</italic>-expressing cells in both control VCS and VCS-specific double <italic>Tbx3</italic>/<italic>Tbx5</italic> knockouts. EYFP-positive cells were isolated for transcriptional studies, ensuring that our analysis exclusively targeted conduction system-lineage marked cells. The ability to isolate <italic>MinKCre</italic>-marked cells from both controls and Tbx5/Tbx3 double mutants indicates that VCS cells persisted in the double knockout. Nonetheless, the suggestion for <italic>in-vivo</italic> marking by Genetic Inducible</p><p>Fate Mapping and morphologic analysis is a valuable recommendation for future studies.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>In a heroic effort, Ozanna Burnicka-Turek et al. have made and investigated conduction system-specific <italic>Tbx3-Tbx5</italic> deficient mice and investigated their cardiac phenotype. Perhaps according to expectations, given the body of literature on the function of the two T-box transcription factors in the heart/conduction system, the cardiomyocytes of the ventricular conduction system seemed to convert to &quot;ordinary&quot; ventricular working myocytes. As a consequence, loss of VCS-specific conduction system propagation was observed in the compound KO mice, associated with PR and QRS prolongation and elevated susceptibility to ventricular tachycardia.</p><p>Previous work suggested the prediction that VCS-specific genetic ablation of both the TBX3 and TBX5 would transform fast-conducting adult VCS into cells resembling working myocardium, eliminating specialized CCS fate. The current study suggests that this prediction is at least to some extent accurate.</p></disp-quote><p>We appreciate Reviewer #1âs summary and recognition of our study. As the review notes, the simultaneous deletion of <italic>Tbx3</italic> and <italic>Tbx5</italic> in the mature ventricular conduction system (VCS) suggests a conversion of VCS to &quot;ordinary&quot; ventricular working myocytes. To our knowledge, this represents a novel observation and experimental model that uniquely captures the combined roles of these essential T-box transcription factors. We believe that this model offers a valuable platform for further investigation into the transcriptional mechanisms underlying conduction system specialization.</p><disp-quote content-type="editor-comment"><p>(1) The huge effort made to generate the DKO model contrasts with the limited efforts made to study the mechanism. Conditional deficiency of <italic>Tbx3</italic> and <italic>Tbx5</italic> creates an artificial situation that is useful for addressing fundamental mechanistic questions. The authors provide a rather superficial analysis of the changes in the VCS upon deletion of these two critically important factors and do not provide really novel insights into their requirement/function in the VCS gene regulatory network and epigenetic state. So to what extent do VCS cardiomyocytes (CMs) from <italic>Tbx3/5</italic> DKO mice resemble &quot;simple&quot; working myocardium? To what extent do these cells acquire the working myocardial (epigenetic) state, do these cells have an epigenetic memory of the <italic>Tbx3/Tbx5+</italic> history, is the enhancer usage between the modified VCS CMs and the working CMs similar or not, etc.? The assumption that the authors' data indicate that the DKO VCS CMs simply acquire a ventricular working &quot;fate&quot; is unlikely. Following this reasoning, the reverse experiment to induce <italic>Tbx3</italic> and <italic>Tbx5</italic> expression in working CMs would result in complete conversion to VCS CMs, which is also unlikely.</p><p>To answer such questions, transcriptomic and epigenetic state analysis, electrophysiologic analysis (e.g. patch-clamp), cell/subcellular level analysis, etc. would be required, as well as a comparison of the changed state of the DKO VCS CMs to that of working CMs.</p></disp-quote><p>This initial study focused on generating the <italic>Tbx3:Tbx5</italic> double-conditional knockout model and characterizing the resulting physiological and molecular changes within the VCS. We analyzed transcriptomic markers of fast conduction (VCS), slow conduction (nodal), and non-conduction (working myocardium). Additionally, we applied optical mapping to evaluate the physiological consequences of the double knockout, which allowed a calculated AP of the VCS to be generated. We agree that a more in-depth mechanistic investigation of the VCS transformation upon <italic>Tbx3/Tbx5</italic> deletion by transcriptomic or cellular electrophysiology could provide a deeper understanding of the precise transcriptional/epigenetic state of the VCS in the double knockout and clarify whether there is a partial or complete conversion of VCS cells to a simple working myocardial phenotype. The suggestions by the reviewer will be considered for future studies.</p><disp-quote content-type="editor-comment"><p>(2) <italic>Tbx3</italic> stimulates BMP-TGFb signaling (e.g. positive loop between <italic>Tbx3-Bmp2</italic>), which in turn stimulates EMT and modulates the behavior of endocardial and mesenchymal cells. Did the authors investigate the impact of <italic>Tbx3/5</italic> DKO on non-CM cells in and around the VCS? (see also comment 1). The insulation of the AVB for example could be a <italic>Tbx3/5</italic> non cell autonomous target.</p></disp-quote><p>We appreciate the Reviewerâs suggestion to examine the impact of <italic>Tbx3/Tbx5</italic> deletion on non-CM cells surrounding the VCS. While this is an intriguing avenue for future exploration, it falls outside the scope of the current study, which focused on the cardiomyocyte-specific roles of <italic>Tbx3</italic> and <italic>Tbx5</italic> in maintaining adult VCS identity.</p><disp-quote content-type="editor-comment"><p>(3) The <italic>MinK-Cre</italic> line used (from the Moskowitz lab) also recombines in the AVN (Arnolds <italic>et al</italic> 2011). The authors do not mention changes in the AVN, and systematically call the line VCS specific (which refers to the AVB, BB, PVCS I assume). This could also impact the PR interval. Please address.</p></disp-quote><p>The <italic>MinK-Cre</italic> line recombines in the atrioventricular bundle (AVB) and bundle branches (BB). It recombines in cardiomyocytes adjacent to the atrioventricular node (AVN). We previously interpreted these cells as the penetrating portion of the His bundle into the AVN. This line does not recombine in the vast majority, if any, physiologic nodal cells. We also assessed nodal conduction parameters by invasive electrophysiologic (EP) studies. Our data showed that non-VCS parameters, including sinus node recovery time, AV node recovery time, and atrial and ventricular effective refractory periods, remained within normal ranges in <italic>Tbx3:Tbx5</italic>-deficient mice (please see Figure 2I). These findings indicate that AVN function is preserved in the VCS-specific double knockout, reinforcing the specificity of the observed conduction defects to the ventricular conduction system.</p><disp-quote content-type="editor-comment"><p>(4) Did the authors also investigate the electrophysiological changes in the (EGFP+) DKO VCS CMs? Would these resemble the properties of ventricular working CMs, or would they still show some VCS properties? (see also comment 1).</p></disp-quote><p>We performed electrophysiologic analysis of the double knockout by optical mapping. Optical mapping provides tissue-level resolution, capturing the functional behavior of clusters of thousands of cells simultaneously, rather than individual cells. While this technique does not achieve single-cell resolution, it allows for a comprehensive assessment of electrophysiological changes across the VCS region. Single cell electrophysiology is a good idea for future studies.</p><disp-quote content-type="editor-comment"><p>(5) Throughout the manuscript, the authors use &quot;patterning&quot; and &quot;fate&quot;, which are applicable to development and differentiation, not to the situation where a gene is removed from fully differentiated cells in an adult organism resulting in a change of these cells. Perhaps more appropriate are &quot;state&quot; change and the requirement for &quot;homeostasis/maintenance&quot; of state.</p></disp-quote><p>We appreciate the Reviewerâs concern regarding the terminology used to describe changes in VCS cell identity. To ensure precision and uniformity, we replaced terms such as âfateâ and âpatterningâ with âstateâ or âmaintenanceâ to reflect the shift in cellular characteristics in a fully differentiated adult tissue context.</p><disp-quote content-type="editor-comment"><p>Minor:</p><p>(1) Please provide all data points in bar graphs.</p></disp-quote><p>We have incorporated individual data points into the bar graphs as suggested, ensuring enhanced transparency and clarity in the data presentation.</p><disp-quote content-type="editor-comment"><p>â(2) Formally, gene expression levels between samples are not normally distributed. The Welch t-test used here assumes a normal distribution. Therefore, nonparametric tests should be used.</p></disp-quote><p>We appreciate Reviewer #1âs consideration of the appropriate statistical approach to the qPCR data and clarify our statistical approach here. Normality within each experimental group was assessed using the Shapiro-Wilk test. Between-group comparisons were conducted using Welch t-test, and multiple comparisons were corrected using the Benjamini &amp; Hochberg method to control the false discovery rate (FDR) (71). If a significant difference was detected between two groups (t-test FDR &lt; 0.05) but normality was rejected in any of the compared groups (Shapiro-Wilk P &lt; 0.05), a non-parametric Wilcoxon rank-sum test was used for verification. A significant group-mean difference was confirmed at one-tailed Wilcoxon Pâ¤0.05 (detailed in Supplementary Data Set I). Furthermore, we have updated the qRT-PCR information in each figure and their respective legends as follows. Statistical analysis was performed using R version 4.2.0. We have included a new Supplementary Data Set I, detailing the statistical analysis of qRT-PCR data. Additionally, we have revised the Methods/Statistics section to detail the applied statistical analysis.</p><disp-quote content-type="editor-comment"><p>(3) Some of the panels of figures are tiny and cannot be evaluated. For example, in Figure 1B the actual data (expression of <italic>Tbx3/5</italic>) is impossible to see.</p></disp-quote><p>We appreciate the Reviewerâs observation and have revised the figures to improve visual clarity and ensure that the presented data are easily interpretable by readers.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>Additional Experiments, Data, Analysis:</p><p>(1) Comparisons between both single knockouts and double knockouts at the phenotypic level are needed. In some instances, the data is shown (e.g., mortality and EKG) but direct statistical comparison is not performed. In other instances (optical mapping and gene expression), data with single knockouts are not shown. If combined VCS <italic>Tbx3/Tbx5</italic> deletion does not change the phenotype of the VCS <italic>Tbx5</italic> single deletion, this should be explicitly stated and discussed.</p></disp-quote><p>We appreciate Reviewer #2âs suggestion to compare the phenotypic outcomes of the <italic>Tbx3</italic> and <italic>Tbx5</italic> single conditional knockout models with those observed in <italic>Tbx3/Tbx5</italic> double conditional knockout model. We have expanded the discussion section of our manuscript to incorporate a more detailed comparison between the double <italic>Tbx3/Tbx5</italic> model and the single <italic>Tbx5</italic> and <italic>Tbx3</italic> models [1-5], highlighting the distinct phenotypic outcomes of the single and double knockouts.</p><p>(1) Burnicka-Turek O, Broman MT, Steimle JD, Boukens BJ, Petrenko NB, Ikegami K, Nadadur RD, Qiao Y, Arnolds DE, Yang XH, Patel VV, Nobrega MA, Efimov IR, Moskowitz IP (2020) Transcriptional Patterning of the Ventricular Cardiac Conduction System. Circulation Research 127:e94-e106. doi:10.1161/CIRCRESAHA.118.314460.</p><p>(2) Mohan RA, Bosada FM, van Weerd JH, van Duijvenboden K, Wang J, Mommersteeg MTM, Hooijkaas IB, Wakker V, de Gier-de Vries C, Coronel R, Boink GJJ, Bakkers J, Barnett P, Boukens BJ, Christoffels VM (2020) T-box transcription factor 3 governs a transcriptional program for the function of the mouse atrioventricular conduction system. Proc Natl Acad Sci U S A. 117:18617-18626. doi: 10.1073/pnas.1919379117.</p><p>(3) Arnolds DE, Liu F, Fahrenbach JP, Kim GH, Schillinger KJ, Smemo S, McNally EM, Nobrega MA, Patel VV, Moskowitz IP (2012) TBX5 drives Scn5a expression to regulate cardiac conduction system function. The Journal of Clinical Investigation 122:2509â2518. doi: 10.1172/JCI62617.</p><p>(4) Frank DU, Carter KL, Thomas KR, Burr RM, Bakker ML, Coetzee WA, Tristani-Firouzi M, Bamshad MJ, Christoffels VM, Moon AM (2012) Lethal arrhythmias in Tbx3-deficient mice reveal extreme dosage sensitivity of cardiac conduction system function and homeostasis. Proc Natl Acad Sci U S A. 109:E154-63. doi: 10.1073/pnas.1115165109. [5] Moskowitz IP, Pizard A, Patel VV, Bruneau BG, Kim JB, Kupershmidt S, Roden D, Berul CI, Seidman CE, Seidman JG (2004) The T-Box transcription factor Tbx5 is required for the patterning and maturation of the murine cardiac conduction system. Development 131:4107-4116. doi: 10.1242/dev.01265.</p><disp-quote content-type="editor-comment"><p>(2) Genome-wide expression analysis including working myocardium would provide stronger evidence for interconversion of cell states. Ideally, this would include single knockouts.</p></disp-quote><p>We agree that a genome-wide expression analysis, including a direct comparison with working myocardium, would provide more comprehensive insights into cell state transitions in <italic>Tbx3:Tbx5</italic>-deficient VCS cells. Additionally, incorporating single knockout models into such analyses would further clarify the distinct and cooperative contributions of <italic>Tbx3</italic> and <italic>Tbx5</italic> to maintaining VCS identity. This is a good suggestion for future studies.</p><disp-quote content-type="editor-comment"><p>(3) This may not be essential to support the authors' claims, but the addition of epigenetic data from single and double KO VCS using ATAC-seq (which can be performed with relatively small numbers of cells) could provide stronger evidence for cell state changes of the kind hypothesized by the authors.</p></disp-quote><p>We agree that epigenetic data such as ATAC-seq would complement transcriptional analyses and provide insight into chromatin states that underlie the observed cellular reprogramming. This is a good suggestion for follow-up studies to further characterize the molecular state of <italic>Tbx3:Tbx5</italic>-deficient VCS cells.</p><disp-quote content-type="editor-comment"><p>(4) Additional clarification of the optical mapping experiments to exclude alternative interpretations like focal right bundle branch block and to include single knockouts for comparison - if the <italic>Tbx5</italic> single KO looks the same as the double KO that would be very important to know and would directly affect interpretation of the experiment.</p></disp-quote><p>Right septal optical mapping preparation involved removing the right ventricular free wall to directly image the right ventricular septum, which contains the VCS. In a healthy mouse, there are two peak components of the optical action potential upstroke, the first peak due to the activation of the VCS and the second due to the activation of the ventricular cardiomyocytes. Importantly, in <italic>Tbx3:Tbx5</italic> double-conditional knockout mice, the first peak was absent, rather than delayed, indicating loss of fast conduction through the VCS. This absence suggests a shift in VCS cells toward a ventricular working myocardial phenotype, rather than a regional conduction block or delayed propagation through a structurally intact VCS.</p><p>Previous studies from our group have extensively characterized the effect of single <italic>Tbx5</italic> knockout on the VCS in murine hearts [1, 2, 3]. Arnolds et al. demonstrated that VCSspecific <italic>Tbx5</italic>-deficiency results in significant slowing of VCS conduction, evidenced by prolonged PR and QRS intervals, along with lengthening of the atrio-Hisian interval, His duration, and Hisioventricular interval [1]. Although both single <italic>Tbx5</italic> knockout and <italic>Tbx3:Tbx5</italic> double knockout mice exhibit slowing of ventricular conduction system, our optical mapping studies reveal distinct differences in their electrophysiological phenotypes. Burnicka-Turek <italic>et al.</italic> showed that the single knockout of <italic>Tbx5</italic> in the VCS leads to a shift toward a pacemaker cell state, evidenced by ectopic beats originating in the ventricles and inappropriate automaticity [3]. During spontaneous beats, electrical impulses were retrogradely activated, propagating from the ventricles to the atria [3]. Whole-cell patch clamping recordings confirmed that <italic>Tbx5</italic>-deficient VCS cells displayed action potentials resembling pacemaker cells, characterized by slower upstroke (phase 0), prolonged plateau (phase 2), delayed repolarization (phase 3), and enhanced phase 4 depolarization [3]. In contrast, our current study on VCS-specific <italic>Tbx3:Tbx5</italic> double knockout demonstrates a loss of the VCS-specific fast conduction propagation. Optical mapping demonstrated the absence of the initial upstroke corresponding to VCS activation in the His bundle region, indicating a shift in the VCS cells toward a ventricular working myocardium state. This loss of fast conduction properties highlights a fundamental distinction between single and double knockouts, suggesting that both <italic>Tbx3</italic> and <italic>Tbx5</italic> are required to maintain VCS identity and function.</p><p>(1) D. E. Arnolds et al., âTBX5 drives Scn5a expression to regulate cardiac conduction system function,â J. Clin. Invest., vol. 122, no. 7, pp. 2509â2518, Jul. 2012, doi: 10.1172/JCI62617.</p><p>(2) Moskowitz, I.P., Pizard, A., Patel, V.V., Bruneau, B.G., Kim, J.B., Kupershmidt, S., Roden, D., Berul, C.I., Seidman, C.E., Seidman, J.G. (2004) The T-Box transcription factor Tbx5 is required for the patterning and maturation of the murine cardiac conduction system. Development 131(16):4107-4116.</p><p>(3) Burnicka-Turek, O., Broman, M.T., Steimle, J.D., Boukens, B.J., Peterenko, N.B, Ikegami, K., Nadadur, R.D., Qiao, Y., Arnolds, D.E., Yang, X.H., Patel, V.V., Nobrega, M.A., Efimov, I.R., Moskowitz, I.P. (2020) Transcriptional Patterning of the Ventricular Cardiac Conduction System. Circ Res. 127(3):e94-e106.</p><disp-quote content-type="editor-comment"><p>Methods:</p><p>(1) Additional methods on FACS are required. The methods section references a paper from 2004 (reference 67) that describes the flow sorting of embryonic cardiomyocytes. However, flow cytometric isolation of intact adult cardiomyocytes, which the authors describe in the present work, is a distinct technique and generally requires special equipment. These need to be described in more detail to be fully replicable.</p></disp-quote><p>We thank Reviewer #2 for highlighting the need to provide additional details regarding our flow cytometric isolation of adult VCS cardiomyocytes. While we referenced earlier methods, we agree that isolating adult cardiomyocytes requires specialized approaches. Therefore, we revised the Methods section to include a detailed description of the equipment, procedures, and adaptations specific to isolating intact adult VCS cells to ensure full replicability.</p><p>Minor Corrections:</p><p>(1) Figure 1D. Please add a statistical test for mortality between the double conditional KO and the <italic>Tbx5</italic> conditional KO.</p><p>We have revised Figure 1D to include the statistical test comparing mortality between the <italic>Tbx3:Tbx5</italic> double conditional knockout and the <italic>Tbx5</italic> conditional knockout cohorts.</p><disp-quote content-type="editor-comment"><p>(2) Figure 2A, 2I, 3A: Please include all individual data points not just a bar graph with error bars.</p></disp-quote><p>We have added all individual data points to the bar graphs as recommended, enhancing the transparency and clarity of the data presentation.</p><disp-quote content-type="editor-comment"><p>(3) Figure 2A: Please consider separate graphs for PR and QRS with appropriately scaled Y-axis so differences are easier to see.</p></disp-quote><p>We appreciate Reviewer #2âs suggestion and fully agree with it. As a result, we have revised Figure 2A to include separate graphs for PR and QRS intervals, each with appropriately scaled Y-axes. This adjustment enhanced both the readability and the clarity of the observed differences.</p><disp-quote content-type="editor-comment"><p>(4) Figure 3 G-K: The figure would be easier to interpret for the reader if genotypes were shown in the figure not just in the legend.</p></disp-quote><p>We agree with Reviewer #2âs suggestion and have revised Figure 3 accordingly by adding genotype labels directly to the histological sections in Panels G-K. This update improves clarity, making the data easier for readers to interpret without needing to refer to the figure legend.</p><disp-quote content-type="editor-comment"><p>(5) Figure 4A, C: Are vertical axes mislabeled? They say, &quot;CON VCS and TBX5OE VCS&quot;. Please double-check axis labels and data on the graph.</p></disp-quote><p>We appreciate the Reviewer bringing the mislabeling of the vertical axis in Figure 4 to our attention. We have corrected the labeling errors and ensured consistency between the graph and the underlying data.</p><disp-quote content-type="editor-comment"><p>(6) Legend to Supplementary Figure 6. Says &quot;<italic>Tbx3:Tbx3</italic>&quot; instead of &quot;<italic>Tbx3:Tbx5</italic>&quot;.</p></disp-quote><p>We thank Reviewer #2 for pointing out the typo. It has been corrected to: âSupplementary Figure 6. <italic>Tbx3:Tbx5</italic> double-conditional knockout mice exhibit QRS prolongationâ.</p><disp-quote content-type="editor-comment"><p>(7) Discussion. The authors write, &quot;In <italic>Tbx3:Tbx5</italic> double VCS knockout, we observed repression of fast VCS markers and also repression of Pan-CCS markers transcribed throughout the entire CCS.&quot; The term 'repression' has a specific connotation with transcription regulators that is likely not intended in this context so perhaps 'reduced expression' would be better here?</p></disp-quote><p>We agree with Reviewer #2 and have replaced ârepressionâ with âreduced expressionâ throughout the text (look below for references).</p><p>âIn the <italic>Tbx3:Tbx5</italic> double VCS knockout, we observed a reduction in the expression of both fast VCS markers and Pan-CCS markers transcribed throughout the entire CCS.â</p><disp-quote content-type="editor-comment"><p>(8) Discussion, the authors write, &quot;This study combined with prior literature (1, 7, 11, 15, 26, 53, 54) indicates that the presence of both <italic>Tbx3</italic> and <italic>Tbx5</italic> is necessary for the specification of the adult VCS (Figure 7).&quot; Since this work presents data from an adult conditional deletion, it's not clear how it informs our understanding of the specification, which occurs during development. Perhaps &quot;maintenance of VCS fate&quot; would be more appropriate here?</p></disp-quote><p>We agree with Reviewer #2 that the term âmaintenance of VCS fateâ is more appropriate in the context of our study. Accordingly, we have updated the text to reflect this terminology.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>(1) Figure 2B: It is hard to see the IF images. What is the cardiac structure studied? Maybe a dashed line and a label to define the region and the structure represented will help. As the authors have described that the crosses used contain a reporter allele (<italic>R26-EYFP</italic>), a clearer way to show these results would be to include images of the linage traced cells with the reporter, not only to identify the CCS structure analyzed, but also to demonstrate that the deletion is specific to the <italic>MinK-creERT</italic> expression in the CCS.</p></disp-quote><p>We appreciate the Reviewerâs suggestion to improve the clarity of Figure 2B by delineating the cardiac structures analyzed. In response, we have added dashed lines and labels to highlight the regions of interest within the IF images. Unfortunately, we were unable to capture high-quality EYFP fluorescence images for these sections. However, to address this concern, we microdissected the region shown in the IF images and performed FACS to isolate EYFP-positive cells from this specific area. These sorted cells were subsequently used for qPCR analysis, which confirmed the presence of <italic>Tbx3</italic> and <italic>Tbx5</italic> in control samples and the successful deletion of both genes in the doubleconditional knockout samples (Figure 2C, middle panel). We believe this approach provides robust evidence for the specificity of the <italic>MinK-CreERT</italic> expression in the CCS and the efficiency of gene deletion in the targeted region.</p><disp-quote content-type="editor-comment"><p>(2) 3G-K: The authors describe the absence of morphological defects in the tissue sections of adult hearts from the different genotypes analyzed. Although this reviewer agrees that there seem to be no major defects in the general cardiac morphology of these animals, the higher magnification images suggest some tissue differences at the level of the AVN especially in the double HET, double HOMO, and the <italic>Tbx3</italic> HOMO. Is that due to the section plane used? If so, more appropriate and comparable sections must be provided. Again, as the crosses used by the authors contain a reporter allele (<italic>R26-EYFP</italic>), it is required that the authors show that the CCS cells, where deletions are induced, are still present in equivalent areas in the mutants and that they remain in similar numbers only failing to maintain their specification into CCS due to <italic>Tbx3</italic> and <italic>Tbx5</italic> loss of function.</p></disp-quote><p>This analysis will reinforce the authors' claims on the role of <italic>Tbx5/Tbx3</italic> in this process.</p><p>We thank the reviewer for their thorough assessment and thoughtful feedback on our histological analysis. The higher magnification images in Figure 3G-K do not specifically present the AVN. These sections primarily represent areas of the ventricular conduction system (VCS), particularly the His bundle and bundle branches, rather than the AVN itself. We do not believe that the observed morphological differences are related to AVN tissue, and there were no functional deficits attributable to the AVN in the double knockout. Furthermore, the <italic>Mink-Cre</italic> allele used in this study does not recombine in the ANV proper. We agree that confirming the presence of CCS cells in equivalent regions across different genotypes is crucial. Our approach using FACS-based isolation of EYFP-positive cells from the VCS, followed by qPCR analysis, provides evidence that these cells remain present in double conditional knockouts, although they fail to maintain their specialized gene expression profile. This reinforces our conclusion that <italic>Tbx3</italic> and <italic>Tbx5</italic> are essential for maintaining the molecular identity of CCS cells, rather than their physical presence.</p><disp-quote content-type="editor-comment"><p>(3) Figure 4: The authors performed molecular analysis by qPCR and WB in <italic>Tbx5/Tbx3</italic> double mutants to demonstrate that CCS cells lose the expression of CCS genes and express working myocardium genes. Could this be further demonstrated by ISH, HCR, or IF together with lineage tracing to provide evidence that these changes are located where the CCS tissues are in the control embryos? Analysis of 2 or 3 of these markers of each type on tissue sections would be enough.</p></disp-quote><p>We thank the Reviewer for their insightful suggestion regarding additional validation of our molecular findings through ISH, HCR, or IF combined with lineage tracing. However, we would like to clarify that the molecular analyses we performed by qPCR and WB were conducted on EYFP-positive cells that were specifically isolated from the ventricular conduction system (VCS) region of both control and double conditional knockout (dCKO) mice. These EYFP-positive cells were obtained through fluorescence-activated cell sorting (FACS), ensuring that our analyses were confined to the targeted VCS population. Alternate approaches are appropriate for future studies to investigate the precise genomic and molecular nature of the transformation observed in the double knockout.</p><disp-quote content-type="editor-comment"><p>(4) Discussion: in the discussion section the authors conclude that the combined role of <italic>Tbx5/Tbx3</italic> is critical for the specification of the adult VCS. However, as the <italic>Tbx5/Tbx3</italic> loss of function conditions are only induced in adult animals 6 weeks old, would it be more appropriate that their function is the maintenance of the VCS cell fate and that if not present these cells return to the working myocardium fate? If the authors believe that these genes are involved in the induction of VCS specification in adults, then they need to demonstrate that, before the loss of function induction at 6 weeks, these cells are not yet specified as adult VCS.</p></disp-quote><p>We appreciate the Reviewerâs clarification regarding terminology. We agree that our study focuses on adult-specific conditional deletion and thus reflects the maintenance, rather than the specification, of VCS cell fate. Accordingly, we have revised the text to explicitly state that <italic>Tbx3</italic> and <italic>Tbx5</italic> are critical for maintaining VCS identity in adult mice, and that their loss leads to a shift toward a working myocardial fate.</p><disp-quote content-type="editor-comment"><p>Minor:</p><p>(1) There is no consistency in the way the quantitative data is shown in graphs. There are some graphs showing only bars, other dot plots, and other a combination of both. The authors must homogenise the representation of quantitative data showing the different data points in dot plots and not in bar graphs.</p></disp-quote><p>We have standardized the quantitative data presentation across all figures, by including individual data points in bar graphs, ensuring enhanced transparency and clarity.</p><disp-quote content-type="editor-comment"><p>(2) Figure 3: The labels defining the genotypes corresponding to the different histological sections of adult hearts (Panels G-K) are missing. Panels J and K are not referenced in the text.</p></disp-quote><p>We thank Reviewer #3 for highlighting these omissions. We have added the genotype labels to the histological sections in Panels G-K of Figure 3 to ensure clarity. Furthermore, we have now referenced Panels J and K in the results and in the supplementary material (please look below for references).</p><p>âHistological examination of all four-chambers demonstrated no discernible differences between VCS-specific <italic>Tbx3:Tbx5</italic> double-knockout (<italic>Tbx3fl/fl;Tbx5fl/fl;R26EYFP/+; MinKCreERT2/+</italic>) and control (<italic>Tbx3+/+;Tbx5+/+;R26EYFP/+; MinKCreERT2/+</italic>) mice, nor between . the double-knockout (<italic>Tbx3fl/fl;Tbx5fl/fl;R26EYFP/+; MinKCreERT2/+</italic>) and single-knockout models for either <italic>Tbx3</italic> (<italic>Tbx3fl/fl;Tbx5+/+;R26EYFP/+; MinKCreERT2/+</italic>) or <italic>Tbx5</italic> (<italic>Tbx3+/+;Tbx5fl/fl;R26EYFP/+; MinKCreERT2/+</italic>).Ventricular muscle appeared normal without hypertrophy or myofibrillar disarray and no fibrosis was present (Figure 3G, 3I, 3J, and 3K, respectively).â</p><p>âAdditionally, we confirmed the absence of histological and structural abnormalities in these mice, aligning with previous findings (Figures 3A, 3F versus 3B, and 3K versus 3G, respectively)(1, 11).â</p><disp-quote content-type="editor-comment"><p>(3) Typo: Supplementary Figure 6. <italic>Tbx3:Tbx3</italic> double-conditional knockout: it should say <italic>Tbx5:Tbx3</italic> double-conditional knockout.</p></disp-quote><p>We thank Reviewer #3 for pointing out the typo. It has been corrected to: âSupplementary Figure 6. <italic>Tbx3:Tbx5</italic> double-conditional knockout mice exhibit QRS prolongationâ.</p></body></sub-article></article>